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 Schizophrenia is the most extreme manifestation of schizotypy, a continuum of 
symptoms and impairment that ranges from minimal impairment to full-blown psychosis. 
Schizophrenia has been described as a disorder of disrupted context integration (CI), the 
ability to assimilate internal and external information into coherent mental 
representations. CI in schizotypy is often measured with the AX-Continuous Performance 
Task (AX-CPT) and the Dot Pattern Expectancy (DPX) task. Research using these tasks 
indicated CI deficits along the schizotypy spectrum, but has primarily been conducted 
with schizophrenia patients. There have been mixed findings regarding outcomes such as 
error patterns and the association of CI deficits with schizotypy symptom dimensions. 
Further, conclusions were limited by generally small sample sizes, heterogeneous patient 
variables, and varied task parameters across studies. The current study used systematic 
review and meta-analysis to collect and synthesize data on AX-CPT and DPX 
performance across the schizotypy spectrum. CI impairment was present across the 
schizotypy spectrum. CI deficits in schizophrenia were substantial in magnitude and 
correlated with disorganized and negative symptom dimensions. Error patterns suggested 
a specific deficit in CI, which was larger than deficits attributed to broader cognitive 
impairment and general psychopathology. When examining subgroups, CI performance 
was comparable between chronic and first-episode schizophrenia patients. Groups at risk 
to develop schizophrenia demonstrated moderate CI impairment. The results were 
generally robust across task parameters and there was no evidence of reporting biases. In 
 
 
sum, these findings lend additional support to theories suggesting that CI is a stable 
vulnerability factor for schizophrenia.    
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 1 
CHAPTER I 
 
INTRODUCTION 
 
 
Overview 
 The current study is a meta-analysis of context integration (CI) deficits in 
schizotypy-spectrum psychopathology. The study followed best practices and employed 
systematic review procedures to gather empirical data on CI in different groups along the 
schizotypy spectrum. Two CI tasks from the Cognitive Neuroscience Test Reliability and 
Clinical Applications for Schizophrenia (CNTRACS; Gold et al., 2012) battery were 
included: the AX-Continuous Performance Task (AX-CPT; Servan-Schreiber, Cohen, & 
Steingard, 1996) and the Dot Pattern Expectancy (DPX; Jones, Sponheim, & MacDonald, 
2010; MacDonald, Goghari et al., 2005) task. Meta-analysis was used to synthesize 
results and estimate the magnitude of CI impairment across the schizotypy spectrum. 
Variables thought to moderate or predict effect size were also examined, including 
factors such as symptom subtypes, patient characteristics, and task parameters. This is the 
first known, comprehensive meta-analysis of CI across the schizotypy spectrum. 
Context Integration 
   
 
I only saw fragments: a few people, a kiosk, a house. To be quite correct, I cannot 
say that I see all of that, because the objects seemed altered from the usual. They
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did not stand together in an overall context, and I saw them as meaningless 
details…My impressions did not flow as they normally do (Matussek, 1987, pg. 
92).  
 
 
 This account confronts us with the importance of context, which usually goes 
unnoticed but leaves a strange and fragmented world when disrupted. Context is a 
complicated construct that has been broadly used, but poorly defined, in the 
psychopathology literature. In this paper, I use context to mean both internal 
information—such as task schemas—and external information—such as perceptual 
features of the surrounding environment—that affect attention, interpretation, or behavior 
(Barch et al., 2004; Barch et al., 2001; Cohen & Servan-Schreiber, 1992). I conceptualize 
context integration (CI) as the adaptive, dynamic ability to assimilate internal and 
external information into a coherent mental representation.  
Schizophrenia and Schizotypy 
 Schizophrenia is a severe mental illness that affects about 1% of the population 
(Diagnostic and Statistical Manual of Mental Disorders: DSM-5; American Psychiatric 
Association, 2013). It is part of a spectrum of psychotic and nonpsychotic illnesses, 
which in turn represent the most severe manifestations of a broader continuum of clinical 
and subclinical symptoms and impairment referred to as schizotypy (e.g., Kwapil & 
Barrantes-Vidal, 2015; Lenzenweger, 2010; Meehl, 1989). This paper will use the term 
schizotypy to refer to the broad construct ranging from subclinical to psychotic 
expression. 
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 The schizotypy spectrum is heterogeneous and includes positive, negative, and 
disorganized symptom dimensions (Kwapil & Barrantes-Vidal, 2015; Liddle, 1987). 
Positive schizotypy involves excesses and distortions in perception and thought content. 
Perceptual abnormalities can occur in any sensory modality and range from mild 
illusions, or misperceptions of sensory stimuli, to hallucinations, or perceptions in the 
absence of sensory stimulation. Disruptions in thought content range from mild and 
transient magical, referential, and suspicious ideation all the way to full-blown delusions. 
Negative schizotypy includes diminished pleasure, social interest, thoughts, speech, 
affect, and motivation, and ranges from mild diminutions in these experiences to a 
complete lack of enjoyment, thought, expression, and engagement in the world (Kwapil 
& Barrantes-Vidal, 2015). 
 Disorganized schizotypy, which is thought to be especially relevant for disrupted 
context integration, involves impairment in the ability to regulate thoughts and actions, 
manifesting as odd or disrupted speech and peculiar behavior (Kwapil & Barrantes-Vidal, 
2015). Disorganized speech is often hard to follow and involves disruptions such as 
tangentiality or inappropriate use of words. Disorganized behavior includes atypical 
movements and inappropriate affect (Arndt, Alliger, & Andreasen, 1991; Liddle, 1987). 
Disorganized symptoms range from mild cognitive disruption, circumstantial and 
tangential speech, and difficulty organizing and completing tasks to formal thought 
disorder, such as completely derailed thinking, incoherent speech, and grossly impaired 
behavior. 
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Theoretical Basis of CI Impairment in Schizotypy 
 Early phenomenologists described the development of schizophrenia in terms of 
impaired CI. These theorists were heavily influenced by Gestalt theory, which relies on 
principles of the tendency to perceive groups or complete forms from individual visual 
elements (e.g., Wertheimer, 1912; Wertheimer 1922). Incorporating ideas from Gestalt 
psychology, Matussek (1952) and Conrad (1958) proposed that schizophrenic impairment 
in integrating individual stimuli within the perceptual context could eventually lead to 
delusions. This occurs as the dimming of the perceptual field causes stimuli to stand out, 
which leads to attentional capture, feelings of uncertainty and anxiety, and ultimately, the 
formation of delusional thought as a means of restructuring the disorganized perceptual 
framework. As the delusion becomes stronger, experiences are interpreted as part of the 
newly formed context. 
 Modern theories have focused on a neural basis for impaired CI in schizophrenia. 
CI is proposed to occur at both the globalized cellular and the perceptual level (e.g., 
Phillips & Singer, 1997). Put simply, neurons have a contextual field that is sensitive to 
input from nearby cells. This causes nearby cells to synchronize firing, which is needed 
for normal perceptual integration (e.g., Phillips & Singer, 1997). The neural processing 
activates and influences top-down processing, which in turn can modulate contextual 
field responding (e.g., König, Chiang, & von Stein, 1997). It is thought that impaired 
coordination between bottom-up and top-down processing of contextual information may 
be associated with some symptoms of schizophrenia (e.g., Silverstein & Schenkel, 1997), 
which would indicate a problem with the neural mechanism of integration rather than 
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with vision. Accordingly, researchers have proposed that CI involves distributed network 
connectivity that is not limited to a particular area of the brain nor a singular cognitive 
function (e.g., Phillips & Silverstein, 2013; Ray et al., 2017). Phillips and Silverstein 
(2013) review information suggesting that widespread disruptions in coordination 
between nearby neurons and across longer-range brain regions have been found in 
schizophrenia, and that these processes are related to CI impairment. 
 It has been argued that impaired CI is not just an outcome of schizophrenia, but an 
underlying mechanism contributing to a number of cognitive, behavioral, and 
symptomatic manifestations of the illness (Barch & Braver, 2009; Cohen & Servan-
Schreiber, 1992). It is proposed that a single CI process underlies attention, working 
memory, and inhibition aspects of executive control. In this way, context representations 
have been proposed as a top-down mechanism for focusing on task-relevant processes 
and for maintaining and updating these representations over time (Barch & Braver, 2009; 
Barch & Sheffield, 2017). For example, poor representation and maintenance of context 
may manifest as behavioral symptoms such as disorganized speech resulting from failure 
to interpret a phrase’s meaning from the broader context of a sentence or conversation 
(Cohen & Servan-Schreiber, 1992). 
 Among other neurological abnormalities, schizophrenia involves disrupted 
dopamine functioning in the dorsolateral prefrontal cortex (DLPFC), which is associated 
with deficits in neurocognition and specifically, executive function (e.g., Cools, Brouwer, 
de Jong, & Slooff, 2000; Knable & Weinberger, 1997). CI deficits are thought to 
represent impaired function in the DLPFC and its connection with numerous neural 
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regions and neurotransmitter systems (see Barch & Sheffield, 2017 for review). In line 
with these predictions, CI deficits have been associated with diminished DLPFC 
activation and increased noise in the mesocortical dopamine system—that is, lower 
signal-to-noise ratio across the network—in empirical and computational studies (e.g., 
Barch et al., 2001; Braver, Barch, & Cohen, 1999; Lesh, Westphal, Niendam et al., 2013; 
MacDonald & Carter, 2003). 
 Phenomenological and neuroscientific theories of schizophrenia both posit a key 
role of disruptions in processing context at behavioral and neurological levels. However, 
there is ongoing debate about whether the underlying neural abnormalities are broadly 
distributed or more localized. Thus, questions remain about whether the mechanisms 
described above are actually interrelated, and about the timing of possible interactive 
processes. For example, do early neurodevelopmental abnormalities give rise to later 
impaired neural processing, which then result in abnormal perceptual experiences and 
manifestation of symptoms? In what ways is the process more nuanced, with disruptions 
at various levels of processing being interleaved or dependent upon environmental 
factors? As with many scientific fields, cross-cutting, interdisciplinary research is sorely 
needed to bridge together siloed theories from separate approaches. 
 Once CI deficits in schizophrenia were initially discovered, researchers began 
investigating two key questions: whether CI may be an endophenotype—a heritable, 
vulnerability marker (Gottesman & Gould, 2003)—of the disorder, and whether it is 
specific to schizophrenia versus related to psychopathology in general. To aid in the  
 
 
 
 7 
detection of endophenotypes, Gottesman and colleagues have proposed six criteria 
throughout the years: 
 
1) The endophenotype is associated with illness in the population. 2) The 
endophenotype is heritable. 3) The endophenotype is primarily state-independent 
(manifests in an individual whether or not illness is active) but may require a 
challenge to elicit the indicator...4) The endophenotype found in affected family 
members is found in non-affected family members at a higher rate than in the 
general population (familial association). 5) The endophenotype is more prevalent 
among the ill relatives of ill probands compared with the well relatives of the ill 
probands (i.e., co-segregation). 6) The endophenotype should be a trait that can be 
measured reliably, and ideally is more strongly associated with the disease of 
interest than with other psychiatric conditions (Chan & Gottesman, 2008, pg. 961-
962).  
 
 
 Similarly, Nuechterlein and colleagues (1992) distinguished among three types of 
developmental processes: episode indicators, mediating vulnerability factors, and stable 
vulnerability indicators. Episode indicators are processes that are disrupted only during 
an illness episode; mediating vulnerability factors show continual impairment that is 
exacerbated during episodes; and stable vulnerability indicators involve consistent 
impairment, with severity unaffected by episodes (Nuechterlein et al., 1992). 
 Researchers have examined the diagnostic specificity of CI. Barch and colleagues 
(2003) proposed that CI is impaired in schizophrenia and in psychotic disorders more 
broadly. However, Barch et al. found a key distinction in timing between these 
psychiatric conditions: in non-schizophrenia psychotic disorders, impairment was not 
stable over time. Thus, CI may be an episode indicator in non-schizophrenia psychoses. 
In contrast, Barch and colleagues found that CI was consistently impaired in patients with 
schizophrenia across the span of a month, despite marked reductions in psychotic 
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symptoms during that time. Accordingly, they proposed that CI impairment is either a 
mediating vulnerability factor or stable vulnerability indicator for schizophrenia, 
supporting the suggestion that CI may represent an endophenotype for schizophrenia.  
 Overall, CI deficits are not unique to schizophrenia but patients with 
schizophrenia generally demonstrate impairment that is both more severe and more stable 
than other psychiatric groups, such as patients with other psychotic disorders or mood 
disorders (e.g., Barch et al., 2003; Cohen, Barch, Carter, & Servan-Schreiber, 1999; 
Reilly et al. 2017; Richard, Carter, Cohen, & Cho, 2013). In sum, the descriptive 
psychopathology and neuroscience literature both provide theoretical models for 
understanding the development and expression of schizophrenic psychopathology in 
terms of impaired CI. 
Measurement of Context Integration 
 This review and meta-analysis specifically focused on measurement of CI using 
the AX-CPT and the DPX laboratory tasks. These tasks were selected because they map 
on to neural mechanisms implicated in CI (Braver, Barch, & Cohen, 1999). Furthermore, 
the tasks were designed to reveal a specific deficit in context processing; that is, greater 
impairment in CI compared to other areas of general cognition (Chapman & Chapman, 
1973). This is accomplished through examination of differential error patterns, as 
described below.  
 AX-Continuous Performance Task. One of the most commonly used CI 
assessments is the AX-CPT, a modified continuous performance task (CPT) designed to 
assess the mental representation and maintenance of context. CPT tasks were originally 
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developed to assess sustained attention (Cohen, 2011). There are a variety of CPT tasks 
(Rosvold, Mirsky, Sarason, Bransome, & Beck, 1956) used in cognitive testing; for 
example, the single letter version, in which participants must respond to the letter X, the 
identical pairs version, in which participants must respond when a letter is shown twice in 
a row, or the standard AX version of the task, in which participants must respond when 
an A is followed by an X. In these CPT tasks, stimuli are presented rapidly and target 
trials occur infrequently so participants must maintain attention in order to respond 
correctly and detect the target amidst other stimuli. Standard versions are often used with 
patients with schizophrenia to assess vigilance (e.g., Nuechterlein, 1991).  
 Servan-Schreiber and colleagues (1996) modified the AX-CPT to include a higher 
proportion of target (AX) trials (80% in their original version) to keep the task goal 
relevant; because this new format creates a tendency to respond to X, they planned to 
assess BX errors in schizophrenia as an indication of difficulty with response inhibition. 
The AX-CPT and its nonverbal analog, the DPX (described below) were selected by the 
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia 
consortium as goal maintenance tasks for the CNTRACs battery, which includes 
cognitive measures recommended for cross-cutting research in schizophrenia (Barch et 
al., 2009). CNTRACs tasks were chosen by breakout groups of experts from various 
domains on the basis of each task demonstrating construct validity, mapping onto neural 
systems and animal models, demonstrating predicted outcomes in response to 
pharmacological manipulation in healthy subjects, showing evidence of impairment in 
schizophrenia, and exhibiting adequate psychometric properties. 
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 The modified AX-CPT presents participants with a series of letters presented in 
succession; an item pair is made up of two sequentially presented letters, the cue 
followed by the probe. Researchers often manipulate the delay interval between the cue 
and probe, which may be different than the intertrial interval. They must make a positive 
(target) response when they see the letter A followed by the letter X (AX trials), and a 
negative (non-target) response to other letter pairs: AY, BX, and BY, with B representing 
any non-A cue and Y representing any non-X target. Although there are several versions 
of the task, the most common CI version involves 70% AX, 10% AY, 10% BX, and 10% 
BY trials. 
 Dot Pattern Expectancy Task. A nonverbal variant of the AX-CPT is the dot 
pattern expectancy task, which involves dot patterns instead of letters. This allows 
researchers to examine CI using novel spatial stimuli that may eliminate the potential 
confound of verbal strategies. Additionally, this variation typically involves a different 
proportion of trial types (69% AX, 12.5% AY, 12.5% BX, and 6% BY trials), providing a 
slightly greater number of the critical trials most strongly related to CI (BX trials) 
compared to the traditional AX-CPT format. The DPX is reportedly sensitive to CI 
impairment in both patients and their unaffected siblings (e.g., MacDonald, Goghari et 
al., 2005, Study 2), suggesting that it can detect deficits in less impaired individuals. 
Thus, it appears to be a promising tool for assessing CI deficits across the schizotypy 
spectrum. 
 The AX-CPT and DPX correlate between .63 and .80 (Strauss et al., 2014) and 
demonstrate comparable, adequate internal consistency and test-retest reliability overall; 
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however, the DPX has lower internal consistency for AY trials than the AX-CPT (Jones 
et al., 2010). A confirmatory factor analysis showed that BX trials from the AX-CPT and 
DPX tasks loaded on a context-processing factor, whereas AY trials from both tasks 
loaded on a preparatory factor. AX trials from both tasks loaded simultaneously on the 
context processing and preparatory factors, which were uncorrelated overall. Finally, BY 
errors serve as a check that participants understood task instructions and attended to the 
task – in that they neither are the correct target, nor follow the correct cue (MacDonald, 
Goghari et al., 2005, Study 1).  
 The cognitive neuroscience theories described above are particularly useful 
because they provide specific, testable predictions that relate AX-CPT/DPX performance 
to neurocognitive dysfunction in schizophrenic psychopathology. With these tasks, 
researchers are generally more interested in error patterns than in overall performance. 
Theoretically, AY trials should be the most difficult for individuals with intact context 
processing because they keep the task goal in mind and prepare to respond once they see 
the letter A. BX trials should be the most difficult for people with impaired context 
processing because the X triggers a response when the goal is not properly maintained (a 
target pair never begins with B) (Barch & Braver, 2009). This differentiation in cognitive 
abilities by trial allows for the examination of differential deficits in CI within a single 
task. For example, some studies have shown a double dissociation pattern, in which 
individuals on the schizotypy spectrum who presumably have impaired CI made more 
errors than controls on trials where poor CI is a disadvantage (BX trials) but fewer errors  
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on trials where poor CI is advantageous (AY trials) (Barch et al., 2001; MacDonald, 
Pogue-Geile, Johnson, & Carter, 2003). 
 Performance on CPT tasks is typically evaluated using signal detection theory to 
quantify participants’ ability to distinguish a signal amidst background noise (e.g., Swets, 
1961). For example in the standard AX-CPT, correctly detected AX targets are 
considered hits, failures to detect targets are considered misses, and inappropriate positive 
responses to non-target trials are considered false alarms. A sensitivity or detectability 
index, d-prime (d’), is calculated to quantify a person’s ability to detect hits and ignore 
false alarms (Atkinson, 1963). The index of d’ is the primary measure of vigilance in 
CPT studies in the schizophrenia literature (e.g., Nuechterlein, Green, Calkins et al., 
2015; Wohlberg & Kornetsky, 1973).  
 Response patterns from the CNTRACs tasks are often used to compute d’context, 
a modified d’ index designed to measure context sensitivity: d’context = z(AXhits) - 
z(BXfalse alarms). This value compares proportions of responses between AX hits and BX 
errors (rather than all false alarms) using a z-transformation, with lower d’context (more 
BX false alarms and AX misses) reflecting worse CI ability. d’context is thought to yield 
a better estimate of sensitivity to context than independent examination of errors (Cohen 
et al., 1999; Servan-Schreiber et al., 1996) and has become a gold standard for measuring 
context-processing ability in schizophrenia.  
 If differential error patterns and d’context reflect initial representation of context, 
then manipulation of the cue-probe delay is thought to reveal processes related to the 
maintenance of context representations (Barch & Braver, 2009). When CI abilities are 
 
 
 13 
intact, BX accuracy should increase across longer delay periods (that is, at least across 
those typically reported in these tasks) because participants have more time to prepare a 
non-target response following the B-cue. In contrast, longer cue-probe delays should 
diminish AY accuracy in healthy participants because they have more time to prepare (an 
incorrect) positive response to the A-cue. The opposite pattern is predicted for people 
with poor CI, who have difficulty keeping task instructions in mind and maintaining the 
context of how a given cue should prepare them to respond. In schizotypy-spectrum 
groups, therefore, longer cue-probe delays should result in lower BX accuracy because 
the appropriate mental context (“B means I should prepare a negative response”) is not 
maintained well across time, making them more likely to commit a false alarm when 
presented with an X. On the other hand, AY accuracy should theoretically increase with 
longer delay time in schizotypy-spectrum groups because deterioration of the appropriate 
mental context (“A means I should prepare a positive response”) is actually beneficial in 
AY trials, which require a negative response (Barch & Braver, 2009). 
Empirical Review of CI Impairment in Schizotypy Spectrum Psychopathology 
 To examine disrupted context processing as a potential endophenotypic marker of 
the illness, it must be assessed premorbidly. Simply demonstrating that patients with 
schizophrenia have difficulty integrating context cannot distinguish whether CI deficits 
reflect an underlying risk factor or are an outcome of the disorder due to experience of 
symptoms, stigma, or medication effects and simply part of the generalized performance 
deficit reported in schizophrenia (Chapman & Chapman, 1978). However, if CI 
impairment manifests early in the disorder and is present in people without clinically 
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significant levels of symptoms and functional impairment, this—among other criteria—
lends credence to the theory of CI as an endophenotype. Thus, it is important to assess CI 
in different types of samples along the schizotypy spectrum. Studies using the AX-CPT 
and DPX have been conducted with participants who have schizophrenia and 
schizoaffective disorder, schizotypal personality disorder (SPD; a non-psychotic 
personality disorder on the schizotypy spectrum) (American Psychiatric Association, 
2013), those at ultra-high risk to develop schizophrenia, first-degree relatives, and 
psychometrically identified schizotypy. However, the majority of these studies were 
conducted with patients with schizophrenia.  
 Published patient studies report CI deficits on CNTRACs tasks in terms of error 
patterns, reaction time, and d’context scores when comparing schizophrenia groups to 
healthy and psychiatric control groups (e.g., Barch et al., 2003; Cohen et al., 1999; Reilly 
et al., 2017). For example, patients with schizophrenia show diminished d'context—
indicative of poorer CI ability—compared to healthy controls on both the AX-CPT (e.g., 
Barch et al., 2001) and the DPX (e.g., Henderson et al., 2012). 
 Regarding specific error patterns in schizophrenia, increased BX errors are 
reported in patient studies; however, the literature is variable on findings for AX, AY, 
and BY accuracy. Although findings are mixed in patients with schizophrenia, the most 
common pattern appears to be more AX and BX errors than AY and BY errors, relative 
to controls. Additionally, even when patients were found to perform worse than controls 
across all trials, a specific deficit was still seen in which patients perform worse on BX 
trials relative to AY trials (Henderson et al., 2012). Some studies even show a crossover 
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effect, in which patients outperform controls on AY trials despite worse BX performance 
(Barch et al., 2001; MacDonald et al., 2003). In sum, there is variability in error patterns 
across studies, but published studies seem to support CI deficits in patients with 
schizophrenia. 
 Only two identified studies have compared individuals with SPD to controls on 
the AX-CPT and DPX. They found CI deficits in SPD compared to healthy subjects and 
non-Cluster A personality disorders (Barch et al., 2004; McClure, Barch, Flory, Harvey, 
& Siever, 2008). Two other studies have examined CI in people with SPD pre- and post-
pharmaceutical treatment (McClure et al., 2007; McClure et al., 2010). All four SPD 
studies showed greater BX relative to AY errors within (pre-treatment) SPD. Taken 
altogether, this provides initial evidence of a specific deficit in CI in non-psychotic 
individuals with schizotypy-spectrum disorders. 
 Only one known study has examined CI in ultra high-risk (prodromal) 
participants who have no history of psychosis (Niendam et al., 2014). These at-risk 
individuals showed 1) attenuated psychotic symptoms, 2) brief, limited intermittent 
psychotic symptoms, or 3) a substantial decline in functioning over the past year plus 
either SPD or a first-degree relative with psychotic disorder. In this study, the ultra high-
risk participants showed more BX errors and lower d’context than healthy controls, again 
demonstrating preliminary support for CI impairment in earlier stages of schizotypic 
psychopathology. 
 Unaffected relatives of patients with schizophrenia are at greater risk for 
schizophrenia-spectrum psychopathology than the general population, presumably due to 
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shared genetic vulnerability (e.g., Tandon, Keshavan, & Nasrallah, 2008; MacDonald, 
Goghari et al., 2005). Unaffected relatives often show impairment intermediate to 
patients and control participants across a number of domains but there have been mixed 
findings in the literature (e.g., Delawalla, Csernansky, & Barch, 2008; Lopez-Garcia, 
Espinoza, Santos, Marin, & Sanchez-Pedreño, 2013; MacDonald, Goghari et al., 2005, 
Study 2; MacDonald et al., 2003; Richard et al., 2013). Thus, there is inconclusive 
evidence regarding the magnitude of possible CI impairment in unaffected relatives of 
patients with schizophrenia. 
 Only one group study (Sloat 2007, unpublished dissertation) was identified that 
used the AX-CPT to examine CI in a subclinical group scoring high on schizotypy 
questionnaires. Using two-tailed t-tests, no group differences were found for BX errors or 
d’context scores compared to healthy controls (our calculations from group summary 
data). However, extreme group designs can be problematic in psychometric identification 
studies because of the use of arbitrary cutoff points and the likelihood of underestimating 
effect sizes due to reduced statistical power (e.g., Preacher, Rucker, MacCallum, & 
Nicewander, 2005). Therefore, since continuous ratings of schizotypy have been shown 
to predict psychopathology better than extreme group scores (Kwapil, Gross, Silvia, & 
Barrantes-Vidal, 2013), we believe an examination of CI in subclinical schizotypy using 
continuous scores is indicated for future research.  
 In sum, CI deficits are frequently found across the schizotypy continuum in 
clinical samples and some at-risk samples. Studies assessing unaffected relatives and 
psychometrically identified schizotypy were few and reported mixed findings. 
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Nonetheless, there is preliminary evidence that CI impairment may begin early in the 
course of schizotypy-spectrum psychopathology. Additionally, these findings do not 
appear to simply reflect generalized performance deficits and suggest a specific 
impairment in context processing. 
Other Factors That May Influence CI Impairment in the Schizotypy Spectrum 
 Diagnostic status alone may not necessarily explain poor CI ability in people with 
schizotypy-spectrum disorders. There are a number of other factors that may affect 
cognitive performance—and specifically, CI—in both clinical and subclinical 
manifestations of schizotypy, including medication status, illness duration and symptom 
dimensions. 
 Medication Status. Psychotropic medications can influence performance on 
cognitive tasks as certain commonly prescribed medications have been known to aid or 
impair cognition in schizophrenia (see Barch, 2005 for review). Barch and colleagues 
(2001) previously suggested that CI impairment is not likely caused by antipsychotic 
medication, since CI deficits are seen in medication-naïve patients with schizophrenia. 
Indeed, the current literature points to CI impairment compared to controls in both 
medicated (e.g., Chung, Mathews, & Barch, 2011; Fornito, Yoon, Zalesky, Bullmore, & 
Carter, 2011; MacDonald & Carter, 2003; Yoon et al., 2012) and unmedicated patients 
(e.g., Barch et al., 2003; Lesh et al., 2015; Niendam et al., 2014; Richard et al., 2013); 
however, it is still important to assess and rule out medication effects whenever possible.  
 Illness Duration. It has been suggested that length of illness may play a role in CI 
ability in schizophrenia (Lesh et al., 2013). However, the AX-CPT/DPX literature 
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suggests that both patients with first-episode (e.g., Braver, Barch, Cohen, 1999, Study 4; 
Lesh et al., 2013) and chronic (e.g., Cohen et al., 1999; Perlstein, Dixit, Carter, Noll, & 
Cohen, 2003; Stratta, Daneluzzo, Bustini, Prosperini, & Rossi, 2000) schizophrenia show 
substantial CI deficits compared to controls. Further, Thoma and Daum (2008) did not 
find any effect of illness duration on CI deficits within a group of chronic patients. Only 
one published study has directly compared recent-onset and chronic patient groups: 
Servan-Schreiber et al. (1996) found that unmedicated, multi-episode patients had lower 
d’context scores than unmedicated, first-episode patients, though they did not report the 
magnitude of this effect. Therefore, there is little direct evidence of how illness duration 
impacts CI in schizophrenia. 
 However, studies comparing patients with first-episode schizophrenia and chronic 
schizophrenia often are confounded with medication status (as first-episode patients are 
more likely than chronic patients to be medication naïve). Studies have examined 
interactions between medication status and illness duration. Lesh and colleagues (2015) 
found that both medicated and unmedicated first-episode patients were impaired relative 
to healthy subjects but that, not surprisingly, deficits were significantly more pronounced 
in the unmedicated group. However, few studies have conducted such nuanced 
examinations of task performance. Thus, medication status and illness duration are both 
important factors to consider when assessing CI abilities in schizotypy-spectrum 
disorders.  
 Symptom Dimensions. Because schizotypy and schizophrenia are heterogeneous, 
it is important to consider the effect of their symptom dimensions. Different schizotypic 
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symptom dimensions are proposed to have distinct etiological pathways (e.g., Andreasen 
& Carpenter, 1993; Myin-Germeys, Krabbendam, Jolles, Delespaul, & van Os, 2002) and 
differential patterns of cognitive impairment (e.g., Bora, Yucel, & Pantelis, 2009; Keefe 
et al., 2006; Liddle, 1987). Assessing schizotypy as a singular construct can lead to 
inconsistent, uninterpretable, and invalid findings (Kwapil & Chun, 2015); thus it is 
important to examine CI deficits in relation to specific symptom dimensions. 
 Disorganized Symptoms. Disorganized symptoms have the strongest theoretical 
and empirical link with CI deficits. Disorganized symptoms have been associated with 
decreased cortical activity in the dorsolateral prefrontal cortex (Goghari, Sponheim, & 
MacDonald, 2010; Yoon et al., 2008) and with impairment in certain aspects of executive 
function (Nieuwenstein, Aleman, & de Haan, 2001) broadly. Cohen and colleagues 
(1999) proposed an association between CI (as measured by the AX-CPT) and 
disorganization, especially formal thought disorder (Cohen et al., 1999). Of the 
schizotypic symptom dimensions, the greatest support has been found for the association 
of CI deficits and disorganized symptoms, with almost every study showing significant 
associations in various groups along the schizotypy spectrum (e.g., Ceccherini-Nelli, 
Turpin-Crowther, & Crow, 2007; Jones et al., 2010, Study 3; McClure et al., 2008; 
Richard et al., 2013; Sloat, 2007, unpublished dissertation). 
 Negative Symptoms. Cohen and Servan-Schreiber (1992) were the first to propose 
a theoretical link between negative symptoms and CI deficits. Negative symptoms are 
associated with diminished frontal and prefrontal cortex dopamine-linked activity 
(hypofrontality) and executive functioning deficits (e.g., Andreasen, Flaum, Swayze, 
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Tyrrell, & Arndt, 1990; Bora et al., 2009; Servan-Schreiber et al., 1996). Further, recent 
work in patients with schizophrenia has shown hypoactivation of the fronto-parietal 
network, which is thought to be important for cognitive control, in relation to task-based 
negative symptoms (poor reward learning) (Culbreth, Gold, Cools, & Barch, 2016). Thus, 
there are theoretical and functional bases for associations between negative symptoms 
and poor executive functioning; logically, this theory would extend to CI deficits but 
there have been less explicit connections between negative symptoms and CI in the 
theoretical literature compared to disorganized symptoms. Accordingly, associations 
between CI and negative symptoms have been demonstrated in the empirical literature 
but less reliably than in the disorganized symptom dimension. Patient studies have shown 
mixed results, with both significant negative (e.g., Barch et al., 2003; Javitt, Rabinowicz, 
Silipo, & Dias, 2007; Owoso et al., 2013; Niendam et al., 2014) and null (e.g., 
Ceccherini-Nelli et al., 2007; Cohen et al., 1999; MacDonald & Carter, 2003; Stratta et 
al., 2000) correlations between negative symptoms and CI ability. Additionally, the 
association between negative symptoms and CI deficits has not been supported across the 
entire schizotypy spectrum: null findings were found in clinical high-risk (Niendam et al., 
2014), SPD (McClure et al., 2008), and psychometrically identified schizotypy (Sloat, 
2007, unpublished dissertation) groups. 
 Positive Symptoms. Early phenomenologists described a possible connection 
between CI and delusions (a prominent positive symptom of schizophrenia) (Conrad, 
1958; Matussek, 1952). Similarly, Kapur (2003) noted that the development of psychotic 
symptoms is associated with a sense of “aberrant salience” that arises when exaggerated 
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significance is assigned to inappropriate stimuli. He proposed that this process is 
mediated by excessive, context-independent dopamine release. Stratta and colleagues 
(2000) have further suggested that hallucinations might represent a failure in source 
monitoring associated—to some extent—with poor CI. Thus, there is some theoretical 
basis for the association between CI and positive symptoms. However, these theories 
have not received strong empirical support: most studies using the AX-CPT and DPX 
find no associations between positive symptoms and CI in various schizotypy groups 
(e.g., Gold et al., 2012; Javitt et al., 2007; McClure et al., 2008; Niendam et al., 2014; 
Owoso et al., 2013). Furthermore, one study found that associations with positive 
symptoms were no longer significant after accounting for disorganized symptoms 
(Becker, 2012, unpublished dissertation), suggesting that co-occurring symptoms may 
explain findings in the few studies that do show a relationship between the positive 
dimension and CI deficits. 
 Summary and Limitations of Symptom Association Studies. Disorganized 
symptoms show consistent associations with CI impairment across the schizotypy 
spectrum, negative symptoms show associations with CI impairment that are less 
consistent than the findings for disorganization and may not be present in all at-risk 
groups, and positive symptoms do not show strong associations with CI across the 
schizotypy spectrum. Bear in mind that the use of inappropriate measures or items in 
symptom dimension conceptualizations may limit the validity of findings; examples 
include social anxiety conceptualized as a disorganized symptom, increased excitability 
as a negative symptom, and conceptual disorganization as a positive symptom. 
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Inconsistent operationalization and measurement of symptom dimensions makes it 
difficult to draw valid conclusions from an already inconsistent literature. 
Conceptualization of symptom dimensions driven by theory rather than by measurement 
tools would allow for a better understanding of how these symptoms relate to cognitive 
factors such as CI. 
Summary and Limitations of the Literature 
 In summary, the published literature suggests that a specific deficit in CI ability is 
present in patients with schizophrenia and some subclinical schizotypy groups. Studies 
examining symptom correlations indicated that CI may be associated with both negative 
and disorganized symptoms, but is most clearly related to the disorganization dimension. 
However, most researchers have treated schizotypy spectrum groups as unidimensional 
and have not specifically designed their studies to assess symptom associations. Because 
schizotypy is heterogeneous, differential patterns of impairment may exist within 
symptom dimensions and mask overall effects. Furthermore, studies that did employ a 
multidimensional perspective often measured symptom dimensions in ways that were 
inconsistent with the theoretical literature and were inconsistent across studies. 
Examining symptom correlations across studies using theory-driven symptom 
conceptualizations would provide a more valid assessment of associations between 
symptoms and CI ability.  
 There was considerable heterogeneity among studies regarding factors such as 
patient characteristics, control group characteristics, task parameters, and analyses 
conducted. This heterogeneity can make it difficult to directly compare studies in a 
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qualitative manner. Meta-analysis allows for a quantitative examination of the factors that 
account for variance in CI ability, which would provide a more powerful test of whether 
variables such as participant characteristics and task parameters moderate CI outcomes in 
different schizotypy spectrum groups. It is also likely that many of the reviewed studies 
may have been underpowered due to small sample sizes. In this case, a meta-analysis 
would provide greater power to examine CI impairment in schizotypy.  
 Selective reporting presents a potential issue in this literature: researchers often 
conduct planned contrasts on specific variables, but do not report outcomes for each trial 
type, which could affect the results of a meta-analysis due to missing data. There is also a 
possibility that file drawer effects, in which null and negative results are less likely to be 
published, have inflated the appearance of positive results (Rosenthal, 1979). Qualitative 
review of the literature is particularly susceptible to file drawer effects and fails to 
estimate the magnitude of CI deficits in the patient population (e.g., Cooper, 2010). Using 
systematic review to collect unpublished data can diminish the impact of publication bias. 
Examination of reported results across studies can also give an idea of how selective 
reporting affects results. 
 In summary, the foundational literature on CI deficits in schizophrenia is 
extensive, but we know much less about CI in subclinical schizotypy, particularly from a 
multidimensional perspective. The use of small samples and inclusion of heterogeneous 
study variables have limited the conclusions that can be drawn. Many of these 
shortcomings could be improved through use of systematic review and meta-analysis. 
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 Despite the large number of studies examining CI in schizophrenia and 
schizotypy, there are no known, comprehensive meta-analyses of AX-CPT and DPX 
performance. Other meta-analyses have included various CPT tasks to assess factors such 
as cognitive remediation (e.g., Grynszpan et al., 2011) or executive function-related brain 
abnormalities (e.g., Fusar-Poli et al., 2007; Goghari, 2011; Minzenberg, Laird, Thelen, 
Carter, & Glahn, 2009) but this is the first meta-analysis to specifically assess AX-CPT 
and DPX for this purpose. Thus, this will be the first known meta-analysis to assess CI 
deficits across the schizotypy spectrum using the CNTRACs tasks.  
Meta-Analysis 
 Meta-analysis is a statistical methodology that allows researchers to synthesize 
research in a systematic manner, estimate effect sizes, and increase overall power through 
the accumulation of data. Meta-analysis offers many advantages over traditional narrative 
approaches for summarizing research, which may: a) lack a standardized approach, b) 
employ imprecise search strategies, c) miss relevant research, d) gather information 
improperly, and e) be unable to show the overall magnitude of effect across studies 
(Cooper, 2010).  
 With meta-analysis, design flaws from the primary research studies being 
analyzed tend to “wash out,” similar to how random sampling in experimental research 
can prevent confounds from participant characteristics. Meta-analysis can also address 
the file drawer effect, in which null results or findings that challenge accepted research 
are less likely to be reported, by obtaining data from unpublished studies and applying  
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corrective techniques. Thus, there are meta-analytic techniques that can protect validity 
of the synthesized results even when drawn from an imperfect literature base. 
Goals 
 The goals of this project were to conduct an exhaustive review of the published 
and unpublished literature and to conduct a meta-analysis to: 1) examine overall CI 
impairment in the schizotypy-spectrum, 2) examine CI impairment in specific clinical 
and at-risk groups along the schizotypy spectrum, 3) examine associations between CI 
impairment and symptom dimensions in the existing literature and in a subset of studies 
with theory-driven symptom conceptualizations, and 4) examine the impact of patient 
characteristics and task variables on between-group outcomes. Specific hypotheses are 
detailed in the Method section below. Although hypotheses are not always specified in 
meta-analysis, it is recommended that meta-analytic studies running subgroup analyses 
make a priori predictions to demonstrate credibility (Sun, Briel, Walter & Guyatt, 2010).
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CHAPTER II 
 
METHOD 
 
 
 Project planning and a priori decisions for this project were pre-registered at 
Open Science Framework (https://osf.io/qhguz/) before analyses were conducted. The 
meta-analysis was conducted in keeping with the evidence-based guidelines proposed by 
the Meta-Analysis Reporting Standards (MARS; APA Publications and Communications 
Board Working Group on Journal Article Reporting Standards, 2008). The MARS 
guidelines were the outcome of an American Psychological Association task force that 
evaluated various standards for reporting meta-analyses from other scientific domains 
and made them more applicable to the social sciences. These steps are considered the 
gold standard for conducting meta-analyses in psychology. A list of general 
methodological decisions made in this study based upon best practices is provided in 
Appendix B. 
Literature Search 
 As recommended by Cooper (2010), broad search terms were used (see Table 1) 
to search the databases of PsycInfo, PubMed, Google Scholar, and Scopus. In addition, 
searches were conducted in the following leading journals that publish empirical studies 
of schizotypy and schizophrenia: Journal of Abnormal Psychology, Archives of General 
Psychiatry, Biological Psychology, Biological Psychiatry, Schizophrenia Research, 
Schizophrenia Bulletin, JAMA Psychiatry, Neuropsychology, American Journal of 
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Psychiatry, Psychological Medicine, Journal of Clinical Neuropsychology, Psychiatry 
Research, and Schizophrenia Research: Cognition. Additionally, references were 
examined from key papers and 227 known researchers in the field were contacted for 
unpublished data. The researchers that manage the CNTRACS battery provided a contact 
list for individuals that have requested the use of the AX-CPT and DPX; therefore, this 
information was used as the basis of the contact list, adding in other key authors in the 
field. The primary author, who is an advanced graduate student in clinical psychology, 
screened studies found using the literature search using the criteria presented in Table 1.  
Gathering Information from Studies 
 Information from the studies that met inclusion criteria were coded using a 
systematic spreadsheet, adapted from Cooper (2010): see Appendix C. The following 
general categories were coded: article characteristics, task characteristics, setting 
characteristics, and participant characteristics. Information was gathered by two coders: 
the primary author and a trained senior undergraduate research assistant. Discrepancies 
were discussed and resolved between coders. In rare cases when the resolution was 
unclear, Thomas Kwapil, Ph.D. (clinical psychologist), who has expertise in schizotypy 
spectrum research, was consulted. The two coders had an 82% initial agreement rate for 
38 samples that were dual-coded. 
Analyses 
 General Analysis Strategy. Analyses were planned a priori—that is, before 
analyses were begun—and pre-registered at Open Science Framework. Analyses were 
run using Comprehensive Meta-Analysis (CMA) (Borenstein, Hedges, Higgins, & 
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Rothstein, 2015), Version 3, a software program designed to conduct meta-analyses. 
There are two main models used in meta-analysis: fixed-effects and random-effects. 
Briefly, a fixed-effect model assumes that variance in the average effect size is due to 
sampling error, whereas a random-effects model assumes it is due to systematic error 
(Cooper, 2010). Based on consultation with Paul Silvia, Ph.D. (social psychologist), who 
has expertise in meta-analysis, a random-effects model was selected for the proposed 
meta-analysis. Random-effects models are more commonly used in psychology and there 
is reason to believe that error may vary systematically across the studies reviewed in this 
project. 
 Between-group effect sizes on task performance were calculated as or converted 
to Hedges g and within-group effect sizes on symptom-task associations were calculated 
as or converted from bivariate Pearson correlations (r) to Fisher’s z scores. Effect sizes 
from each study were weighted by inverse variance and summarized using CMA 
software. 95% confidence intervals were computed to estimate the variance for each 
average effect size. 
 Heterogeneity among effects was analyzed using the Q-statistic, tau2, and I2. The 
Q-statistic is based on a chi-squared distribution and represents the ratio of observed 
variation among studies to sampling error within studies. Tau2, which estimates the 
variance of true effects, and I2, which estimates the ratio of observed variance 
representing true differences among studies, are both derived from Q (Borenstein, 2009). 
For subgroups, analyses were calculated with separate estimates of tau2 for each 
subgroup. This statistical method is most appropriate for studies and subgroups in which 
 
 
 29 
effect sizes are assumed to vary naturally. Throughout data analysis, best practices 
according to Borenstein (2009) and Higgins and Green (2011) were followed. 
 Although a large number of analyses were conducted, analyses were limited to 
those that were planned a priori. Post-hoc alpha adjustment procedures (e.g., Bonferroni 
correction) were not used so alpha was set at 0.05. As noted by O’Keefe (2003), post-hoc 
alpha adjustment procedures have three serious limitations: 1) they reduce statistical 
power, 2) the principles justifying their use are not consistently applied, and 3) the 
consistent application of the principle leads to undesirable research practices. 
Nevertheless, results are interpreted with caution, giving more credence to findings in the 
predicted direction and those showing consistent patterns across the literature. Due to the 
issues with null hypothesis significance testing, hypotheses generally focus more on the 
size of predicted effects than on significance, using suggested effect size interpretations 
as general guidelines (Cohen, 1988; Cohen, 1992; Sawilowsky, 2009). For Cohen’s mean 
difference, d of 1.20 is considered very large, d of 0.80 to 1.19 is considered large, d of 
0.50 to 0.79 is considered medium, d of 0.20 to 0.49 is considered small, and d of less 
than 0.20 is considered very small/negligible. For Pearson’s bivariate correlations, r of 
|0.50| and above is considered large, r of |0.30| to |0.49| is considered medium, r of |0.10| 
to |0.29| is considered small, and r of less than |0.10| is considered very small/negligible.  
 Multiple comparisons from within the same group of participants were handled by 
halving the sample size for that group based on the number of comparisons, in order to 
include both sets of comparisons without “double counting” that group. This method is 
recommended by meta-analysis experts for dealing with multiple groups from one study 
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(Higgins & Green, 2011). For example, for studies in which a schizophrenia group was 
compared to two different psychiatric comparison groups, the effect size for the 
schizophrenia group versus the first psychiatric comparison group was entered with half 
of the schizophrenia group sample size, and the same for the schizophrenia group versus 
the second psychiatric comparison group.  
 All outcomes were assessed for primary comparisons between the schizotypy-
spectrum group and healthy controls for short and long delay conditions: errors and 
reaction time for all four trial types, and d’context. To limit the number of analyses for 
primary psychiatric comparison, subgroup, moderation, and meta-regression analyses, 
only key outcomes were examined: typically AY errors, BX errors, and d’context 
combined across delay conditions, which are considered the most critical variables for 
assessing CI. For symptom correlations, only BX errors and d’context (again, combined 
across delay conditions) associations were assessed since these are the best indicators of 
CI impairment. Although these outcomes all tap CI ability, it was decided a priori to 
assess them both (rather than selecting one or averaging outcomes) for theoretical 
reasons. Intact CI could theoretically lead to greater AY errors in healthy controls when 
the A cues preparation for response, whereas disrupted CI may lead to greater BX errors 
in those at risk for schizophrenia when the X probe triggers a response if cue context is 
not held in mind. Thus, the results for these two outcomes were examined in parallel. 
d’context was selected because it is thought to yield a better estimate of sensitivity to 
context than independent error rates (Servan-Schreiber et al., 1996). Therefore, even 
though d’context and BX errors are not independent (BX errors are used to calculate 
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d’context), they are not redundant and both contribute helpful information based on 
theoretical considerations. Results for d’context and BX errors were run separately so as 
not to violate the assumption of independent data in meta-analysis. 
 Note that candidate subgroups and moderating factors were decided before data 
was collected (although some of the originally planned analyses could not be conducted 
due to limited number of studies). Candidate analyses were also planned a priori but 
were modified based on power estimations according to availability of the data collected; 
thus the final subset of pre-planned analyses was selected after studies were coded but 
before analysis was begun. 
 There is no consensus on appropriate cutoffs for planning subgroup analyses; 
however, in line with recommendations from Borenstein (2009) and Fu et al. (2011), 
planned subgroup analyses were only carried out when there were at least 6 studies per 
subgroup or characteristic being assessed. Although the participant sample sizes in this 
literature are often small, key effect sizes for this literature tend to be moderate to large. 
Furthermore, many of the planned analyses far surpassed this sample cutoff; therefore, I 
estimated that most of the analyses described below would have adequate power. Note, 
however, that actual power in a random-effects model will also be determined by the 
variance across studies (Borenstein, 2009); therefore, I kept in mind that when 
heterogeneity among studies is large, the study may be underpowered to detect subtle 
effects. 
 Medication status of patients with schizophrenia was initially proposed as a 
moderating factor but there were not enough studies examining unmedicated patients to 
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provide adequate power for these analyses; additionally, medication status and number of 
illness episodes were confounded (i.e., unmedicated patients were typically experiencing 
their first episode of schizophrenia). I also hoped to examine results across short and long 
delay conditions separately for key outcomes in subgroup, symptom correlation, 
moderation, and meta-regression analyses but there were not enough studies to allow for 
this so results were collapsed across delay for most analyses (see below for exceptions). 
 Specific Analyses and Detailed Hypotheses 
 Primary Analyses, Between-Group 
 Healthy Control Comparisons. All schizotypy-spectrum groups (all 
schizophrenia-spectrum diagnoses, unaffected relatives, and psychometrically-identified 
schizotypy groups) together were compared against healthy controls for AX, AY, BX, 
and BY errors and reaction time, and d’context for short (<3500ms) and long (>3500ms) 
length of cue-probe intervals. 
 The schizotypy-spectrum group was expected to demonstrate worse performance 
than healthy controls on AX1 and BX trials at the level of a medium effect size, and 
somewhat better performance on AY trials at the level of a small effect size. No 
substantial effect (i.e., effect size in the very small range) was hypothesized for BY 
                                                        
1 An initial hypothesis of no difference in AX errors was posted to Open Science 
Framework. However, this hypothesis was made in error as it misrepresents CI theory, 
which would predict deficits in both BX and AX errors since both trial types tap CI 
ability (MacDonald, Goghari et al., 2005). 
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errors, consistent with theory of a specific deficit in CI. It was expected that the 
schizotypy-spectrum group would demonstrate slower performance (longer reaction 
times) across all trial types. The schizotypy-spectrum group was hypothesized to have 
lower d’context scores compared to healthy controls, at the level of a medium effect size. 
 Psychiatric Comparisons. All patients with schizophrenia (chronic and first-
episode) were compared on AY errors, BX errors, and d’context against all psychiatric 
comparison groups. Patients with schizophrenia were expected to demonstrate worse 
performance on BX trials and d’context scores compared to psychiatric comparison 
patients, at the level of a small to medium effect. No substantial effect was predicted for 
AY errors. 
 Subgroup Analyses, Between-Group 
 Diagnostic Groups. The magnitude of the difference between patients with 
schizophrenia and healthy controls on AY errors, BX errors and d’ prime context was 
compared to the magnitude of the difference between the at-risk group and healthy 
controls on the same measures. 
 Patients with schizophrenia were expected to demonstrate poorer performance 
than healthy controls on BX trials and d’context scores, at the level of a medium to large 
effect size, and somewhat better performance on AY trials compared to healthy controls 
at the level of a small to medium effect. It was hypothesized that the at-risk group would 
show somewhat worse performance on BX trials and d’context scores—though these 
effects were predicted to be small—and no difference in AY errors compared to healthy 
controls. Thus, it was predicted that effect sizes for indirect comparison analyses 
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examining BX errors and d’context would be larger in patients with schizophrenia versus 
healthy controls compared to the at-risk group versus healthy controls. 
 Diagnostic Groups by Illness Length. The magnitude of the difference between 
patients with chronic schizophrenia and healthy controls on AY errors, BX errors, and 
d’context was compared to the magnitude of the differences between first-episode 
patients and healthy controls, and between the at-risk group and healthy controls on the 
same measures. 
 It was predicted that patients with schizophrenia (both chronic and first-episode) 
and the at-risk group would show the same pattern of results described above (for 
diagnostic groups). In terms of effect sizes for d’context and BX errors for indirect 
comparisons, it was expected that the difference between patients with chronic 
schizophrenia and healthy controls would be greater than the difference between first-
episode patients and healthy controls, which in turn would be larger than the difference 
between the at-risk group and healthy controls. 
 Symptom-Task Correlations, Within-Group. Meta-analyses were run on within-
group correlations of positive, negative, and disorganized symptoms with d’context and 
BX errors in patients with schizophrenia (chronic and first-episode). Symptom-task 
correlations were conducted: 1) using all correlations from authors’ original symptom 
dimension conceptualizations (or from our conceptualizations when no conceptualization 
was provided and/or raw data was available) and 2) using only correlations from 
symptom dimension conceptualizations that were decided a priori to appropriately 
measure the symptom constructs (conceptualizations were made in consultation with Dr. 
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Kwapil; see Appendix D for details). These subset analyses were planned because there 
appeared to be inappropriate symptom conceptualizations in the initial pool of studies 
examined for inclusion, as described earlier. 
 Symptom-Task Correlation Hypotheses. It was predicted that disorganized and 
negative symptoms would be associated with worse performance for both outcome 
measures, that is, positively associated with BX errors (lower accuracy) and negatively 
associated with d’context (worse CI). No substantial effect was predicted for the 
association of positive symptoms with BX errors or d’context. It was predicted that 
disorganization symptoms would be more strongly associated with both BX errors and 
d’context than either positive or negative symptoms. Additionally, it was expected that 
associations would be stronger in analyses using the subset of appropriate symptom 
conceptualizations: a small effect was predicted for negative symptom associations with 
task performance and a medium effect for disorganization symptom associations. 
Moderation Analyses, Between-Group. Moderation analyses were conducted by 
grouping data according to a moderating variable and calculating the Q-statistic to 
determine whether effect sizes from the different groups are homogenous—that is, 
whether the grouping variable explains a significant amount of variance in the average 
effect size—according to best practices in the field (Borenstein, 2009; Higgins & Green, 
2011).  
 Moderation analyses were conducted to examine whether between-group effect 
sizes for all schizotypy-spectrum groups compared to healthy controls for AY errors, BX 
errors, and d’context were affected by cue duration (dichotomized at 500 ms) and cue-
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probe interval (dichotomized at 3500ms). For the cue-probe interval analyses 
(categorically in this section, as well as continuously in the section below), short and long 
delay outcomes were not averaged; studies that examined both long and short cue-probe 
interval delays were entered with two sets of outcomes at half the sample size each. 
Because there were not enough studies for each diagnostic group using the DPX, I only 
assessed AX-CPT versus DPX task as a moderator of effect size for the difference 
between patients with chronic schizophrenia and healthy controls (again, for AY errors, 
BX errors, and d’context) to avoid confounding task effects with diagnostic effects. 
These analyses were planned to help inform task parameters for future research. 
 Moderation Analysis Hypotheses. For cue duration analyses, it was predicted that 
effect sizes for schizotypy-spectrum groups versus healthy controls would be slightly 
larger for the short cue condition (cues displayed for 500ms or shorter) compared to the 
long cue condition (cue displayed for 1000ms), but that these effects would be small at 
best. For cue-probe interval analyses, it was predicted that effect sizes for schizotypy-
spectrum groups versus healthy controls would be larger for the long delay condition 
(3500ms or longer) than the short delay condition (less than 3500ms), at the level of a 
small to medium effect. For task type analyses, it was predicted that effect sizes for 
patients with schizophrenia versus healthy controls would be slightly larger for the DPX 
compared to the AX-CPT, but that these effects would be small at best. 
 Meta-Regression, Between-Group. Meta-regression analyses were conducted to 
assess the extent to which key task performance outcomes were predicted by a pre-
planned set of continuous variables (Borenstein, 2009). Between-group effect sizes for all 
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schizotypy-spectrum groups versus healthy controls for AY errors, BX errors, and 
d’context were regressed on the following continuous variables: cue-probe interval 
duration (short and long delay outcomes not averaged; see above) and total number of 
trials. These analyses were planned to assess whether there were clear cut-points in the 
data relevant to recommendations for future research (e.g., “Large effects were observed 
in studies that ran at least X number of trials.”). Between-group effect sizes for all 
patients with schizophrenia versus healthy controls for AY errors, BX errors, and 
d’context were regressed on patients’ length of illness. 
 Meta-Regression Hypotheses. Cue-probe interval duration, total number of trials, 
and length of illness in patients with schizophrenia were expected to positively predict 
effect sizes for the schizotypy-spectrum group versus healthy controls. That is, effects 
were hypothesized to be larger for longer delays, more trials, and more chronic patients. 
Interpreting the Evidence 
 There are a number of ways to interpret results in light of potential file-drawer 
effects and p-hacking. P-hacking occurs when researchers obtain significant results by 
various post-hoc methods; for example, by stopping data collection as soon as significant 
results are reached, altering statistical analyses selected, or only reporting analyses that 
are statistically significant (Simonsohn, Nelson, & Simmons, 2014). Funnel plots, the 
trim-and-fill method, and Simonsohn’s p-curve (Simonsohn, 2017) were used to assess 
for asymmetry and skew in the distribution of findings, as rough estimations of possible 
publication bias and selective reporting to aid in the interpretation of the meta-analytic 
findings.  
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 Funnel Plots and the Trim-and-Fill Method. Using Comprehensive Meta 
Analysis software, funnel plots were created by plotting effect size (using a random 
effects model) on standard error, which is the recommended choice of axis to display a 
study’s precision. The graphs are inverted so studies that are more precise (i.e., have the 
largest sample sizes) are shown at the top of the graph. A vertical line is drawn through 
the summary effect estimate and diagonal lines are drawn representing the expected 95% 
confidence intervals around the summary effect estimate: summary effect estimate + 
1.96*standard error and summary effect estimate – 1.96*standard error. When between-
study heterogeneity is not significant, 95% of study effects fall within the bounds of these 
confidence interval lines (Sterne & Egger, 2001). When a plot is asymmetrical and more 
than 5% of studies fall outside the confidence interval lines, it may be indicative of 
reporting bias, heterogeneity among studies, or chance. Reporting biases that can lead to 
asymmetrical funnel plots include publication bias, selective reporting of outcomes, or p-
hacking (Sterne et al., 2011). However, asymmetrical funnel plots do not necessarily 
indicate inappropriate research practices: they can also reflect true variability among 
effects across samples, in which sample size has an influence on effect size (Sterne et al., 
2011). 
 Using Comprehensive Meta Analysis software, Duval & Tweedie’s (2000) trim-
and-fill method was applied to the funnel plots. This method uses symmetry assumptions 
to estimate the number of missing studies, impute these missing values, and calculate an 
adjusted summary effect estimate incorporating the imputed values. This method can 
reveal the extent to which possible biases influence findings (if the funnel plot 
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asymmetry is indeed due to reporting bias) and can provide a more conservative estimate 
of the overall effect. 
 Funnel plots were examined and the trim-and-fill method was applied for key 
outcomes: AY errors, BX errors, and d’context for short and long delay conditions in 
primary analyses of schizotypy-spectrum groups versus healthy control groups, and for 
combined delay conditions in primary analyses of schizophrenia patient groups versus 
psychiatric comparison groups. Note that the choice of which outcomes to examine was 
not pre-registered but paralleled previous decisions to reduce the number of results 
presented by only examining key outcomes. Funnel plots and trim-and-fill techniques 
were not used to assess outcomes for subgroup, moderation, or meta-regression analyses 
since they are redundant; that is, the same outcomes are described in these types of 
analyses, just organized in a different manner. 
 The P-Curve. Simonsohn’s (2017) p-curve application is a tool designed to 
detect p-hacking. It involves plotting out reported p-values from a set of pre-defined 
studies in the literature and interpreting the evidential value: an effect has evidential 
value if is not likely caused by p-hacking alone. Evidential value is determined by 
examining the shape of the p-curve, relying on the assumption that it is more likely to 
obtain small statistically significant p-values than large ones (Simonsohn, Nelson, & 
Simmons, 2014; Simonsohn, Simmons, & Nelson, 2014). This technique is an important 
complement to Duval and Tweedie’s trim-and-fill method because trim-and-fill theory 
relies on the assumption that reporting biases arise from small effect sizes. In reality, 
statistical significance is often what drives reporting and publication in psychology 
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research (Simonsohn, Simmons et al., 2014); therefore, it is important to assess the 
distribution of p-values in addition to effect sizes. 
 When examining p-values that are less than 0.05, if the curve is skewed to the 
right—that is, if there are more low p-values (e.g., 0.001) than high p-values (e.g., 
0.045)—evidential value is demonstrated. When the p-curve is skewed to the left—that 
is, if the number of p-values just below 0.05 are greater than the number of p-values 
much smaller than 0.05—it suggests that “intensive p-hacking” is likely present and the 
effect lacks evidential value (Simonsohn, Simmons et al., 2014; Simonsohn, Nelson et 
al., 2014). Specifically, a combination test probing both the half p-curve (p-values<0.025) 
and the full p-curve (p-values<0.05) is used. Evidential value is considered to be present 
if a) the half p-curve is skewed to the right at p<0.05, or b) both the half and full p-curve 
are skewed to the right at p<0.10 (Simonsohn, Simmons, & Nelson, 2015). 
 Analytical decisions were made before p-curve analysis began and were pre-
registered. The reported p-values were plotted using Simonsohn’s online p-curve 
application, version 4.052 (Simonsohn, 2017). The p-values were plotted onto separate p-
curves for positive, negative, and disorganized symptom correlations with BX errors and 
with d’context. Authors’ original symptom dimension conceptualizations were used (or 
our conceptualizations when no conceptualization was provided and/or raw data was 
available). Because the p-curve method is designed to assess for selective reporting, I 
only plotted p-values that were reported directly in the text (i.e., not those that 
corresponded to any values I calculated or received via correspondence with authors).  
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 The p-values for symptom correlations were plotted by inputting r statistics into 
the online application. It is not appropriate to plot dependent effects on the same p-curve 
(Simonsohn, Nelson et al., 2014); therefore, decisions were made to handle multiple 
outcomes reported by a single study. Short and long delay conditions were plotted 
separately: one set of p-curves was created with p-values from short delay conditions and 
combined or unknown delay conditions, and a second set of p-curves was made with p-
values from long delay conditions and combined or unknown delay conditions. Thus, 
these curves should be considered independently. See Appendix E for description of 
other issues with multiple outcomes and justification of methodological decisions. 
 It was decided a priori not to create p-curves for error patterns or d’context 
because the data were not well-suited for this purpose: most studies used ANOVA tests to 
assess global between-group effects and/or group by delay interactions, and then ran 
follow-up tests for simple effects. Only p-values obtained from directly testing simple 
effects should be included in a p-curve because using simple effects that were part of an 
interaction will bias the p-curve towards demonstrating evidential value even when there 
is none (Simonsohn, Nelson et al., 2014). Thus, it would not be appropriate to include 
studies that tested interactions; however, including those that did not would limit analyses 
to a small collection of studies that are perhaps unrepresentative of the broader literature. 
With these considerations in mind, p-curves were only created for symptom correlation 
effects within patients with schizophrenia and not for any between-group effects. 
 The Fail-Safe N. The fail-safe N estimates how many studies with null findings it 
would take to yield the calculated average effect size insignificant (Rosenthal, 1979). 
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However, the fail-safe N relies on null hypothesis significance testing, ignoring the effect 
sizes of hypothetical, unpublished studies (Higgins & Green, 2011) and is insensitive to 
p-hacking (Simonsohn, Nelson et al., 2014). Thus, it is not recommended for use in meta-
analysis by the leading experts in the field and was not reported in the current study. 
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CHAPTER III 
 
RESULTS 
 
 
Outcomes of the Literature Search 
 A total of 47 independent samples were selected for final inclusion, displayed in 
Appendix F; 41 studies were included in meta-analyses and 6 studies were only included 
in summary point estimates According to guidelines from Preferred Reporting Items for 
Systematic reviews and Meta-Analyses statement (PRISMA; Moher, Liberati, Tetzlaff, & 
Altman, 2009), a diagram of search results is presented as a flowchart in Figure 1, 
including reasons for study exclusion. 39 independent samples were included using 
patients with schizophrenia, 8 samples with unaffected relatives of patients with 
schizophrenia, 4 samples with individuals with SPD, 1 sample with those at ultra high 
risk to develop schizophrenia, and 1 sample with psychometric identification of 
schizotypy. Psychiatric comparison groups included non-schizophrenia psychotic 
patients: 5 samples of bipolar disorder with psychotic features and 4 samples of non-
psychotic depressed patients. 
 Appendix B provides a detailed description of the a priori methodological 
decisions that were made for obtaining, reviewing, coding, and excluding studies; 
Appendix G provides additional information and methodological decisions pertaining to 
specific studies. Great care was taken to follow these pre-planned procedures and data 
were recorded and coded using the systematic and exhaustive coding sheet in Appendix
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C. Note that both published and unpublished studies often lacked complete information 
including sample characteristics, results of statistical analyses, and descriptions of the 
task parameters. Repeated efforts were made to contact investigators during 7 weeks to 
obtain missing information. However, at times determinations about specific studies had 
to be made. For the sake of transparency, these are summarized in Appendix G.  
 As described in detail in Appendix B, the use of overlapping samples and 
reporting on data in multiple published articles was a substantial issue. Furthermore, 
authors often did not provide adequate descriptions of their samples or respond to direct 
communication; thus, unambiguous identification of sample overlap was not always 
possible. When unclear, a conservative approach was taken and the study was excluded. 
Overall, 20 samples were excluded due to confirmed or likely re-use of participants 
across articles. Note that inclusion of multiple studies reporting the same data runs the 
risk of artificially inflating conclusions about effects. 
Demographic Information 
 Summary demographic information for all included studies is provided in Table 2. 
Schizotypy-spectrum groups included patients with chronic schizophrenia, patients with 
first-episode schizophrenia (medicated and unmedicated), individuals with SPD, those at 
ultra high risk, unaffected relatives of patients with schizophrenia, and those with 
psychometrically identified schizotypy. There was a large majority of patients with 
chronic schizophrenia in the schizotypy-spectrum group. Healthy control groups included 
those with no current (and often no past) mental illness. Psychiatric comparison groups 
included non-schizophrenia psychotic patients, non-psychotic depressed patients, bipolar  
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patients (with and without psychotic features), non-Cluster A personality disorders, and a 
psychometrically-identified "vulnerable to depression" group. 
Point Estimates of Task Performance 
 Point estimates representing average mean and standard deviation weighted by 
sample size were computed in both short and long delay conditions for errors and 
reaction times across trial type and d’context. Graphs of these point estimates are 
presented in Figures 2 to 7. For visibility, error bars were not included on error and 
reaction time graphs, but precise weighted means and standard deviations can be found in 
Tables H1 to H3 in Appendix H.  
 Point estimates were computed for the following groups: first-episode 
unmedicated schizophrenia patients, first-episode medicated schizophrenia patients, 
chronic schizophrenia patients, individuals at-risk, healthy controls, and psychiatric 
controls. Note that these basic point estimates do not take into account between-study 
variance and are weighted by sample size rather than by inverse variance; thus 
observations of possible group differences may not be synonymous with meta-analysis 
findings. Nonetheless, these estimates combine data from a larger set of participants since 
several studies did not include control participants and thus could not contribute between-
group effect sizes for the meta-analyses.  
 There were not enough studies reporting medication status across different 
schizophrenia groups to examine medication status as a moderator. The point estimates 
displayed in the figures show first-episode groups separately by medication status and 
thus offer a complementary view of the data; however, note that some estimates include 
 
 
 46 
few samples or only a single study. In sum, these point estimates are observational and 
meant only to aid the reader in visualizing the magnitude of unstandardized deficits. 
Therefore, information on group differences will only be interpreted from meta-analysis 
results presented below. 
Primary Analyses 
 Healthy Control Comparisons. A combined schizotypy-spectrum group (all 
patients with schizophrenia and at-risk schizotypy groups) was compared to the healthy 
control group across all outcomes. Results are presented in Tables 3 and 4; forest plots of 
d’context effects for short and long delay conditions are presented in Figure 8. Due to the 
large number of primary comparisons presented here, confidence intervals around effect 
estimates are not described in the text for this section but the reader is encouraged to 
consider confidence intervals from the tables. 
 Contrary to hypotheses, the schizotypy-spectrum group showed worse 
performance than healthy controls on almost every outcome. They demonstrated 
significantly more errors across all trial types for short delay intervals, and across AX, 
BX, and BY trials for long delay intervals; there was no significant between-group 
difference for AY errors in the long delay condition. In line with hypotheses, the 
schizotypy-spectrum group showed significantly longer reaction times across all trial 
types and lower d’context for both short and long delay intervals. Very small effects were 
found for AY and BY errors (long delay). Small effect sizes were found for AY and BY 
errors (short delay), BX reaction time (long delay), and AY reaction time (short and long 
delay). As predicted, medium effects were found for BX reaction times and d’context 
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(short delay), AX and BX errors, and for AX and BY reaction times (short and long 
delay). A large effect was found for d’context in the long delay condition. Significant 
heterogeneity across studies was found for all outcomes, except short delay BX errors. 
 Confidence intervals around effects were indirectly compared to make 
observational inferences about effect size differences among trial types. For short delay 
trials, the confidence intervals around AX errors slightly overlapped with those for AY 
and BY errors; the confidence intervals for BX errors showed no overlap with those for 
AY and BY errors. For long delay trials, neither AX errors nor BX errors’ confidence 
intervals overlapped with those for AY and BY errors, suggesting that the effects for CI-
critical trials were larger than for trials that tap preparatory or general ability. 
 Confidence intervals were also used to make post-hoc inferences about the 
influence of cue-probe delay on task performance. See results sections IV and V below 
for planned assessments of cue-probe interval as a categorical moderator and a 
continuous predictor of key outcomes; the current indirect observations provide 
complementary information across a broader range of outcomes. There were no 
significant differences in magnitude of between-group effect sizes between short and 
long delay conditions for any error, reaction time, or d’context outcomes. 
 In summary, the schizotypy-spectrum group generally performed worse than the 
healthy control group. Significant between-study variance in these effects was observed. 
As predicted, effects for AX and BX errors were generally larger than those for AY and 
BY errors, suggesting a specific deficit in context processing. Post-hoc observations 
suggested that the magnitude of between-group effects may not differ between delay 
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conditions but these comparisons should be interpreted with caution and in light of 
subsequent analyses. 
 Psychiatric Comparisons. A combined schizophrenia group was compared with 
a combined psychiatric comparison group. Results are presented in Table 5; a forest plot 
of d’context effects is presented in Figure 9. As predicted, the schizophrenia group 
showed significantly lower d'context than psychiatric comparison groups, at the level of a 
medium effect size, with confidence intervals ranging from a small to large effect and 
significant heterogeneity across studies. Patients with schizophrenia made significantly 
more BX errors than other psychiatric patients at the level of a small effect size, with 
confidence intervals ranging from a very small to small effect. Finally, there was no 
overall between-group difference in AY errors: a very small effect was observed with 
confidence intervals in the very small effect range. There was no significant 
heterogeneity across studies for BX and AY errors. In sum, the schizophrenia group 
demonstrated worse CI ability compared to other psychiatric groups and the magnitude of 
these effects conformed to hypotheses. 
Subgroup Analyses 
 Diagnostic Groups. As planned, results were re-run dividing the schizotypy-
spectrum group into subgroups of individuals with schizophrenia and those at risk. 
Results are presented in Tables 6 to 8; a forest plot of d’context effects is presented in 
Figure 10. As hypothesized, the schizophrenia group showed significantly lower 
d'context than healthy controls at the level of a large effect size, with confidence intervals 
ranging from a medium to large effect, and more BX errors at the level of a medium 
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effect size, with confidence intervals in the medium effect range. Contrary to predictions, 
patients with schizophrenia made more AY errors at the level of a small effect size, with 
confidence intervals ranging from a very small to small effect. Significant heterogeneity 
across studies was observed for all effects in the schizophrenia group. 
 The pattern and magnitude of CI deficits in the at-risk group conformed to 
hypotheses: compared to healthy controls, the at-risk group demonstrated significantly 
lower d'context at the level of a small effect size, with confidence intervals ranging from 
a small to medium effect, and more BX errors at the level of a small effect size, with 
confidence intervals ranging from a very small to medium effect. There were no between-
group differences for AY errors: a very small effect was observed, with confidence 
intervals ranging from a very small to small effect. There was no significant 
heterogeneity across studies for any effects in the at-risk group. 
 Indirect comparisons showed that when each group was compared to healthy 
controls, the schizophrenia group had stronger effects than the at-risk group for AY 
errors, BX errors, and d'context, as predicted. Indirect comparisons are observational and 
should be interpreted cautiously. Additionally, a significant amount of unexplained 
variance remained in the model after accounting for diagnostic status. In sum, as 
expected both patients with schizophrenia and at-risk individuals showed CI deficits, and 
indirect comparisons suggested that these effects are more pronounced in patients. 
 Diagnostic Groups by Illness Length. As planned, results were re-run dividing 
the schizotypy-spectrum group into subgroups of patients with chronic schizophrenia, 
first-episode patients, and individuals at risk to develop the disorder. Results are 
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presented in Tables 9 to 11. Results for at-risk groups versus healthy control groups were 
identical to those presented in the previous section above (Section 1, Diagnostic groups). 
Findings for chronic and first-episode patients generally conformed to hypotheses. When 
compared to healthy controls, both patient groups showed significantly lower d'context at 
the level of a large effect size, with confidence intervals ranging from a medium to large 
effect; and more BX errors at the level of a medium effect size, with confidence intervals 
ranging from a medium to large effect. Contrary to predictions, however, the chronic 
group made more AY errors than controls at the level of a small effect, with confidence 
intervals ranging from a very small to medium effect. The first-episode group did not 
make significantly more AY errors than controls: a very small effect was observed, with 
confidence intervals ranging from a very small to small effect. There was significant 
heterogeneity across studies for all effects in the chronic group and for BX errors in the 
first-episode group. 
 The overall strength of effects differed significantly across groups for AY errors, 
BX errors, and d’context; however, there was still unexplained variance left in the model 
after accounting for diagnostic grouping by illness length. Using indirect comparisons 
with healthy controls, the chronic patient group showed stronger effects than the at-risk 
group for AY errors and d'context. The first-episode patient group showed a stronger 
effect than at-risk group for d'context. Although the overall group effect for BX errors 
was significant, confidence intervals around the at-risk group estimate overlapped 
slightly with confidence intervals for both the chronic and first-episode groups.  
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Unexpectedly, there was no difference in strength of effects between the chronic and 
first-episode patients groups for any outcomes. 
 In sum, hypothesized CI deficits were found in those at-risk for developing 
schizophrenia and in patients with both first-episode and chronic schizophrenia. Indirect 
comparison indicated that, contrary to predictions, the magnitude of deficits in first-
episode and chronic patients was similar relative to healthy controls. 
Symptom-Task Correlations 
 Authors’ Conceptualizations and Our Conceptualizations. Within-group 
correlations between symptom dimensions and key task outcomes were examined for 
patients with schizophrenia. Contrary to expectations, results did not appreciably differ 
when analyses were re-run with a subset of studies corresponding to our narrower, a 
priori conceptualizations of symptom dimensions: effects were slightly—but not 
significantly—larger using our symptom conceptualizations. Therefore, results are only 
described in the text for the full set of studies, corresponding to the authors’ original 
conceptualizations (or to our conceptualization when none was provided or when raw 
data was available). See Tables 12 to 14 for results from authors’ conceptualizations and 
Tables 15 to 17 for results from our conceptualizations. 
 Forest plots of d’context correlations with symptom dimensions are presented in 
Figures 11 to 13. Based on authors’ conceptualizations, positive symptoms did not show 
significant associations with d'context or BX errors: as expected, very small effects were 
found, with confidence intervals in the small to very small effect range. As hypothesized, 
negative symptoms were significantly correlated with d'context and BX errors at the level 
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of a small effect size, with confidence intervals ranging from a very small to small effect. 
No significant heterogeneity across studies was observed for positive or negative 
symptom correlations. Disorganization symptoms showed significant associations with 
d'context and BX errors at the level of a small effect size, with confidence intervals 
ranging from a very small to medium effect. Note that these findings were in the 
predicted direction but the associations were somewhat smaller than expected. All 
significant symptom effects indicated worse performance in the schizophrenia group: 
disorganization and negative symptoms were negatively correlated with d’context scores 
and positively correlated with BX errors. Significant heterogeneity was present across 
studies for disorganized symptom correlations. 
 In sum, disorganized and negative symptoms showed small associations with CI 
deficits in patients with schizophrenia; the positive symptom dimension showed 
negligible associations consistent with hypotheses. However, contrary to hypotheses, the 
magnitude of effects did not significantly differ among the three symptom dimensions. 
Moderation Analyses 
 Cue Duration. Length of cue presentation was assessed as a categorical 
moderator of between-group outcomes for a combined schizotypy-spectrum group versus 
healthy controls. Results are presented in Tables 18 to 20. Long cues (those lasting for 
1,000ms) showed significantly stronger effects than short cues (those lasting 500ms or 
less) for AY errors. Note that the schizotypy-spectrum group made more errors than the 
healthy control group so cue duration moderated the effect in the opposite direction from  
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what was predicted. Cue duration did not moderate effects for BX errors or d’context, 
consistent with predictions that effects would be small at best. 
 Cue-Probe Interval. Length of cue-probe delay was assessed as a categorical 
moderator of outcomes between schizotypy-spectrum and healthy control groups. Results 
are presented in Tables 21 to 23. Cue-probe interval moderated outcomes for AY 
accuracy: short cue-probe intervals (less than 3500ms) showed significantly stronger 
effects than long cue-probe intervals (3500ms or longer) for AY errors. Again, these AY 
errors were in the opposite direction from what was hypothesized. Significant variance in 
AY errors across studies still remained with cue-probe duration in the model. Contrary to 
predictions, cue-probe interval did not moderate BX or d’context outcomes. 
 Task Type. Use of AX-CPT versus DPX task was assessed as a categorical 
moderator of outcomes between patients with chronic schizophrenia and healthy control 
groups; as noted earlier, analyses were limited to these groups because there were not 
enough studies using the DPX with other schizotypy-spectrum groups. Results are 
presented in Tables 24 to 26. Task type did not moderate the magnitude of effect between 
patients with chronic schizophrenia and healthy controls for AY errors, BX errors, or 
d’context, consistent with predictions that effects would be small at best.  
 In summary, long cues and short cue-probe delays were associated with stronger 
effects for AY errors (with the schizotypy spectrum group making more errors than 
controls). Note, however, that these variables are moderating effects of negligible to 
small magnitude against the predicted direction. None of the variables moderated BX  
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error or d’context effects, suggesting that schizotypy-spectrum CI deficits are robust 
across the examined task parameters.  
Meta-Regression 
 Total Number of Trials. Total number of trials run in the experiment was 
assessed as a continuous predictor of outcomes between schizotypy-spectrum and healthy 
control groups. All results are presented in Tables 27 to 29. A graph of number of trials 
regressed on AY errors is presented in Figure 14 and a graph of number of trials 
regressed on d’context is presented in Figure 15. Number of trials explained significant 
variance in the magnitude of effect for AY errors and d’context; however, significant 
variance still remained with this predictor in the model. Number of trials was negatively 
associated with these effects, meaning that as the number of trials increased, studies 
tended to find smaller positive effects for AY errors and stronger negative effects for 
d'context (each moving more in the predicted direction). Contrary to hypotheses, number 
of trials did not predict the magnitude of the between-group effect for BX errors. 
 As seen by examining the regression lines on the graph in Figure 14, the AY error 
effect approaches zero around 300 trials. In Figure 15, the regression line for d’context 
predicts medium effects for studies using 250 trials or less and large d'context effects for 
studies using more than 250 trials.  
 Cue-Probe Interval. Cue-probe delay was assessed as a continuous predictor of 
outcomes between schizotypy-spectrum and healthy control groups. Results are presented 
in Tables 30 to 32. Contrary to hypotheses, duration of the cue-probe interval did not 
predict effect magnitudes for AY errors, BX errors, or d’context. 
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 Length of Illness. Length of illness in patients with schizophrenia (both chronic 
and first-episode) was assessed as a continuous predictor of outcomes between patients 
and healthy control groups. Results are presented in Tables 33 to 35. Patients’ length of 
illness did not predict effect size for AY errors, BX errors, or d’context, contrary to 
predictions. 
 In sum, total number of trials predicted outcomes for AY errors and d’context, 
with more trials associated with effects more strongly in the direction of CI deficits. Cue-
probe duration and length of illness were not significant predictors of CI outcomes. 
Interpreting the Evidence 
 Funnel Plots and the Trim-and-Fill Method 
 Primary Analyses: Healthy Control Comparisons. Funnel plots were examined 
for AY errors, BX errors, and d’context scores in short and long delay conditions for 
effects in all schizotypy-spectrum groups versus healthy controls. The trim-and-fill 
method was applied using a random effects model for all analyses. Trim-and-fill results 
are presented in Table 36, including estimated confidence intervals around adjusted effect 
sizes. Three to nine values were imputed per outcome. None of the adjusted Hedges’ g 
estimates differed significantly from (unadjusted) observed estimates, based on 
overlapping confidence intervals around the estimates. A funnel plot of d’context effects 
for short and long delay conditions including imputed values is presented in Figure 16. 
 Primary Analyses: Psychiatric Comparisons. Funnel plots were examined and 
the trim-and-fill method was applied for AY and BX errors, and d’context scores 
(combined across delay conditions) for effects in schizophrenia groups versus psychiatric 
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comparison groups. Results are presented in Table 37. Zero to three values were imputed 
per outcome and none of the adjusted estimates differed significantly from observed 
estimates. A funnel plot of d’context effects including imputed values is presented in 
Figure 17. 
 Symptom Correlations. Funnel plots were examined and the trim-and-fill method 
was applied for disorganized, negative, and positive symptom correlations with BX errors 
and d’context scores (combined across delay conditions) within patients with 
schizophrenia. Results are presented in Table 38. Zero to three values were imputed per 
outcome and none of the adjusted estimates differed significantly from observed 
estimates. A funnel plot of disorganization symptom correlations with d’context 
including imputed values is presented in Figure 18. 
  Simonsohn’s P-Curve. Separate p-curves were created for symptom correlations 
of positive, negative, and disorganized symptoms with BX errors and d’context at short 
and long delay. Results are presented in Tables 39 and 40. None of the generated p-
curves were significant for p-hacking. P-curves for disorganized and negative symptom 
correlations with d'context demonstrated evidential value for both short and long delay 
conditions, meaning that there is evidence these effects are not solely due to p-hacking. 
All other p-curves either could not be generated because all p-values were greater than 
0.05 or results were inconclusive, meaning that evidential value could neither be 
established nor ruled out. Because there were few significant p-values per condition, 
power was low for these inconclusive analyses, ranging from 5% to 53%. Overall, there 
was no evidence that symptom correlation findings were solely due to p-hacking.  
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CHAPTER IV 
 
DISCUSSION 
 
 
Summary of Findings 
 Impaired CI ability is proposed to be a specific deficit in schizophrenia that 
presents before the onset of psychosis and may be implicated in the development of 
certain schizotypic symptoms. Numerous studies have used the CNTRACs tasks to assess 
CI in patients with schizophrenia, but fewer have examined CI in non-psychotic 
manifestations of schizotypy. The literature to date is limited by the use of small samples 
(which is not unusual in studies of patients with severe mental illness), varying task 
parameters, and heterogeneous patient characteristics that complicate interpretation of 
findings (especially from individual studies). Meta-analysis is particularly suitable for 
mitigating many of these limiting factors. Thus, the magnitude of CI impairment in 
schizotypy-spectrum groups and the impact of variables thought to moderate performance 
outcomes were examined using meta-analysis. The current study was the first 
comprehensive meta-analysis to examine CI impairment on AX-CPT and DPX tasks in 
schizotypy-spectrum psychopathology. Furthermore, the study followed best practices for 
meta-analytic review described by experts in the field (Borenstein, 2009; Higgins & 
Green, 2011). 
 A final total of 47 independent samples was included for point estimates of task 
outcomes, between-group comparisons, and within-group associations of people with 
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schizophrenia and schizoaffective disorder (chronic, first-episode, medicated, and 
unmedicated), SPD, ultra high-risk to develop schizophrenia, unaffected relatives of 
patients with schizophrenia, and schizotypy identified using psychometric methods. 
Meta-analysis results supported predicted levels of CI impairment across the schizotypy-
spectrum. As hypothesized, deficits in patients with schizophrenia were substantial and, 
unexpectedly, appeared stable across illness duration. As expected, the at-risk groups 
showed milder CI disruption compared to healthy controls than patients with 
schizophrenia. Consistent with hypotheses, disorganized and negative symptoms were 
negatively correlated with CI ability, whereas positive symptoms were unrelated. Larger 
between-group effects were found when more trials were given but, contrary to 
predictions, no other task parameters appreciably predicted or moderated outcomes.  
 Results did not differ when the trim-and-fill method was used to adjust effect size 
estimates. Further, p-curve analyses showed no evidence that symptom correlation 
findings were due solely to p-hacking. Although reporting biases can never be fully ruled 
out, they do not seem to have grossly impacted findings from this literature, which 
supports the validity of the current meta-analysis results. 
Interpretation of Results 
 When CI abilities were examined across the entire schizotypy-spectrum, the 
schizotypy group performed worse than healthy controls on most task outcomes. It is 
important to demonstrate differential patterns of impairment in psychopathology—and 
specifically, in schizophrenia—to distinguish a specific cognitive impairment from 
generalized performance deficits due to issues such as inattention and amotivation 
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(Chapman & Chapman, 1973; MacDonald & Carter, 2002). Accordingly, meta-analysis 
results revealed substantial deficits on AX and BX trials in the schizotypy-spectrum 
group that surpassed errors made on BY trials. Since AX and BX trials are thought to tap 
CI ability (MacDonald, Goghari et al., 2005) and BY trials are considered a rough 
estimator of general ability to perform the cognitive task (and hence, generalized 
impairment), these differential effect sizes are consistent with theory of a specific 
cognitive deficit in CI.  
 Negligible to small effects were found for AY accuracy, which theoretically 
reflects maintenance of the task goal. The schizotypy-spectrum group made slightly more 
AY errors than the healthy control group. It was hypothesized that the schizotypy-
spectrum group would make fewer AY errors, thus, these findings were against the 
predicted direction. AY errors were proposed to reflect intact context processing, since 
good maintenance of task goals would theoretically result in the A cue leading 
participants to prepare response (Barch & Braver, 2009). The proposed crossover 
effect—in which patients with schizophrenia would perform worse than controls on BX 
trials but better on AY trials—is theoretically compelling but has not received strong or 
consistent empirical support. 
 Only two published studies have found patients with schizophrenia to out-perform 
controls on AY trials (Barch et al., 2001; MacDonald et al., 2003), and the current meta-
analysis showed worse performance across the board in schizotypy-spectrum groups. One 
group of researchers has suggested that greater AY errors in schizophrenia may reflect 
difficulty with response inhibition (MacDonald, Goghari, et al., 2005), which could 
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explain why they did not globally out-perform healthy controls. Thus, it seems more 
likely that the BX-AY discrepancy constitutes a relative difference within the schizotypy-
spectrum psychopathology—as has often been demonstrated in the literature (e.g., Barch 
et al., 2004; Henderson et al., 2012)—rather than an absolute difference between groups. 
The fact that individuals on the schizophrenia spectrum perform worse on BX trials than 
on AY trials is indicative of a specific deficit: that is, CI is more disrupted than response 
inhibition (or other cognitive abilities tapped by the task). 
 Differentiating CI Deficits in the Schizotypy Spectrum. CI disruption is 
proposed to demonstrate diagnostic specificity, that is, to be impaired in schizophrenia 
beyond deficits that may be due to psychosis in general or to psychopathology more 
broadly (e.g., Cohen et al., 1999; MacDonald, Carter et al., 2005). To examine this 
hypothesis, we compared schizophrenia groups with a variety of other psychiatric 
patients, including those with non-schizophrenia psychosis. Disruptions in CI were more 
pronounced in patients with schizophrenia than in other psychiatric groups, indicating 
that poor CI may be specifically disrupted in schizophrenia beyond general psychiatric 
impairment. 
 It follows logically that CI deficits would be stronger in more severe 
manifestations of schizotypy-spectrum psychopathology; however only a handful of 
studies have examined this hypothesis directly. Relative to patients with schizophrenia, 
unaffected family members have shown attenuated deficits in some studies (Delawalla et 
al., 2006; MacDonald et al., 2003; Richard et al., 2013) and comparable levels of 
impairment in other studies (MacDonald, Goghari et al., 2005; Poppe et al., 2015). 
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Niendam and colleagues (2014) found no difference between ultra high-risk participants 
and first-episode patients. However, no published studies have compared individuals with 
SPD or psychometrically identified schizotypy to patients with schizophrenia. Thus, to 
test the hypothesis that patients will be more impaired than at-risk groups across a 
broader range of studies, we examined CI deficits among different schizotypy-spectrum 
subgroups according to diagnostic status and illness length using indirect comparisons. 
Indirect comparisons should be interpreted with caution, but suggested that patients with 
schizophrenia have more severe CI deficits than at-risk individuals. In terms of 
unstandardized errors, results translated to patients and at-risk groups making 
approximately 4% more BX errors than healthy controls (with a larger standardized effect 
in patients by indirect comparison due to a narrower confidence interval). It is important 
to note that individuals who have never experienced psychosis, and most of whom will 
never develop schizophrenia, are still showing significant, albeit attenuated, cognitive 
impairment. This supports theories that CI may be a precursor to schizophrenia, or—as 
some have proposed (Barch & Braver, 2009)—even a mechanism influencing its 
development. 
 To further analyze CI deficits in schizophrenia, we ran additional subgroup 
analyses with chronic patients, first-episode patients (those whose illness had lasted 1.5 
years or less), and again with the same at-risk group. Results were similar for chronic and 
first-episode groups: both showed large CI deficits compared to healthy controls. 
Although indirect comparisons should be interpreted cautiously, these results were 
supported by meta-regression analyses showing that continuous measures of illness 
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duration did not predict CI outcomes. This is partially consistent with findings from 
Richard and colleagues’ (2013) longitudinal study that showed that CI performance in 
first-episode patients was comparable between baseline and 1-year follow up for short 
delay conditions, but improved for long delay conditions. Current meta-analysis results 
(collapsed across delay conditions) suggest that CI deficits may be stable throughout the 
illness, but additional longitudinal designs examining changes from initial episodes 
across the course of the illness are required to clarify these relationships. Given that CI 
appears to be present premorbidly and at initial episodes, persists throughout the illness, 
and is not episode-limited, it may be a stable vulnerability indicator for schizophrenia 
(Nuechterlein et al., 1992), consistent with previous researchers’ theories (Barch et al., 
2003; Richard et al., 2013). 
 Current evidence of impaired context processing in schizotypy-spectrum 
psychopathology does not contradict any of Chan and Gottesman’s (2008) requirements 
for the demonstration of an endophenotypic marker. Further, based on research to date, 
CI appears to fulfill 5 of the 6 criteria for an endophenotype: CI deficits are associated 
with illness, state-independent, found in non-affected family members, can be measured 
reliably, and shows diagnostic specificity. Although the current meta-analysis did not 
address heritability, previous research has shown that DPX performance is influenced by 
Val158Met COMT polymorphism, a gene associated with risk for schizophrenia (Lopez-
Garcia et al., 2015; MacDonald, Carter, Flory, Ferrell, & Manuck, 2007). However, it 
remains unclear whether CI is more prevalent among affected versus unaffected relatives  
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of schizophrenia probands. Investigating this final criterion is an important next step if CI 
is to be established as an endophenotype. 
 In sum, poor CI is a strong candidate to be considered an endophenotypic marker 
of schizophrenia, but further research is required. If CI were shown to be an 
endophenotype, it would allow researchers to quickly and non-intrusively identify those 
purportedly at-risk to develop schizophrenia. This could aid in the identification of 
individuals for prophylactic intervention and would open the door for research 
investigating risk and protective variables that may be implicated in cognitive ability and 
development of schizophrenia-spectrum disorders. 
 CI and Schizotypy Symptom Dimensions. The schizotypy spectrum is 
multidimensional, with different symptom dimensions showing differential patterns of 
cognitive impairment; thus, outcomes were examined separately for each symptom 
dimension. Within the schizophrenia group, disorganized and negative symptoms showed 
inverse correlations with CI, whereas positive symptoms were unassociated. Correlations 
between CI ability and the disorganized symptoms were smaller than expected. This may, 
in part, reflect that assessment of CI across symptom dimensions has not been a primary 
goal of most studies. Much of the literature on the topic includes correlations that were 
run in mixed symptom patient groups with varying levels of each symptom type, using 
conceptualizations driven largely by measures rather than by theory. We propose that 
future studies should be directly designed to assess symptom correlations with CI, 
beginning with a strong theoretical conceptualization of each symptom dimension, valid 
operationalization and measurement of these symptoms, recruitment of schizotypy-
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spectrum groups that have strong representation of each symptom dimension, and 
examination of these symptom-CI relationships in an adequately powered sample. 
 Despite the shortcomings of the literature on multidimensional expression of CI in 
schizotypic psychopathology, the current findings of disorganized and negative symptom 
associations with CI indicate that these relationships are robust. These differential 
symptom correlations lend support to research describing distinct cognitive versus 
emotional pathways for schizophrenia (e.g., Myin-Germeys et al., 2002) and are 
consistent with neuroscience theories and reviews connecting neurocognitive impairment 
with disorganized and negative symptoms (Barch et al., 2001; Cohen et al., 1999; 
Goghari et al., 2010; Yoon et al., 2008). 
 CI associations in the literature have been particularly prominent for disorganized 
symptoms. For example, MacDonald, Carter, and colleagues (2005) showed that within 
patients with schizophrenia, diminished prefrontal activity following B-cues was 
associated with greater BX errors, as well as greater disorganized symptoms (showing 
stronger associations than with negative or positive symptoms). The authors concluded 
that cognitive disorganization in schizophrenia is related to impairment in the top-down 
ability to represent and maintain appropriate context of the B-cue, which should cue 
participants not to respond to any letter that follows, even the letter X (MacDonald, 
Carter et al., 2005). Furthermore, Yoon and colleagues (2008) found that disorganized 
symptoms were related to decreased activity in the DLPFC and diminished connectivity 
to a broader neural network implicated in cognitive control. The authors theorized that 
altered DLPFC function and connectivity may lead to poor top-down control underlying 
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impaired task performance and behavioral symptoms of disorganization (Yoon, et al., 
2008). 
 Early phenomenologists (e.g., Conrad, 1958; Matussek, 1952) proposed 
connections between positive symptoms and the dis-integration of an individual from 
their environmental context. These purported associations described in the 
phenomenological literature were not supported by the results of the present meta-
analysis: positive symptoms showed negligible correlations with CI. This seems to 
indicate that the cognitive-perceptual disruptions associated with positive symptoms of 
schizophrenia may not involve the same processes as CI assessed with cognitive tasks 
such as the AX-CPT and DPX. 
 There is further debate on the extent to which neural mechanisms of CI are 
broadly distributed versus localized in the specific regions of the brain, such as the 
DLPFC (and its interactions with other regions). Overall, there are gaps in our 
understanding of the integration of “context” across different levels of processing. 
Whether impairments found on neurocognitive tasks are synonymous with behavioral 
manifestations of poorly integrated context remains an empirical question. Longitudinal 
studies integrating CI measurements across multiple domains should help reveal 
confluence or discontinuity of the processes proposed to underlie neural, cognitive, 
perceptual, and behavioral outcomes, and could help scientists in different fields of 
research refine the language they use when describing these phenomena. 
 Factors Moderating CI Deficits. Effects of different task parameters were 
examined using moderation and meta-regression analyses. When comparing schizotypy-
 
 
 66 
spectrum participants with healthy controls, categorical measures of task type and cue 
duration did not moderate BX accuracy or d’context effects, nor did categorical or 
continuous measures of cue-probe interval duration. This is surprising given theories that 
CI ability should deteriorate more for schizotypy-spectrum groups than for controls 
across longer delay periods (Barch & Braver, 2009). This may suggest that any 
performance deficits due to poor maintenance of context do not reliably manifest above 
and beyond those due to initial poor representation of context, at least across the delay 
periods used in these tasks (the maximum delay period in the included studies was 
9500ms). Authors aiming to investigate the possible distinction between representation 
and maintenance of context may want to consider using a cue-probe interval of longer 
than one second in the long delay condition because delays shorter than one second did 
not affect outcomes across studies; it is still possible that context maintenance difficulties 
are present and would only be revealed using longer delay periods. 
 Because the use of novel dot patterns makes cue maintenance more challenging in 
the DPX compared to the AX-CPT (Barch et al., 2009), it is logical that the DPX may be 
more sensitive to subtle deficits in at-risk individuals by avoiding possible ceiling effects. 
Since use of DPX versus AX-CPT was not distributed evenly across studies with 
different diagnostic groups, task type could only be assessed as a moderator in 
schizophrenia groups versus healthy control groups. Task type did not moderate 
outcomes; however, at-risk groups were not included in these comparisons. Therefore 
these results do not address whether the DPX may find larger effects in at-risk groups  
 
 
 
 67 
than the AX-CPT. Further study of the DPX with at-risk groups is needed to examine 
whether it may be a more appropriate task to measure CI in less impaired individuals. 
Overall, CI deficits were generally robust across task type and various timing 
parameters, but total number of trials did predict the size of between-group differences 
with more trials predicting stronger d’context effects. Based on regression line 
predictions, it is therefore recommended that researchers use at least 250 trials to capture 
large effects.  
Limitations and Recommendations for Future Research 
 The current study was limited according to gaps in the literature. The presented 
meta-analysis ignored the possibly confounding factor of medication status. There were 
not enough studies examining medicated, first-episode patients (k=3 studies) to provide 
adequate power for subgroup analysis. Most patients with chronic schizophrenia included 
in this literature were medicated and in non-acute phases of the illness. More research is 
needed that examines the impact of medication and distinguishes chronicity from 
medication status. Only a few studies have directly approached these issues (Barch et al., 
2003; Lesh et al., 2015; Woodward, 2016, personal communication). Using a cross-
sectional design, Lesh and colleagues (2015) found that unmedicated first-episode 
patients had lower d’context scores than medicated first-episode patients, at the level of a 
medium effect size (Hedges’ g=-0.67). In preliminary cross-sectional results from Neil 
Woodward, Ph.D., at the time of personal communication, medicated first-episode 
patients (n=15) had lower d’context scores than chronic medicated patients (n=35) at the 
level of a small effect size (Hedges’ g=-0.19). Finally, Barch and colleagues’ (2003) 
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longitudinal design showed that first-episode patients had comparable CI performance 
when they were medication-naïve at baseline and following antipsychotic treatment 4 
weeks later. Overall, it is still unclear how medication status may impact CI ability or 
whether it might interact with illness length to affect cognitive outcomes. Research 
directly comparing medicated and unmedicated chronic schizophrenia patients with 
medicated and medication-naïve first-episode patients could help clarify these 
relationships, including research differentiating among various types of unmedicated 
patients: never medicated, currently medication non-compliant, individuals who do not 
need or want medication, etc. 
 Cognitive impairment often predicts functional outcome in schizophrenia, thus, it 
would be beneficial to understand how CI impairments may influence functioning in 
social, community, occupational, as well as related domains such as quality of life. These 
relationships could not be assessed in the current meta-analysis because few studies 
looked at associations with functional outcome. Those that did reported some significant 
correlations of CI with global and community functioning and with performance-based 
skills in patients with schizophrenia (Gold et al., 2012; Richard et al., 2013; Sheffield et 
al., 2014; Stratta et al., 2000; Todd et al., 2014), with effect sizes ranging from negligible 
to large. Especially given the possible applications to intervention, assessing functional 
outcome in conjunction with CI is an area in need of further study. 
 As described earlier, treating schizotypy-spectrum psychopathology as 
unidimensional is problematic because it can mask true effects that are differentially 
expressed across symptom dimensions. Use of unidimensional models, inconsistent or 
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invalid symptom measurements, and unequal representation of symptom dimensions in a 
sample could limit the validity of findings and may account for some of the significant 
heterogeneity among studies. Therefore, theory-driven, multidimensional assessments of 
CI deficits in schizotypy are recommended. 
 Some of the most prolific researchers in this field frequently re-used participants 
across multiple published studies. This is problematic (and contrary to the American 
Psychological Association’s piecemeal publication practices), especially when sample 
sizes are often very small; for example, there are multiple instances in which data has 
previously been reported for over half of the published sample. Further, the overlap in 
samples is not always clearly described in the main text—or sometimes at all. Ethical 
issues in publishing aside, this practice is problematic because it inflates the perceived 
reliability of findings from individual research groups in qualitative reviews and hinders 
synthesis of data in quantitative reviews. If researchers insist on re-using participant data 
across publications, it is recommended that they state this clearly in the main text of the 
article and provide subset analyses in the group of new participants so readers can 
distinguish what data is novel. 
 Finally, while interpreting results from the current meta-analysis, it is important to 
keep in mind that significant heterogeneity among studies was present in many of the 
analyses. The diagnostic and parametric variables used to predict CI outcomes did not 
fully account for variability in task performance, suggesting that there is still much to 
learn about what impacts CI ability. I put forth several hypotheses about variables that 
may have contributed to heterogeneity, such as unexamined medication effects and 
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poorly measured variation in symptom expression, but it cannot be ruled out that other 
confounding factors (e.g., educational background, intelligence quotient, socioeconomic 
status, or motivation) are partially accounting for results. 
Summary and Conclusions 
 CI impairment appears to be a component of schizotypy-spectrum 
psychopathology that is present across the schizotypy spectrum and in premorbid, active, 
and residual phases of schizophrenia, as opposed to simply being a disease marker or a 
consequence or sequelae of the many catastrophic effects of schizophrenia. CI is 
associated with disorganized and negative symptoms of schizophrenia and appears stable 
throughout the course of illness. These results support theories that CI may be a stable 
vulnerability factor for schizophrenia. Further study is still warranted to confirm if CI is 
indeed an endophenotype, to understand the neural mechanisms underlying CI, to clarify 
CI’s role in the expression of schizotypy spectrum symptoms and impairment, and to 
determine the extent to which CI impairment can be remediated by interventions. 
 To summarize, recommendations for future research include focus on longitudinal 
studies; inclusion of at-risk samples, particularly SPD, prodromal individuals or those at 
ultra high-risk to develop schizophrenia, and psychometrically identified schizotypy; 
research designed to differentiate effects of antipsychotic medication and duration of 
illness in or number of illness episodes; research specifically designed to measure 
differential associations of symptom dimensions with CI; and examination of the 
relationship between CI and functional outcome. Researchers wishing to assess goal 
maintenance with the AX-CPT or DPX may find it beneficial to use long delay periods of 
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ten seconds or longer. Administration of at least 250 trials is suggested in order to detect 
large effects. 
 The implication of CI in the development and expression of schizotypy-spectrum 
psychopathology has strong roots in phenomenological, neural, and cognitive 
neuroscience theories. Foundational research in this area has established a strong basis 
for CI impairment that is linked to cognitive and neurological outcomes. Important next 
steps include achieving a more nuanced understanding of the ways specific factors may 
interact to influence CI ability in schizotypy and integrating this research across other 
fields of study for a more holistic understanding of the mechanisms at play.  
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APPENDIX A 
 
TABLES AND FIGURES 
 
 
Table 1  
Literature Search and Screening Criteria 
Literature Search Terms Title/Abstract Screening Criteria Full-Text Screening Criteria 
• AX-CPT and schizo*; dot pattern 
expectancy task and schizo*; DPX 
and schizo*; CNTRACS and 
schizo*; context* integration and 
schizo*; context* processing and 
schizo*; context* and ultra high risk 
• AX-CPT and prodromal; dot pattern 
expectancy task and prodromal; 
DPX and prodromal; CNTRACS 
• If the title was completely 
irrelevant, I did not read abstract 
• If the title mentioned any neural, 
cognitive, or behavioral topic and 
schizotypy or another psychiatric 
disorder in which researchers use 
patients with schizophrenia as a 
psychiatric comparison group 
(e.g., mood disorder, other 
• For each article, I electronically 
searched for “CPT,” “DPX,” 
“CNTRACS,” and “supplem*.” I used 
additional search functions for other 
article types, as described below. 
• I first skimmed the article to determine 
whether it was empirical. If the article 
did not appear to be an empirical article 
or did not have the structure of a 
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and prodromal; context* integration 
and prodromal; context* processing 
and prodromal 
• AX-CPT and high risk; dot pattern 
expectancy task and high risk; DPX 
and high risk; CNTRACS and high 
risk; context* integration and high 
risk; context* processing and high 
risk 
• AX-CPT and psychosis; dot pattern 
expectancy task and psychosis; DPX 
and psychosis; CNTRACS and 
psychosis; context* integration and 
psychosis; context* processing and 
psychosis 
psychotic disorder, personality 
disorders), I read the abstract. 
• If the abstract mentioned using 
the CNTRACS tasks or broadly 
mentioned neuropsychological or 
cognitive testing without listing 
which measures, I flagged it for 
full-text screening. 
• If the title and/or abstract was 
written in English or French, I 
screened it as-is. If the title and 
or/abstract was written in another 
language, I used Google 
translation to screen for 
appropriateness. 
traditional article, I skimmed the entire 
full-text to make sure the article did not 
contain new empirical data (e.g., a 
review article with a brief empirical 
section). If the article was not empirical, 
I also used the search function to search 
for “method*.” 
• If the article was empirical, I read the 
methods section to determine whether 
they used CNTRACS tasks (AX-CPT or 
DPX with 10+ total trials and 60+% AX 
trials). I also skimmed the structure of 
the article to look for multiple 
experiments within the article.  
• If the article did use the AX-CPT and/or 
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DPX, I then read the methods section to 
determine whether they used a 
schizotypy measure or diagnosis. If the 
article used one of the CNTRACS tasks 
but did not include a measure of 
schizotypy, I also searched for 
“schizo*.” 
• I read supplemental materials when 
available, to look for relevant empirical 
data 
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Table 2  
Summary of Demographic Information Across all Included Studies. 
 
 
First-Episode, 
Unmedicated 
First-Episode, 
Medicated 
Chronic 
Schizophrenia  
At-Risk  
Group 
Healthy 
Controls 
Psychiatric 
Controls 
Age: M (SD) 
23.51 (1.60) 
[k=6, n=176] 
20.37 (0.59) 
[k=4, n=112] 
34.83 (5.00) 
[k=30, n=2096] 
33.63 (9.77) 
[k=14, n=442] 
30.42 (6.65) 
[k=41, n=2674] 
33.37 (6.47) 
[k=12, n=447] 
Education 
(years): M (SD) 
12.68 (0.43) 
[k=6, n=176] 
12.47 (0.35) 
[k=4, n=112] 
11.83 (1.69) 
[k=24, n=1553] 
13.61 (1.17) 
[k=10, n=347] 
12.93 (2.66) 
[k=34, n=2201] 
13.76 (1.30) 
[k=7, n=156] 
Length of illness 
(years): M (SD) 
0.58 
[k=1, n=22] 
0.59 (0.21) 
[k=2, n=38] 
8.06 (4.36) 
[k=12, n=864] 
-- -- -- 
% Female 
29.16% 
[k=6, n=176] 
26.84% 
[k=4, n=112] 
35.81% 
[k=30, n=2096] 
49.94% 
[k=14, n=442] 
48.96% 
[k=40, n=2654] 
53.97% 
[k=12, n=447] 
% White -- 
0% 
[k=1, n=15] 
52.00% 
[k=13, n=676] 
54.06% 
[k=7, n=227] 
60.67% 
[k=15, n=1181] 
69.86% 
[k=3, n=259] 
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% Black -- 
80.00% 
[k=1, n=15] 
43.67% 
[k=8, n=798] 
43.42% 
[k=3, n=108] 
27.98% 
[k=7, n=527] 
21.15% 
[k=4, n=284] 
% Latino -- 
0% 
[k=1, n=15] 
28.00% 
[k=5, n=243] 
34.92% 
[k=4, n=126] 
53.77% 
[k=4, n=160] 
2.70% 
[k=2, n=37] 
% Asian -- -- 
50.75% 
[k=4, n=1180] 
8.33% 
[k=3, n=108] 
69.70% 
[k=3, n=1066] 
3.3% 
[k=2, n=240] 
% Other 
Race/Ethnicity 
-- 
20.00% 
[k=1, n=15] 
7.22% 
[k=3, n=611] 
2.60% 
[k=2, n=84] 
7.10% 
[k=3, n=385] 
4.23% 
[k=3, n=259] 
% Medicated 
0% 
[k=6, n=176] 
78.22% 
[k=3, n=61] 
98.05% 
[k=18, n=1126] 
-- -- -- 
       
k=number of studies providing information. n=number of participants providing information. Note that for categorical 
variables, k and n do not correspond to the total percentage in that category for the entire group, but rather to the percentage 
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only within the subset of studies providing data for that category. See Results section in text for a description of group 
composition. 
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Table 3  
Primary Analyses: Random Effects Model of Schizotypy-Spectrum Groups versus Healthy Control Groups for Short Delay.  
 
 Hedges’ g Lower CI Upper CI p-value Q df(Q) p-value I2 Tau2 
Short AXErr 0.59 0.41 0.77 1.22E
-10 51.59 20 1.31E-4 61.23 0.095 
Short AYErr 0.33 0.19 0.46 1.94E
-6 33.59 21 0.040 37.48 0.036 
Short BXErr 0.61 0.50 0.71 0 22.22 21 0.39 5.49 0.0035 
Short BYErr 0.32 0.14 0.50 6.48E
-4 51.73 19 7.26E-5 63.27 0.099 
Short AXRT 0.50 0.30 0.69 4.24E
-7 36.42 16 0.0025 56.07 0.083 
Short AYRT 0.48 0.29 0.66 2.53E
-7 41.18 17 8.79E-4 58.72 0.080 
Short BXRT 0.62 0.44 0.81 6.71E
-11 43.12 17 4.61E-4 60.57 0.088 
Short BYRT 0.68 0.50 0.85 5.15E
-14 30.25 16 0.017 47.11 0.060 
Short d’context -0.84 -1.06 -0.63 1.64E-14 96.00 23 6.84E-11 76.04 0.20 
  
Err=errors. RT=reaction time. Hedges’ g: medium effects in bold, large effects in bold italics.  
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Table 4  
Primary Analyses: Random Effects Model of Schizotypy-Spectrum Groups versus Healthy Control Groups for Long Delay. 
  
 Hedges’ g Lower CI Upper CI p-value Q df(Q) p-value I2 Tau2 
Long AXErr 0.55 0.42 0.68 0 38.35 24 0.032 37.43 0.033 
Long AYErr 0.00 -0.17 0.18 0.97 82.07 25 5.38E
-8 69.54 0.12 
Long BXErr 0.59 0.47 0.72 0 44.53 27 0.018 39.36 0.037 
Long BYErr 0.19 -0.01 0.39 0.06 100.39 24 2.57E
-11 76.09 0.17 
Long AXRT 0.66 0.46 0.85 2.29E
-11 62.61 21 5.11E-6 66.46 0.12 
Long AYRT 0.47 0.31 0.64 1.77E
-8 47.08 21 9.15E-4 55.40 0.072 
Long BXRT 0.49 0.33 0.65 3.67E
-9 45.00 21 0.0017 53.34 0.066 
Long BYRT 0.58 0.41 0.74 5.67E
-12 41.21 20 0.0035 51.46 0.062 
Long d’context -0.76 -0.91 -0.61 0 67.11 27 2.87E-5 59.77 0.08 
 
Err=errors. RT=reaction time. Hedges’ g: medium effects in bold.   
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Table 5  
Primary Analyses: Random Effects Model of Schizophrenia Groups versus Psychiatric Comparison Groups 
 
Study Name Hedges’ g Lower CI Upper CI p-value Q df(Q) p-value I2 Tau2 
AYErr Total 0.02 -0.12 0.15 0.81 1.95 5 0.86 0.00 0.00 
Richard et al., 2013 -0.16 -0.54 0.21 0.40      
Woodward, 2016 -0.15 -0.85 0.54 0.66      
Barch et al., 2003 -0.10 -0.55 0.35 0.67      
Holmes et al., 2005 -0.05 -0.97 0.87 0.91      
Woodward, 2016 -0.01 -0.81 0.79 0.98      
Reilly et al., 2017 0.08 -0.09 0.25 0.34      
BXErr Total 0.33 0.19 0.46 1.65E
-6 3.30 7 0.86 0.00 0.00 
Woodward, 2016 0.00 -0.69 0.69 1.00      
Richard et al., 2013 0.26 -0.12 0.63 0.18      
Woodward, 2016 0.29 -0.51 1.10 0.471      
Ceccherini-Nelli et al., 2007 0.33 -0.51 1.17 0.44      
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Reilly et al., 2017 0.33 0.16 0.50 1.04E-4      
Barch et al., 2003 0.34 -0.12 0.79 0.14      
Holmes et al., 2005 0.56 -0.37 1.50 0.24      
Ceccherini-Nelli et al., 2007 0.94 0.10 1.78 0.028      
d’context Total -0.73 -1.07 -0.40 1.73E
-5 36.38 9 3.39E-5 75.26 0.19 
Cohen et al., 1999 -1.87 -2.42 -1.31 4.17E-11      
Holmes et al., 2005 -1.55 -2.61 -0.50 0.0039      
Ceccherini-Nelli et al., 2007 -1.29 -2.17 -0.41 0.0039      
Thoma & Daum, 2008 -0.90 -1.50 -0.30 0.0035      
Ceccherini-Nelli et al., 2007 -0.69 -1.55 0.17 0.11      
Woodward, 2016 -0.41 -1.10 0.29 0.25      
Reilly et al., 2017 -0.37 -0.54 -0.20 1.55E-5      
Barch et al., 2003 -0.36 -0.81 0.09 0.12      
Richard et al., 2013 -0.35 -0.73 0.03 0.072      
Woodward, 2016 -0.13 -0.93 0.67 0.75      
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Err=errors. Total meta-analytic effects for each outcome in gray. Hedges’ g: medium effects in bold, large effects in bold 
italics. 
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Table 6  
Subgroup Analyses: Random Effects Model of Diagnostic Groups for AY Errors. 
 
Subgroup Study Name Hedges’ g Lower CI Upper CI p-value 
Schz Total  0.29 0.16 0.42 1.79E-5 
Schz vs. HC Todd et al., 2014 -0.46 -0.89 -0.033 0.035 
Schz vs. HC Barch et al., 2001 -0.34 -1.09 0.41 0.37 
Schz vs. HC Chung et al., 2011 -0.19 -0.67 0.30 0.45 
Schz vs. HC Yoon et al., 2014 -0.07 -0.81 0.66 0.85 
Schz vs. HC Stratta et al., 2000 -0.05 -0.66 0.56 0.87 
Schz vs. HC MacDonald, 2002 0.00 -0.89 0.89 1.00 
Schz vs. HC MacDonald, 2002 0.00 -0.93 0.93 1.00 
Schz vs. HC Richard et al., 2013 0.03 -0.35 0.42 0.87 
Schz vs. HC Barch et al., 2008 0.03 -0.38 0.44 0.87 
Schz vs. HC Barch et al., 2003 0.11 -0.25 0.47 0.54 
Schz vs. HC Lopez-Garcia et al., 2016 0.12 -0.65 0.90 0.75 
 
 
 
1
0
1
 
 
Schz vs. HC Becker, 2012 0.13 -0.33 0.59 0.58 
Schz vs. HC Lesh et al., 2015 0.17 -0.62 0.95 0.68 
Schz vs. HC Jones et al., 2010  0.17 -0.23 0.57 0.41 
Schz vs. HC Yoon et al., 2012 0.17 -0.21 0.56 0.38 
Schz vs. HC Lesh et al., 2015 0.21 -0.39 0.81 0.49 
Schz vs. HC Sheffield et al., 2015 0.30 -0.10 0.69 0.14 
Schz vs. HC Woodward, 2016 0.37 -0.30 1.04 0.28 
Schz vs. HC Reilly et al., 2017 0.43 0.28 0.58 1.66E-8 
Schz vs. HC Woodward, 2016 0.49 -0.06 1.04 0.081 
Schz vs. HC Lopez-Garcia et al., 2015 0.53 0.06 1.00 0.027 
Schz vs. HC Sheffield et al., 2014 0.53 0.17 0.90 0.0045 
Schz vs. HC Braver et al., 1999 0.55 -0.14 1.24 0.119 
Schz vs. HC Edwards et al., 2010 0.61 -0.06 1.27 0.077 
Schz vs. HC Zhang et al., 2015 0.70 0.57 0.84 0 
Schz vs. HC Gold et al., 2012; Henderson et al., 2012 0.71 0.47 0.95 1.13E-8 
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Schz vs. HC Sheffield et al., 2014 0.71 0.34 1.08 1.81E-4 
Schz vs. HC MacDonald & Carter, 2003 0.79 0.11 1.47 0.024 
Schz vs. HC Holmes et al., 2005 0.81 -0.17 1.78 0.10 
At-risk Total  -0.04 -0.24 0.15 0.66 
At-risk vs. HC MacDonald, 2002 -0.39 -1.25 0.48 0.38 
At-risk vs. HC Barch et al., 2004 -0.30 -0.80 0.20 0.24 
At-risk vs. HC MacDonald, 2002 -0.22 -1.18 0.73 0.65 
At-risk vs. HC Lopez-Garcia et al., 2015 -0.14 -0.66 0.37 0.59 
At-risk vs. HC McClure et al., 2008 -0.08 -0.47 0.30 0.67 
At-risk vs. HC Sloat, 2007 0.08 -0.42 0.58 0.75 
At-risk vs. HC Lopez-Garcia et al., 2016 0.20 -0.56 0.97 0.60 
At-risk vs. HC Richard et al., 2013 0.25 -0.21 0.72 0.28 
 
Schz=schizophrenia. HC=healthy controls. Total meta-analytic effects for each subgroup in gray. Hedges’ g: medium effects in 
bold, large effects in bold italics.  
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Table 6, Continued 
 
Question Being Answered Model Q df(Q) p-value I2 Tau2 
 Fixed effect      
-Is there significant variance in effects within 
schizophrenia groups? 
Schizophrenia 75.72 28 2.84E-6 63.02 0.065 
-Is there significant variance in effects within at-
risk groups? 
At-Risk 4.14 7 0.76 0.00 0.00 
-Does the grouping variable explain significant 
variance in the model? 
Total within 79.86 35 2.30E-5   
 Mixed effects      
-Does the effect differ between subgroups? Total between 7.82 1 0.0052   
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Table 7 
Subgroup Analyses: Random Effects Model of Diagnostic Groups for BX Errors. 
 
Subgroup Study Name Hedges’ g Lower CI Upper CI p-value 
Schz Total  0.71 0.61 0.80 0 
Schz vs. HC Lopez-Garcia et al., 2016 -0.04 -0.81 0.73 0.92 
Schz vs. HC Holmes et al., 2005 0.29 -0.65 1.23 0.54 
Schz vs. HC Sheffield et al., 2014 0.46 0.09 0.83 0.014 
Schz vs. HC Woodward, 2016 0.47 -0.20 1.14 0.17 
Schz vs. HC MacDonald & Carter, 2003 0.50 -0.17 1.17 0.14 
Schz vs. HC Reilly et al., 2017 0.50 0.35 0.66 4.92E-11 
Schz vs. HC Barch et al., 2008 0.52 0.10 0.94 0.015 
Schz vs. HC Jones et al., 2010 0.54 0.14 0.95 0.0088 
Schz vs. HC Ceccherini-Nelli et al., 2007 0.56 -0.12 1.24 0.11 
Schz vs. HC Woodward, 2016 0.56 0.0066 1.11 0.047 
Schz vs. HC Chung et al., 2011 0.58 0.092 1.07 0.020 
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Schz vs. HC Lesh et al., 2015 0.58 -0.024 1.19 0.060 
Schz vs. HC Richard et al., 2013 0.59 0.19 0.99 0.0035 
Schz vs. HC Edwards et al., 2010 0.63 -0.041 1.30 0.066 
Schz vs. HC Barch et al., 2001 0.64 -0.13 1.40 0.10 
Schz vs. HC Yoon et al., 2010 0.65 0.26 1.05 0.0012 
Schz vs. HC Sheffield et al., 2014 0.68 0.31 1.06 3.02E-4 
Schz vs. HC Todd et al., 2014 0.70 0.27 1.14 0.0015 
Schz vs. HC Sheffield et al., 2015 0.71 0.31 1.11 5.40E-4 
Schz vs. HC Gold et al., 2012; Henderson et al., 2012 0.74 0.50 0.99 2.21E-9 
Schz vs. HC MacDonald, 2002 0.75 -0.17 1.68 0.11 
Schz vs. HC Lesh et al., 2015 0.76 -0.055 1.57 0.07 
Schz vs. HC Zhang et al., 2015 0.79 0.66 0.93 0 
Schz vs. HC Perlstein et al., 2003 0.85 0.13 1.57 0.020 
Schz vs. HC MacDonald, 2002 0.88 -0.10 1.86 0.079 
Schz vs. HC Barch et al., 2003 0.90 0.52 1.28 2.88E-6 
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Schz vs. HC Braver et al., 1999 0.93 0.22 1.65 0.01 
Schz vs. HC Fornito et al., 2011 1.04 0.45 1.64 6.07E-4 
Schz vs. HC Yoon et al., 2014 1.10 0.31 1.89 0.0066 
Schz vs. HC Stratta et al., 2000 1.14 0.49 1.80 6.53E-4 
Schz vs. HC Becker, 2012 1.21 0.71 1.70 2.04E-6 
Schz vs. HC Lopez-Garcia, 2015 1.84 1.29 2.39 5.60E-11 
At-risk Total  0.36 0.15 0.58 0.0011 
At-risk vs. HC Richard et al., 2013 -0.08 -0.54 0.38 0.74 
At-risk vs. HC Sloat, 2007 -0.06 -0.56 0.44 0.82 
At-risk vs. HC Lopez-Garcia, 2016 0.20 -0.56 0.97 0.60 
At-risk vs. HC Paavola, 2013 0.35 -0.04 0.73 0.078 
At-risk vs. HC MacDonald, 2002 0.47 -0.40 1.33 0.29 
At-risk vs. HC Barch et al., 2004 0.53 0.02 1.04 0.043 
At-risk vs. HC MacDonald, 2002 0.53 -0.44 1.50 0.29 
At-risk vs. HC McClure et al., 2008 0.58 0.19 0.98 0.0038 
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At-risk vs. HC Lopez-Garcia, 2015 0.87 0.34 1.41 0.0015 
 
Schz=schizophrenia. HC=healthy controls. Total meta-analytic effects for each subgroup in gray. Hedges’ g: medium effects 
 
in bold, large effects in bold italics, very large effects in underlined bold italics. 
 
Table 7, Continued 
 
Question Being Answered Model Q df(Q) p-value I2 Tau2 
 Fixed effect      
-Is there significant variance in effects within 
schizophrenia groups? 
Schizophrenia 43.80 31 0.063 29.22 0.02 
-Is there significant variance in effects within 
at-risk groups? 
At-Risk 11.64 8 0.17 31.29 0.033 
-Does the grouping variable explain 
significant variance in the model? 
Total within 55.44 39 0.042   
 Mixed effects      
-Does the effect differ between subgroups? Total between 8.14 1 0.0043 8.14 1 
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Table 8  
 
Subgroup Analyses: Random Effects Model of Diagnostic Groups for d’context 
 
Subgroup Study Name Hedges’ g Lower CI Upper CI p-value 
Schz Total  -0.94 -1.08 -0.80 0 
Schz vs. HC Sheffield et al., 2014 -1.83 -2.26 -1.40 0 
Schz vs. HC Cohen et al., 1999 -1.47 -1.96 -0.97 5.25E-9 
Schz vs. HC Todd et al., 2014 -1.39 -1.86 -0.92 6.00E-9 
Schz vs. HC MacDonald, 2002 -1.37 -2.41 -0.32 0.010 
Schz vs. HC Holmes et al., 2005 -1.36 -2.40 -0.31 0.011 
Schz vs. HC Lesh et al., 2015 -1.29 -2.15 -0.44 0.0029 
Schz vs. HC Ceccherini-Nelli et al., 2007 -1.27 -2.01 -0.54 6.67E-4 
Schz vs. HC MacDonald, 2002 -1.25 -2.23 -0.28 0.012 
Schz vs. HC Braver et al., 1999 -1.20 -1.94 -0.47 0.0014 
Schz vs. HC Merrill et al., 2017 -1.20 -1.77 -0.62 4.33E-5 
Schz vs. HC Barch et al., 2003 -1.18 -1.57 -0.79 2.96E-9 
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Schz vs. HC Dias et al., 2013 -1.08 -1.83 -0.33 0.0050 
Schz vs. HC Gold et al., 2012; Henderson et al, 2012 -1.03 -1.28 -0.78 1.11E-15 
Schz vs. HC Woodward, 2016 -1.03 -1.73 -0.32 0.0043 
Schz vs. HC Chung et al., 2011 -1.02 -1.53 -0.51 8.98E-5 
Schz vs. HC Poppe et al., 2015 -0.98 -1.60 -0.36 0.0020 
Schz vs. HC Sheffield et al., 2014 -0.83 -1.20 -0.45 1.60E-5 
Schz vs. HC Barch et al., 2001 -0.80 -1.58 -0.026 0.043 
Schz vs. HC Barch et al., 2008 -0.71 -1.13 -0.29 9.81E-4 
Schz vs. HC Richard et al., 2013 -0.69 -1.09 -0.29 6.71E-4 
Schz vs. HC Poppe et al., 2016 -0.66 -1.06 -0.27 9.95E-4 
Schz vs. HC Reilly et al., 2017 -0.66 -0.82 -0.51 0 
Schz vs. HC Delawalla et al., 2006 -0.65 -1.15 -0.16 0.0098 
Schz vs. HC Woodward, 2016 -0.59 -1.14 -0.039 0.036 
Schz vs. HC Lesh et al., 2015 -0.58 -1.19 0.027 0.061 
Schz vs. HC Jones et al., 2010 -0.51 -0.91 -0.10 0.014 
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Schz vs. HC Thoma & Daum, 2008 -0.45 -1.05 0.14 0.13 
Schz vs. HC MacDonald & Carter, 2003 -0.20 -0.86 0.46 0.55 
At-risk Total  -0.40 -0.56 -0.23 3.70E-6 
At-risk vs. HC McClure et al., 2008 -0.72 -1.12 -0.32 4.29E-4 
At-risk vs. HC MacDonald, 2002 -0.70 -1.69 0.29 0.16 
At-risk vs. HC Poppe et al., 2015 -0.49 -1.01 0.034 0.067 
At-risk vs. HC Barch et al., 2004 -0.40 -0.91 0.10 0.12 
At-risk vs. HC Richard et al., 2013 -0.37 -0.84 0.094 0.12 
At-risk vs. HC MacDonald, 2002 -0.34 -1.21 0.52 0.44 
At-risk vs. HC Delawalla et al., 2008 -0.29 -0.71 0.12 0.16 
At-risk vs. HC Sloat, 2007 -0.28 -0.79 0.22 0.27 
At-risk vs. HC Delawalla et al., 2006 -0.09 -0.55 0.37 0.70 
 
Schz=schizophrenia. HC=healthy controls. Total meta-analytic effects for each subgroup in gray. Hedges’ g: medium effects in 
bold, large effects in bold italics, very large effects in underlined bold italics.  
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Table 8, Continued 
 
Question Being Answered Model Q df(Q) p-value I2 Tau2 
 Fixed effect      
-Is there significant variance in effects 
within schizophrenia groups? 
Schizophrenia 61.62 27 1.61E-4 56.18 0.068 
-Is there significant variance in effects 
within at-risk groups? 
At-Risk 5.12 8 0.74 0 0 
-Does the grouping variable explain 
significant variance in the model? 
Total within 66.74 35 0.00097   
 Mixed effects      
-Does the effect differ between subgroups? Total between 23.45 1 1.30E-6   
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Table 9 
Subgroup Analyses: Random Effects Model of Diagnostic Groups by Illness Length for AY Errors. 
 
Subgroup Study Name Hedges’ g Lower CI Upper CI p-value 
Chronic Total  0.34 0.19 0.50 0.00 
Chronic vs. HC Todd et al., 2014 -0.46 -0.89 -0.033 0.035 
Chronic vs. HC Chung et al., 2011 -0.19 -0.67 0.30 0.45 
Chronic vs. HC Stratta et al., 2000 -0.05 -0.66 0.56 0.87 
Chronic vs. HC MacDonald, 2002 0.00 -0.89 0.89 1.00 
Chronic vs. HC MacDonald, 2002 0.00 -0.93 0.93 1.00 
Chronic vs. HC Barch et al., 2008 0.03 -0.38 0.44 0.87 
Chronic vs. HC Lopez-Garcia et al., 2016 0.12 -0.65 0.90 0.75 
Chronic vs. HC Becker, 2012 0.13 -0.33 0.59 0.58 
Chronic vs. HC Jones et al., 2010 0.17 -0.23 0.57 0.41 
Chronic vs. HC Sheffield et al., 2015 0.30 -0.10 0.69 0.14 
Chronic vs. HC Reilly et al., 2017 0.43 0.28 0.58 1.66E-8 
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Chronic vs. HC Woodward, 2016 0.49 -0.061 1.04 0.081 
Chronic vs. HC Lopez-Garcia et al., 2015 0.53 0.061 1.00 0.027 
Chronic vs. HC Sheffield et al., 2014 0.53 0.17 0.90 0.0045 
Chronic vs. HC Edwards et al., 2010 0.61 -0.065 1.27 0.077 
Chronic vs. HC Zhang et al., 2015 0.70 0.57 0.84 0.00 
Chronic vs. HC Gold et al., 2012; Henderson et al., 2012 0.71 0.47 0.95 1.13E-8 
Chronic vs. HC Sheffield et al., 2014 0.71 0.34 1.08 1.81E-4 
Chronic vs. HC MacDonald & Carter, 2003 0.79 0.11 1.47 0.024 
Chronic vs. HC Holmes et al., 2005 0.81 -0.17 1.78 0.10 
FE Total  0.13 -0.04 0.30 0.14 
FE vs. HC Barch et al., 2001 -0.34 -1.09 0.41 0.37 
FE vs. HC Yoon et al., 2014 -0.07 -0.81 0.66 0.85 
FE vs. HC Richard et al., 2013 0.03 -0.35 0.42 0.87 
FE vs. HC Barch et al., 2003 0.11 -0.25 0.47 0.54 
FE vs. HC Lesh et al., 2015 0.17 -0.62 0.95 0.68 
 
 
 
1
1
4
 
 
FE vs. HC Yoon et al., 2012 0.17 -0.21 0.56 0.38 
FE vs. HC Lesh et al., 2015 0.21 -0.39 0.81 0.49 
FE vs. HC Woodward, 2016 0.37 -0.30 1.04 0.28 
FE vs. HC Braver et al., 1999 0.55 -0.14 1.24 0.12 
At-risk Total  -0.04 -0.24 0.15 0.66 
At-risk vs. HC MacDonald, 2002 -0.39 -1.25 0.48 0.38 
At-risk vs. HC Barch et al., 2004 -0.30 -0.80 0.20 0.24 
At-risk vs. HC MacDonald, 2002 -0.22 -1.18 0.73 0.65 
At-risk vs. HC Lopez-Garcia et al., 2015 -0.14 -0.66 0.37 0.59 
At-risk vs. HC McClure et al., 2008 -0.08 -0.47 0.30 0.67 
At-risk vs. HC Sloat, 2007 0.08 -0.42 0.58 0.75 
At-risk vs. HC Lopez-Garcia et al., 2016 0.20 -0.56 0.97 0.60 
At-risk vs. HC Richard et al., 2013 0.25 -0.21 0.72 0.28 
 
FE= first-episode schizophrenia. HC=healthy controls. Total meta-analytic effects for each subgroup in gray. Hedges’ g: 
medium effects in bold, large effects in bold italics. 
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Table 9, Continued 
 
Question Being Answered Model Q df(Q) p-value I2 Tau2 
 Fixed effect      
-Is there significant variance in effects within 
chronic groups? 
Chronic 58.73 19 6.13E-6 67.65 0.067 
-Is there significant variance in effects within 
first-episode groups? 
First-Episode 4.09 8 0.85 0 0 
-Is there significant variance in effects within 
at-risk groups? 
At-Risk 4.14 7 0.76 0 0 
-Does the grouping variable explain significant 
variance in the model? 
Total within 66.96 34 6.30E-4   
 Mixed effects      
-Does the effect differ between subgroups? Total between 9.79 2 0.0075   
 
 
 
 
 
1
1
6
 
 
Table 10  
Subgroup Analyses: Random Effects Model of Diagnostic Groups by Illness Length for BX Errors. 
 
Subgroup Study Name Hedges’ g Lower CI Upper CI p-value 
Chronic Total  0.70 0.58 0.82 0 
Chronic vs. HC Lopez-Garcia et al., 2016 -0.04 -0.81 0.73 0.92 
Chronic vs. HC Holmes et al., 2005 0.29 -0.65 1.23 0.54 
Chronic vs. HC Sheffield et al., 2014 0.46 0.09 0.83 0.014 
Chronic vs. HC MacDonald & Carter, 2003 0.50 -0.17 1.17 0.14 
Chronic vs. HC Reilly et al., 2017 0.50 0.35 0.66 4.92E-11 
Chronic vs. HC Barch et al., 2008 0.52 0.10 0.94 0.015 
Chronic vs. HC Jones et al., 2010 0.54 0.14 0.95 0.0088 
Chronic vs. HC Ceccherini-Nelli et al., 2007 0.56 -0.12 1.24 0.11 
Chronic vs. HC Woodward, 2016 0.56 0.007 1.11 0.047 
Chronic vs. HC Chung et al., 2011 0.58 0.092 1.07 0.020 
Chronic vs. HC Edwards et al., 2010 0.63 -0.041 1.30 0.066 
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Chronic vs. HC Sheffield et al., 2014 0.68 0.31 1.06 3.02E-4 
Chronic vs. HC Todd et al., 2014 0.70 0.27 1.14 0.0015 
Chronic vs. HC Sheffield et al., 2015 0.71 0.31 1.11 5.40E-4 
Chronic vs. HC Gold et al., 2012; Henderson et al., 2012 0.74 0.50 0.99 2.21E-9 
Chronic vs. HC MacDonald, 2002 0.75 -0.17 1.68 0.11 
Chronic vs. HC Zhang et al., 2015 0.79 0.66 0.93 0 
Chronic vs. HC Perlstein et al., 2003 0.85 0.13 1.57 0.020 
Chronic vs. HC MacDonald, 2002 0.88 -0.10 1.86 0.079 
Chronic vs. HC Stratta et al., 2000 1.14 0.49 1.80 6.53E-4 
Chronic vs. HC Becker, 2012 1.21 0.71 1.70 2.04E-6 
Chronic vs. HC Lopez-Garcia et al., 2015 1.84 1.29 2.39 5.60E-11 
FE Total  0.75 0.58 0.92 0 
FE vs. HC Woodward, 2016 0.47 -0.20 1.14 0.17 
FE vs. HC Lesh et al., 2015 0.58 -0.024 1.19 0.060 
FE vs. HC Richard et al., 2013 0.59 0.19 0.99 0.0035 
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FE vs. HC Barch et al., 2001 0.64 -0.13 1.40 0.10 
FE vs. HC Yoon et al., 2012 0.65 0.26 1.05 0.0012 
FE vs. HC Lesh et al., 2015 0.76 -0.055 1.57 0.068 
FE vs. HC Barch et al., 2003 0.90 0.52 1.28 2.88E-6 
FE vs. HC Braver et al., 1999 0.93 0.22 1.65 0.010 
FE vs. HC Fornito et al., 2011 1.04 0.45 1.64 6.07E-4 
FE vs. HC Yoon et al., 2014 1.10 0.31 1.89 0.0066 
At-risk Total  0.36 0.15 0.58 0.0011 
At-risk vs. HC Richard et al., 2013 -0.08 -0.54 0.38 0.74 
At-risk vs. HC Sloat, 2007 -0.06 -0.56 0.44 0.82 
At-risk vs. HC Lopez-Garcia et al., 2016 0.20 -0.56 0.97 0.60 
At-risk vs. HC Paavola, 2013 0.35 -0.039 0.73 0.078 
At-risk vs. HC MacDonald, 2002 0.47 -0.40 1.33 0.29 
At-risk vs. HC Barch et al., 2004 0.53 0.02 1.04 0.043 
At-risk vs. HC MacDonald, 2002 0.53 -0.44 1.50 0.29 
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At-risk vs. HC McClure et al., 2008 0.58 0.19 0.98 0.0038 
At-risk vs. HC Lopez-Garcia et al., 2015 0.87 0.34 1.41 0.0015 
  
FE= first-episode schizophrenia. HC=healthy controls. Total meta-analytic effects for each subgroup in gray. Hedges’ g: 
medium effects in bold, large effects in bold italics, very large effects in underlined bold italics 
Table 10, Continued 
 
Question Being Answered Model Q df(Q) p-value I2 Tau2 
 Fixed effect      
-Is there significant variance in effects within 
chronic groups? 
Chronic 38.93 21 0.010 46.06 0.030 
-Is there significant variance in effects within 
first-episode groups? 
First-Episode 4.43 9 0.88 0 0 
-Is there significant variance in effects within 
at-risk groups? 
At-Risk 11.64 8 0.17 31.29 0.033 
-Does the grouping variable explain Total within 55.01 38 0.037   
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significant variance in the model? 
 Mixed effects      
-Does the effect differ between subgroups? Total between 8.55 2 0.014   
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Table 11  
Subgroup Analyses: Random Effects Model of Diagnostic Groups by Illness Length for d’context. 
 
Subgroup Study Name Hedges’ g Lower CI Upper CI p-value 
Chronic Total  -0.94 -1.11 -0.77 0 
Chronic vs. HC Sheffield et al., 2014 -1.83 -2.26 -1.40 0 
Chronic vs. HC Cohen et al., 1999 -1.47 -1.96 -0.97 5.25E-9 
Chronic vs. HC Todd et al., 2014 -1.39 -1.86 -0.92 6.00E-9 
Chronic vs. HC MacDonald, 2002 -1.37 -2.41 -0.32 0.010 
Chronic vs. HC Holmes et al., 2005 -1.36 -2.40 -0.31 0.011 
Chronic vs. HC Ceccherini-Nelli et al., 2007 -1.27 -2.01 -0.54 6.67E-4 
Chronic vs. HC MacDonald, 2002 -1.25 -2.23 -0.28 0.012 
Chronic vs. HC Merrill et al., 2017 -1.20 -1.77 -0.62 4.33E-5 
Chronic vs. HC Dias et al., 2013 -1.08 -1.83 -0.33 0.0050 
Chronic vs. HC Gold et al., 2012; Henderson et al., 2012 -1.03 -1.28 -0.78 1.11E-15 
Chronic vs. HC Chung et al., 2011 -1.02 -1.53 -0.51 8.98E-5 
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Chronic vs. HC Poppe et al., 2015 -0.98 -1.60 -0.36 0.0020 
Chronic vs. HC Sheffield et al., 2014 -0.83 -1.20 -0.45 1.60E-5 
Chronic vs. HC Barch et al., 2008 -0.71 -1.13 -0.29 9.81E-4 
Chronic vs. HC Poppe et al., 2016 -0.66 -1.06 -0.27 9.95E-4 
Chronic vs. HC Reilly et al., 2017 -0.66 -0.82 -0.51 0 
Chronic vs. HC Delawalla et al., 2006 -0.65 -1.15 -0.16 0.0098 
Chronic vs. HC Woodward, 2016 -0.59 -1.14 -0.039 0.036 
Chronic vs. HC Jones et al., 2010 -0.51 -0.91 -0.10 0.014 
Chronic vs. HC Thoma & Daum, 2008 -0.45 -1.05 0.14 0.13 
Chronic vs. HC MacDonald & Carter, 2003 -0.20 -0.86 0.46 0.55 
FE Total  -0.94 -1.15 -0.73 0 
FE vs. HC Lesh et al., 2015 -1.29 -2.15 -0.44 0.0029 
FE vs. HC Braver et al., 1999 -1.20 -1.94 -0.47 0.0014 
FE vs. HC Barch et al., 2003 -1.18 -1.57 -0.79 2.96E-9 
FE vs. HC Woodward, 2016 -1.03 -1.73 -0.32 0.0043 
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FE vs. HC Barch et al., 2001 -0.80 -1.58 -0.026 0.043 
FE vs. HC Richard et al., 2013 -0.69 -1.09 -0.29 6.71E-4 
FE vs. HC Lesh et al., 2015 -0.58 -1.19 0.027 0.061 
At-risk Total  -0.40 -0.56 -0.23 3.70E-6 
At-risk vs. HC McClure et al., 2008 -0.72 -1.12 -0.32 4.29E-4 
At-risk vs. HC MacDonald, 2002 -0.70 -1.69 0.29 0.16 
At-risk vs. HC Poppe et al., 2015 -0.49 -1.01 0.034 0.067 
At-risk vs. HC Barch et al., 2004 -0.40 -0.91 0.10 0.12 
At-risk vs. HC Richard et al., 2013 -0.37 -0.84 0.094 0.12 
At-risk vs. HC MacDonald, 2002 -0.34 -1.21 0.52 0.44 
At-risk vs. HC Delawalla et al., 2008 -0.29 -0.71 0.12 0.16 
At-risk vs. HC Sloat, 2007 -0.28 -0.79 0.22 0.27 
At-risk vs. HC Delawalla et al., 2006 -0.09 -0.55 0.37 0.70 
 
FE= first-episode schizophrenia. HC=healthy controls. Total meta-analytic effects for each subgroup in gray. Hedges’ g: 
medium effects in bold, large effects in bold italics, very large effects in underlined bold italics.  
 
 
 
1
2
4
 
 
Table 11, Continued 
 
Question Being Answered Model Q df(Q) p-value I2 Tau2 
 Fixed effect      
-Is there significant variance in effects 
within chronic groups? 
Chronic 55.56 20 3.38E-5 64.00 0.086 
-Is there significant variance in effects 
within first-episode groups? 
First-Episode 5.60 6 0.47 0 0 
-Is there significant variance in effects 
within at-risk groups? 
At-Risk 5.12 8 0.74 0 0 
-Does the grouping variable explain 
significant variance in the model? 
Total within 66.29 34 7.60E-4   
 Mixed effects      
-Does the effect differ between subgroups? Total between 24.68 2 4.40E-6   
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Table 12  
Symptom-Task Correlations: Random Effects Model for Authors’ Conceptualizations of Positive Symptoms in Schizophrenia 
  
Patients 
 
Study Name Pearson’s r Lower CI Upper CI p-value Q df(Q) p-value I2 Tau2 
d’context Total -0.054 -0.12 0.012 0.11 17.35 16 0.36 7.77 0.0015 
Becker, 2012 -0.36 -0.59 -0.07 0.016      
Stratta et al., 2000 -0.32 -0.68 0.16 0.18      
Woodward, 2016 -0.29 -0.70 0.26 0.30      
Woodward, 2016 -0.19 -0.49 0.16 0.28      
Lesh et al., 2015 -0.14 -0.52 0.29 0.53      
Reilly et al., 2017 -0.13 -0.23 -0.031 0.010      
MacDonald, 2002 -0.10 -0.55 0.38 0.69      
Delawalla et al., 2006 -0.10 -0.46 0.29 0.62      
Sheffield et al., 2014 -0.015 -0.21 0.18 0.88      
Gold et al., 2012 -0.010 -0.18 0.16 0.91      
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Henderson et al., 2012 
Poppe et al., 2016 0 -0.28 0.28 1.00      
Barch et al., 2008 0.011 -0.25 0.27 0.94      
Fisher, 2016 0.052 -0.29 0.38 0.77      
Richard et al., 2013 0.064 -0.19 0.31 0.62      
Barch et al., 2003 0.11 -0.18 0.38 0.45      
Sheffield et al., 2015 0.19 -0.11 0.46 0.20      
Ceccherini-Nelli et al., 2007 0.34 -0.18 0.71 0.20      
BXErr Total 0.049 -0.021 0.12 0.17 10.98 11 0.45 0 0 
Ceccherini-Nelli et al., 2007 -0.41 -0.76 0.09 0.13      
Sheffield et al., 2015 -0.15 -0.43 0.14 0.31      
Fisher, 2016 -0.15 -0.46 0.20 0.40      
Barch et al., 2008 -0.010 -0.27 0.25 0.94      
Sheffield et al., 2014 -0.0090 -0.20 0.18 0.93      
Woodward, 2016 0.014 -0.49 0.51 0.96      
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Barch et al., 2003 0.057 -0.23 0.33 0.70      
Reilly et al., 2017 0.090 -0.0090 0.19 0.073      
MacDonald, 2002 0.11 -0.38 0.56 0.67      
Woodward, 2016 0.13 -0.22 0.44 0.47      
Stratta et al., 2000 0.30 -0.18 0.66 0.22      
Lesh et al., 2015 0.40 -0.040 0.71 0.073      
 
Err=errors. Total meta-analytic effects for each outcome in gray. Pearson’s r: medium effects in bold. 
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Table 13  
Symptom-Task Correlations: Random Effects Model for Authors’ Conceptualizations of Negative Symptoms in Schizophrenia 
 
Patients 
 
Study Name Pearson’s r Lower CI Upper CI p-value Q df(Q) p-value I2 Tau2 
d’context Total -0.15 -0.22 -0.069 0 20.80 16 0.19 23.07 0.0055 
Lesh et al., 2015 -0.78 -0.94 -0.35 0.003      
Delawalla et al., 2006 -0.51 -0.77 -0.11 0.0016      
Richard et al., 2013 -0.31 -0.53 -0.059 0.016      
Barch et al., 2003 -0.29 -0.54 0 0.050      
Gold et al., 2012 
Henderson et al., 2012 
-0.23 -0.39 -0.061 0.008      
Woodward, 2016 -0.20 -0.51 0.14 0.24      
Woodward, 2016 -0.18 -0.63 0.36 0.52      
Stratta et al., 2000 -0.18 -0.57 0.29 0.46      
MacDonald, 2002 -0.14 -0.57 0.35 0.59      
 
 
 
1
2
9
 
 
Becker, 2012 -0.13 -0.40 0.16 0.37      
Reilly et al., 2017 -0.13 -0.23 -0.031 0.010      
Sheffield et al., 2014 -0.060 -0.25 0.13 0.55      
Barch et al., 2008 -0.013 -0.27 0.25 0.93      
Poppe et al., 2016 0 -0.28 0.28 1.00      
Ceccherini-Nelli et al., 2007 0.018 -0.45 0.48 0.95      
Sheffield et al., 2015 0.077 -0.22 0.36 0.61      
Fisher, 2016 0.080 -0.26 0.40 0.65      
BXErr Total 0.12 0.017 0.21 0.021 14.64 11 0.20 24.87 0.0068 
Sheffield et al., 2015 -0.097 -0.38 0.20 0.52      
Ceccherini-Nelli et al., 2007 -0.087 -0.53 0.40 0.74      
MacDonald, 2002 -0.024 -0.49 0.45 0.93      
Fisher, 2016 0.0020 -0.33 0.34 0.99      
Woodward, 2016 0.048 -0.46 0.53 0.86      
Sheffield et al., 2014 0.061 -0.13 0.25 0.54      
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Reilly et al., 2017 0.11 0.011 0.21 0.029      
Barch et al., 2008 0.12 -0.14 0.37 0.37      
Woodward, 2016 0.14 -0.20 0.45 0.42      
Stratta et al., 2000 0.15 -0.30 0.55 0.52      
Barch et al., 2003 0.45 0.16 0.66 0.003      
Lesh et al., 2015 0.70 0.26 0.90 0.005      
 
Err=errors. Total meta-analytic effects for each outcome in gray. Pearson’s r: medium effects in bold, large effects in bold  
 
italics. 
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Table 14 
Symptom-Task Correlations: Random Effects Model for Authors’ Conceptualizations of Disorganization Symptoms in  
 
Schizophrenia Patients 
 
Study Name Pearson’s r Lower CI Upper CI p-value Q df(Q) p-value I2 Tau2 
d’context Total -0.22 -0.34 -0.094 0.001 28.65 13 0.0073 54.63 0.029 
Lesh et al., 2015 -0.81 -0.95 -0.38 0.002      
Becker, 2012 -0.51 -0.71 -0.23 0.001      
Barch et al., 2008 -0.42 -0.63 -0.16 0.003      
Richard et al., 2013 -0.41 -0.61 -0.16 0.002      
Barch et al., 2003 -0.40 -0.63 -0.11 0.008      
Stratta et al., 2000 -0.27 -0.64 0.20 0.26      
Delawalla et al., 2006 -0.23 -0.56 0.17 0.26      
Gold et al., 2012 
Henderson et al., 2012 
-0.14 -0.30 0.029 0.10      
Sheffield et al., 2014 -0.11 -0.30 0.085 0.27      
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Sheffield et al., 2015 -0.081 -0.36 0.21 0.59      
Ceccherini-Nelli et al., 2007 -0.009 -0.47 0.46 0.97      
Poppe et al., 2016 0 -0.28 0.28 1.00      
Fisher, 2016 0.084 -0.26 0.41 0.64      
MacDonald, 2002 0.28 -0.23 0.67 0.28      
BXErr Total 0.24 0.070 0.39 0.006 19.13 9 0.024 52.96 0.037 
MacDonald, 2002 -0.11 -0.55 0.38 0.68      
Fisher, 2016 -0.040 -0.37 0.30 0.82      
Ceccherini-Nelli et al., 2007 0.014 -0.46 0.48 0.96      
Sheffield et al., 2015 0.074 -0.22 0.35 0.63      
Sheffield et al., 2014 0.12 -0.080 0.30 0.25      
Stratta et al., 2000 0.25 -0.22 0.63 0.29      
Barch et al., 2003 0.38 0.09 0.61 0.011      
Barch et al., 2008 0.47 0.21 0.67 0.001      
Edwards et al., 2010 0.51 0.053 0.79 0.030      
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Lesh et al., 2015 0.82 0.39 0.96 0.002      
 
Err=errors. Total meta-analytic effects for each outcome in gray. Pearson’s r: medium effects in bold, large effects in bold 
italics. 
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Table 15  
Symptom-Task Correlations: Random Effects Model for Our Conceptualizations of Positive Symptoms in Schizophrenia  
 
Patients 
 
Study Name Pearson’s r Lower CI Upper CI p-value Q df(Q) p-value I2 Tau2 
d’context Total -0.02 -0.10 0.055 0.55 10.65 12 0.56 0 0 
Becker, 2012 -0.36 -0.59 -0.07 0.016      
Stratta et al., 2000 -0.32 -0.68 0.16 0.18      
Lesh et al., 2015 -0.14 -0.52 0.29 0.53      
MacDonald, 2002 -0.10 -0.55 0.38 0.69      
Delawalla et al., 2006 -0.10 -0.46 0.29 0.62      
Sheffield et al., 2014 -0.015 -0.21 0.18 0.88      
Gold et al., 2012 
Henderson et al., 2012 
-0.010 -0.18 0.16 0.91      
Poppe et al., 2016 0 -0.28 0.28 1.00      
Barch et al., 2008 0.011 -0.25 0.27 0.94      
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Fisher, 2016 0.052 -0.29 0.38 0.77      
Richard et al., 2013 0.064 -0.19 0.31 0.62      
Barch et al., 2003 0.11 -0.18 0.38 0.45      
Ceccherini-Nelli et al., 2007 0.34 -0.18 0.71 0.20      
BXErr Total 0.021 -0.11 0.15 0.75 8.02 7 0.33 12.69 0.004 
Ceccherini-Nelli et al., 2007 -0.41 -0.76 0.12 0.13      
Fisher, 2016 -0.15 -0.46 0.20 0.40      
Barch et al., 2008 -0.010 -0.27 0.25 0.94      
Sheffield et al., 2014 -0.009 -0.20 0.18 0.93      
Barch et al., 2003 0.057 -0.23 0.33 0.70      
MacDonald, 2002 0.11 -0.38 0.55 0.67      
Stratta et al., 2000 0.30 -0.18 0.66 0.22      
Lesh et al., 2015 0.40 -0.04 0.71 0.073      
  
Err=errors. Total meta-analytic effects for each outcome in gray. Pearson’s r: medium effects in bold. 
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Table 16  
 
Symptom-Task Correlations: Random Effects Model for Our Conceptualizations of Negative Symptoms in Schizophrenia  
 
Patients 
 
Study Name Pearson’s r Lower CI Upper CI p-value Q df(Q) p-value I2 Tau2 
d’context Total -0.17 -0.27 -0.062 0.002 18.22 12 0.11 34.15 0.012 
Lesh et al., 2015 -0.78 -0.94 -0.35 0.003      
Delawalla et al., 2006 -0.51 -0.77 -0.11 0.016      
Richard et al., 2013 -0.31 -0.53 -0.059 0.016      
Barch et al., 2003 -0.29 -0.54 0 0.050      
Gold et al., 2012 
Henderson et al., 2012 
-0.23 -0.39 -0.061 0.008      
Stratta et al., 2000 -0.18 -0.57 0.29 0.46      
MacDonald, 2002 -0.14 -0.57 0.35 0.59      
Becker, 2012 -0.13 -0.40 0.16 0.37      
Sheffield et al., 2014 -0.060 -0.25 0.13 0.55      
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Barch et al., 2008 -0.013 -0.27 0.25 0.93      
Poppe et al., 2016 0 -0.28 0.28 1.00      
Ceccherini-Nelli et al., 2007 0.018 -0.45 0.48 0.95      
Fisher, 2016 0.080 -0.27 0.40 0.65      
BXErr Total 0.16 -0.003 0.32 0.055 12.33 7 0.090 43.25 0.024 
Ceccherini-Nelli et al., 2007 -0.087 -0.53 0.34 0.74      
MacDonald, 2002 -0.024 -0.49 0.45 0.93      
Fisher, 2016 0.0020 -0.33 0.34 0.99      
Sheffield et al., 2013 0.06 -0.13 0.25 0.54      
Barch et al., 2008 0.12 -0.14 0.37 0.37      
Stratta et al., 2000 0.15 -0.30 0.55 0.52      
Barch et al., 2003 0.45 0.16 0.66 0.003      
Lesh et al., 2015 0.70 0.26 0.87 0.005      
 
Err=errors. Total meta-analytic effects for each outcome in gray. Pearson’s r: medium effects in bold, large effects in bold 
italics. 
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Table 17  
 
Symptom-Task Correlations: Random Effects Model for Our Conceptualizations of Disorganization Symptoms in  
 
Schizophrenia Patients 
 
Study Name Pearson’s r Lower CI Upper CI p-value Q df(Q) p-value I2 Tau2 
d’context Total -0.23 -0.36 -0.10 0.001 27.91 12 0.006 57.01 0.033 
Lesh et al., 2015 -0.81 -0.95 -0.38 0.002      
Becker, 2012 -0.51 -0.71 -0.23 0.001      
Barch et al., 2008 -0.42 -0.63 -0.16 0.003      
Richard et al., 2013 -0.41 -0.61 -0.16 0.002      
Barch et al., 2003 -0.40 -0.63 -0.11 0.008      
Stratta et al., 2000 -0.27 -0.64 0.20 0.26      
Delawalla et al., 2006 -0.23 -0.56 0.17 0.26      
Gold et al., 2012 
Henderson et al., 2012 
-0.14 -0.30 0.029 0.10      
Sheffield et al., 2014 -0.11 -0.30 0.085 0.27      
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Ceccherini-Nelli et al., 2007 -0.009 -0.47 0.46 0.97      
Poppe et al., 2016 0 -0.28 0.28 1.00      
Fisher, 2016 0.084 -0.26 0.41 0.64      
MacDonald, 2002 0.28 -0.23 0.67 0.28      
BXErr Total 0.26 0.08 0.43 0.006 18.11 8 0.020 55.83 0.044 
MacDonald, 2002 -0.11 -0.55 0.38 0.68      
Fisher, 2016 -0.040 -0.37 0.30 0.82      
Ceccherini-Nelli et al., 2007 0.014 -0.46 0.48 0.96      
Sheffield et al., 2014 0.12 -0.080 0.30 0.25      
Stratta et al., 2000 0.25 -0.22 0.63 0.29      
Barch et al., 2003 0.38 0.09 0.61 0.011      
Barch et al., 2008 0.47 0.21 0.67 0.001      
Edwards et al., 2010 0.51 0.05 0.79 0.030      
Lesh et al., 2015 0.82 0.39 0.96 0.002      
 
Err=errors. Meta-analytic effects for each outcome in gray. Pearson’s r: medium effects in bold, large effects in bold italics. 
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Table 18  
Moderation Analyses: Random Effects Model of Cue Duration for AY Errors in  
 
Schizotypy-Spectrum Group versus Healthy Control Group. 
 
AY Errors Hedges’ g Lower CI Upper CI p-value 
Total Short (1000ms) 0.12 -0.01 0.25 0.07 
Total Long (<500ms) 0.38 0.23 0.53 1.04E-6 
 
Table 18, Continued 
 
Question Being Answered Model Q df(Q) p-value I2 Tau2 
 Fixed effect      
-Is there significant 
variance in effects within 
the short cue condition? 
Short Cue 15.53 17 0.56 0 0 
-Is there significant 
variance in effects within 
the long cue condition? 
Long Cue 20.18 12 0.064 40.55 0.026 
-Does the moderator 
explain significant variance 
in the model? 
Total within 35.72 29 0.18   
 Mixed effects      
-Does cue duration 
moderate the overall effect? 
Total between 6.65 1 0.010   
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Table 19  
Moderation Analyses: Random Effects Model of Cue Duration for BX Errors in 
 
Schizotypy-Spectrum Group versus Healthy Control Group. 
 
BX Errors Hedges’ g Lower CI Upper CI p-value 
Total Short (1000ms) 0.61 0.44 0.78 3.17E-12 
Total Long (<500ms) 0.58 0.48 0.67 0 
 
Hedges’ g: medium effects in bold. 
 
Table 19, Continued 
 
Question Being Answered Model Q df(Q) p-value I2 Tau2 
 Fixed effect      
-Is there significant 
variance in effects within 
the short cue condition? 
Short Cue 35.09 20 0.020 43.00 0.065 
-Is there significant 
variance in effects within 
the long cue condition? 
Long Cue 4.62 12 0.97 0 0 
-Does moderator explain 
significant variance? 
Total within 39.71 32 0.16   
 Mixed effects      
-Does cue duration 
moderate the overall effect? 
Total between 0.13 1 0.72   
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Table 20  
Moderation Analyses: Random Effects Model of Cue Duration for d’context in 
 
Schizotypy-Spectrum Group versus Healthy Control Group. 
 
d’context Hedges’ g Lower CI Upper CI p-value 
Total Short (1000ms) -0.73 -0.92 -0.54 8.55E-14 
Total Long (<500ms) -0.86 -1.07 -0.66 2.22E-16 
 
Hedges’ g: medium effects in bold, large effects in bold italics. 
 
Table 20, Continued 
 
Question Being Answered Model Q df(Q) p-value I2 Tau2 
 Fixed effect      
-Is there significant 
variance in effects within 
the short cue condition? 
Short Cue 44.36 18 5.12E-4 59.42 0.10 
-Is there significant 
variance in effects within 
the long cue condition? 
Long Cue 36.01 13 5.92E-4 63.90 0.079 
-Does moderator explain 
significant variance? 
Total within 80.37 31 2.94E-6   
 Mixed effects      
-Does cue duration 
moderate the overall effect? 
Total between 0.88 1 0.35   
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Table 21 
Moderation Analyses: Random Effects Model of Cue-Probe Interval for AY Errors in 
  
Schizotypy-Spectrum Group versus Healthy Control Group.  
 
AY Errors Hedges’ g Lower CI Upper CI p-value 
Total Short (<3500ms) 0.39 0.27 0.52 4.90E-10 
Total Long  (>3500ms) 0.16 -0.02 0.33 0.08 
 
Table 21, Continued 
 
Question Being Answered Model Q df(Q) p-value I2 Tau2 
 Fixed effect      
-Is there significant 
variance in effects within 
short cue-probe condition? 
Short Cue-
Probe Interval 
20.39 21 0.50 0 0 
-Is there significant 
variance in effects within 
long cue-probe condition? 
Long Cue-
Probe Interval 
54.90 26 7.80E-4 52.65 0.087 
-Does the moderator 
explain significant variance 
in the model? 
Total within 75.30 47 0.0055   
 Mixed effects      
-Does cue-probe interval 
moderate the overall effect? 
Total between 4.74 1 0.029   
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Table 22  
Moderation Analyses: Random Effects Model of Cue-Probe Interval for BX Errors in 
 
Schizotypy-Spectrum Group versus Healthy Control Group. 
  
BX Errors Hedges’ g Lower CI Upper CI p-value 
Total Short (<3500ms) 0.60 0.48 0.73 0 
Total Long  (>3500ms) 0.57 0.47 0.67 0 
 
Hedges’ g: medium effects in bold. 
 
Table 22, Continued 
 
Question Being Answered Model Q df(Q) p-value I2 Tau2 
 Fixed effect      
-Is there significant 
variance in effects within 
short cue-probe condition? 
Short Cue-
Probe Interval 
12.37 21.00 0.93 0 0 
-Is there significant 
variance in effects within 
long cue-probe condition? 
Long Cue-
Probe Interval 
27.35 27.00 0.45 1.26 9.99E-4 
-Does moderator explain 
significant variance? 
Total within 39.72 48.00 0.80   
 Mixed effects      
-Does cue-probe interval 
moderate the overall effect? 
Total between 0.13 1 0.72   
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Table 23  
Moderation Analyses: Random Effects Model of Cue-Probe Interval for d’context in 
 
Schizotypy-Spectrum Group versus Healthy Control Group 
.  
d’context Hedges’ g Lower CI Upper CI p-value 
Total Short (<3500ms) -0.82 -1.03 -0.61 7.33E-15 
Total Long  (>3500ms) -0.71 -0.85 -0.56 0 
 
Hedges’ g: medium effects in bold, large effects in bold italics. 
 
Table 23, Continued 
 
Question Being Answered Model Q df(Q) p-value I2 Tau2 
 Fixed effect      
-Is there significant 
variance in effects within 
short cue-probe condition? 
Short Cue-
Probe Interval 
60.55 24 5.34E-5 60.36 0.15 
-Is there significant 
variance in effects within 
long cue-probe condition? 
Long Cue-
Probe Interval 
35.62 26 0.099 27.00 0.031 
-Does moderator explain 
significant variance? 
Total within 96.17 50 9.50E-5   
 Mixed effects      
-Does cue-probe interval 
moderate the overall effect? 
Total between 0.81 1 0.37   
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Table 24  
Moderation Analyses: Random Effects Model of Task Type for AY Errors in Chronic  
 
Schizophrenia Group versus Healthy Control Group. 
  
AY Errors Hedges’ g Lower CI Upper CI p-value 
Total AX-CPT 0.33 0.02 0.64 0.03 
Total DPX 0.50 0.35 0.65 4.97E-11 
 
Hedges’ g: medium effects in bold. 
 
Table 24, Continued 
 
Question Being Answered Model Q df(Q) p-value I2 Tau2 
 Fixed effect      
-Is there significant 
variance in effects within 
AX-CPT results? 
AX-CPT 42.28 11 1.45E-5 73.98 0.21 
-Is there significant 
variance in effects within 
DPX results? 
DPX 17.95 8 0.022 55.44 0.024 
-Does moderator explain 
significant variance? 
Total within 60.23 19 3.60E-6   
 Mixed effects      
-Does task type moderate 
the overall effect? 
Total between 0.98 1 0.32   
 
 
 147 
Table 25  
Moderation Analyses: Random Effects Model of Task Type for BX Errors in Chronic 
 
Schizophrenia Group versus Healthy Control Group. 
  
BX Errors Hedges’ g Lower CI Upper CI p-value 
Total AX-CPT 0.68 0.53 0.82 0 
Total DPX 0.76 0.53 0.99 5.97E-11 
 
Hedges’ g: medium effects in bold. 
 
Table 25, Continued 
 
Question Being Answered Model Q df(Q) p-value I2 Tau2 
 Fixed effect      
-Is there significant 
variance in effects within 
AX-CPT results? 
AX-CPT 10.06 13 0.69 0 0 
-Is there significant 
variance in effects within 
DPX results? 
DPX 40.70 8 2.37E-6 80.34 0.081 
-Does moderator explain 
significant variance? 
Total within 50.76 21 0.00029   
 Mixed effects      
-Does task type moderate 
the overall effect? 
Total 
between 
0.36 1 0.55   
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Table 26  
Moderation Analyses: Random Effects Model of Task Type for d’context in Chronic  
 
Schizophrenia Group versus Healthy Control Group. 
  
d’context Hedges’ g Lower CI Upper CI p-value 
Total AX-CPT -1.04 -1.28 -0.80 0 
Total DPX -0.78 -0.98 -0.59 2.00E-15 
 
Hedges’ g: medium effects in bold, large effects in bold italics. 
 
Table 26, Continued 
 
Question Being Answered Model Q df(Q) p-value I2 Tau2 
 Fixed effect      
-Is there significant 
variance in effects within 
AX-CPT results? 
AX-CPT 37.36 14 6.51E-4 62.52 0.13 
-Is there significant 
variance in effects within 
DPX results? 
DPX 10.60 5 0.060 52.85 0.027 
-Does moderator explain 
significant variance? 
Total within 47.96 19 2.60E-4   
 Mixed effects      
-Does task type moderate 
the overall effect? 
Total between 2.69 1 0.10   
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Table 27  
Meta-Regression: Random Effects Model of Total Number of Trials for AY Errors in Schizotypy-Spectrum Group versus  
 
Healthy Control Group 
 
k=31 studies 
 
Coefficient 
95% Lower CI 95% Upper CI p-value 
Intercept 0.65 1.03 3.37 0.021 
Total Number of Trials -0.0024 -0.0045 -0.00030 0.025 
 
 
Q df(Q) p-value I2 Tau2 
Test that all coefficients (excluding intercept) are zero 5.01 1 0.03   
Goodness of fit: Test that unexplained variance is zero 62.05 29 0.0003 53.27% 0.06 
 
 R2 analog 
Proportion of total between-study 
variance explained by model 
0.12 
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Table 28  
Meta-Regression: Random Effects Model of Total Number of Trials for BX Errors in Schizotypy-Spectrum Group versus  
 
Healthy Control Group 
 
k=34 studies Coefficient 95% Lower CI 95% Upper CI p-value 
Intercept 0.46 0.17 0.74 0.0019 
Total Number of Trials 0.0012 -0.0005 0.0028 0.16 
 
 
Q df(Q) p-value I2 Tau2 
Test that all coefficients (excluding intercept) are zero 1.93 1 0.16   
Goodness of fit: Test that unexplained variance is zero 48.29 9 0.012 33.73% 0.026 
 
 R2 analog 
Proportion of total between-study 
variance explained by model 
0.14 
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Table 29  
Meta-Regression: Random Effects Model of Total Number of Trials for d’context in Schizotypy-Spectrum Group versus 
 
Healthy Control Group 
 
k=31 studies Coefficient 95% Lower CI 95% Upper CI p-value 
Intercept -0.4974 -0.808 -0.1868 0.0017 
Total Number of Trials -0.0016 -0.0031 -0.0001 0.0329 
 
 
Q df(Q) p-value I2 Tau2 
Test that all coefficients (excluding intercept) are zero 4.55 1 0.033   
Goodness of fit: Test that unexplained variance is zero 63.76 29 0.0002 54.52% 0.076 
 
 R2 analog 
Proportion of total between-study 
variance explained by model 
0.17 
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Table 30  
Meta-Regression: Random Effects Model of Cue-Probe Interval for AY Errors in Schizotypy-Spectrum Group versus Healthy  
 
Control Group 
 
k=49 studies Coefficient 95% Lower CI 95% Upper CI p-value 
Intercept 0.3426 0.1299 0.554 0.0016 
Total Number of Trials -0 -0.0001 0 0.3206 
 
 
Q df(Q) p-value I2 Tau2 
Test that all coefficients (excluding intercept) are zero 0.99 1 32.06   
Goodness of fit: Test that unexplained variance is zero 75.97 47 0.0047 38.13% 0.049 
 
 R2 analog 
Proportion of total between-study 
variance explained by model 
0.00 
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Table 31  
Meta-Regression: Random Effects Model of Cue-Probe Interval for BX Errors in Schizotypy-Spectrum Group versus Healthy 
 
Control Group 
 
k=50 studies Coefficient 95% Lower CI 95% Upper CI p-value 
Intercept 0.5739 0.4042 0.7435 0 
Total Number of Trials 0 0 0 0.9325 
 
 
Q df(Q) p-value I2 Tau2 
Test that all coefficients (excluding intercept) are zero 0.01 1 0.9325   
Goodness of fit: Test that unexplained variance is zero 39/88 48 -/79 0 0 
 
 R2 analog 
Proportion of total between-study 
variance explained by model 
0.00 
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Table 32  
Meta-Regression: Random Effects Model of Cue-Probe Interval for d’context in Schizotypy-Spectrum Group versus Healthy 
 
Control Group 
 
k=52 studies Coefficient 95% Lower CI 95% Upper CI p-value 
Intercept -0.8388 -1.0674 -0.6102 0 
Total Number of Trials 0 0 0.0001 0.4671 
 
 
Q df(Q) p-value I2 Tau2 
Test that all coefficients (excluding intercept) are zero 0.53 1 0.47   
Goodness of fit: Test that unexplained variance is zero 97.80 50 0.0001 48.88% 0.083 
 
 R2 analog 
Proportion of total between-study 
variance explained by model 
0.00 
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Table 33  
Meta-Regression: Random Effects Model of Schizophrenia Patients’ Length of Illness for AY Errors in Schizophrenia Group 
 
versus Healthy Control Group 
 
k=9 studies Coefficient 95% Lower CI 95% Upper CI p-value 
Intercept 0.5091 0.0786 0.9397 0.0205 
Total Number of Trials -0.0263 -0.0638 0.0112 0.169 
 
 
Q df(Q) p-value I2 Tau2 
Test that all coefficients (excluding intercept) are zero 1.89 1 0.17   
Goodness of fit: Test that unexplained variance is zero 18.65 7 0.0094 62.46% 0.089 
 
 R2 analog 
Proportion of total between-study 
variance explained by model 
0.42 
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Table 34  
Meta-Regression: Random Effects Model of Schizophrenia Patients’ Length of Illness for BX Errors in Schizophrenia Group 
 
versus Healthy Control Group 
 
k=11 studies Coefficient 95% Lower CI 95% Upper CI p-value 
Intercept 0.7299 0.206 1.2539 0.0063 
Total Number of Trials 0.0049 -0.0393 0.0492 0.8278 
 
 
Q df(Q) p-value I2 Tau2 
Test that all coefficients (excluding intercept) are zero 0.05 1 0.83   
Goodness of fit: Test that unexplained variance is zero 32.01 9 0.0002 71.89% 0.17 
 
 R2 analog 
Proportion of total between-study 
variance explained by model 
0.00 
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Table 35  
Meta-Regression: Random Effects Model of Schizophrenia Patients’ Length of Illness for d’context in Schizophrenia Group 
 
versus Healthy Control Group 
 
k=9 studies Coefficient 95% Lower CI 95% Upper CI p-value 
Intercept -0.7201 -1.1266 -0.3135 0.0005 
Total Number of Trials -0.0303 -0.0634 0.0028 0.0731 
 
 
Q df(Q) p-value I2 Tau2 
Test that all coefficients (excluding intercept) are zero 3.21 1 0.073   
Goodness of fit: Test that unexplained variance is zero 9.23 7 0.24 24.19% 0.032 
 
 R2 analog 
Proportion of total between-study 
variance explained by model 
0.58 
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Table 36  
Trim-and-Fill Results: Adjusted Results for All Schizotypy-Spectrum Groups versus 
 
Healthy Control Groups Using a Random Effects Model. 
 
 
# Studies 
Trimmed 
Hedges’ g 
Estimate 
Lower 
Limit 
Upper 
Limit 
Q-Value 
Short AY Errors      
Observed Values  0.33 0.19 0.46 33.59 
Adjusted Values 3 0.37 0.23 0.51 40.36 
Short BX Errors      
Observed Values  0.61 0.50 0.71 22.22 
Adjusted Values 5 0.68 0.55 0.81 41.19 
Short d’Context      
Observed Values  -0.84 -1.06 -0.63 96.00 
Adjusted Values 4 -0.97 -1.20 -0.75 142.78 
Long AY Errors      
Observed Values  0.0034 -0.17 0.18 82.07 
Adjusted Values 9 0.24 0.065 0.41 143.33 
Long BX Errors      
Observed Values  0.59 0.47 0.72 44.53 
Adjusted Values 7 0.47 0.34 0.60 75.74 
Long d’Context      
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Observed Values  -0.76 -0.91 -0.61 67.11 
Adjusted Values 5 -0.66 -0.82 -0.50 99.51 
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Table 37  
Trim-and-Fill Results: Adjusted Results for Schizophrenia Patient Groups versus  
 
Psychiatric Comparison Groups Using a Random Effects Model. 
 
 
# Studies 
Trimmed 
Hedges’ g 
Estimate 
Lower 
Limit 
Upper 
Limit 
Q-Value 
AY Errors      
Observed Values  0.017 -0.12 0.15 1.95 
Adjusted Values 3 0.073 -0.049 0.29 5.06 
BX Errors      
Observed Values  0.33 0.19 0.46 3.30 
Adjusted Values 1 0.31 0.18 0.45 5.49 
d’Context      
Observed Values  -0.73 -1.07 -0.40 36.38 
Adjusted Values 0 -- -- -- -- 
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Table 38  
Trim-and-Fill Results: Adjusted Results for Symptom-Task Performance Correlations  
 
Within Schizophrenia Patient Groups Using a Random Effects Model with Authors’  
 
Symptom Conceptualizations. 
 
 
# Studies 
Trimmed 
Fisher’s z 
Estimate 
Lower 
Limit 
Upper 
Limit 
Q-Value 
Disorganized Symptom-BX Error Correlations    
Observed Values  0.29 0.089 0.46 31.32 
Adjusted Values 2 0.36 0.17 0.52 43.05 
Disorganized Symptom-d’Context Correlations    
Observed Values  -0.25 -0.38 -0.11 41.65 
Adjusted Values 3 -0.33 -0.46 -0.19 62.92 
Negative Symptom-BX Error Correlations    
Observed Values  0.14 0.023 0.26 20.62 
Adjusted Values 3 0.19 0.076 0.30 28.21 
Negative Symptom-d’Context Correlations    
Observed Values  -0.17 -0.27 -0.077 31.59 
Adjusted Values 3 -0.21 -0.30 -0.12 40.93 
Positive Symptom-BX Error Correlations    
Observed Values  0.044 -0.034 0.12 11.68 
Adjusted Values 0 -- -- -- -- 
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Positive Symptom-d’Context Correlations    
Observed Values  -0.054 -0.12 0.015 18.10 
Adjusted Values 0 -- -- -- -- 
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Table 39  
Results of p-curve Analysis for Authors’ Symptom Correlations in Short and Combined/Unknown Delay Conditions 
 
 Evidential value present? Evidential value absent?    
Short Delay 
Correlation 
Binomial 
Test 
Continuous 
Test, Full 
(p's<0.05) 
Continuous 
Test, Half 
(p's<0.025) 
Binomial 
Test 
Continuous 
Test, Full 
(p's<0.05) 
Statistical 
Power 
# studies 
included/ 
excluded 
Conclusion 
Disorganized
-d'context 
p=0.125 Z=-3.5 
p=0.0002 
Z=-2.91 
p=0.0018 
p>0.9999 Z=2.14 
p=0.9837 
91% 3/4 Evidential 
value present 
Negative 
-d'context 
p=0.125 Z=‐ 2.18, 
p=0.0148 
Z=-1.4, 
p=0.0806 
p>0.9999 Z=0.92, 
p=0.8222 
67% 3/4 Evidential 
value present 
Positive 
-d'context 
p=0.5 Z=-0.77, 
p=0.2212 
Z=-0.14, 
p=0.4424 
p>0.9999 Z=0.12, 
p=0.5478 
42% 1/6 Evidential 
value not 
present/absent 
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Disorganized
-BX errors 
p=0.25 Z=-0.39, 
p=0.0973 
Z=-0.34, 
p=0.3652 
p>0.9999 Z=0.39, 
p=0.6519 
53% 2/2 Evidential 
value not 
present/absent 
Negative 
-BX errors 
-- -- -- -- -- -- 0/3 Could not be 
generated: all 
results p>0.05 
Positive 
-BX errors 
-- -- -- -- -- -- 0/3 Could not be 
generated: all 
results p>0.05 
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Table 40  
Results of p-curve Analysis for Authors’ Symptom Correlations in Long and Combined/Unknown Delay Conditions 
 
 Evidential value present? Evidential value absent?    
Long Delay 
Correlation 
Binomial 
Test 
Continuous 
Test, Full 
(p's<0.05) 
Continuous 
Test, Half 
(p's<0.025) 
Binomial 
Test 
Continuous 
Test, Full 
(p's<0.05) 
Statistical 
Power 
# studies 
included/ 
excluded 
Conclusion 
Disorganized
-d'context 
p=0.0625 
Z=-3.28, 
p=0.0005 
Z=‐ 2.46, 
p=0.007 
p>0.9999 
Z=1.82, 
p=0.9655 
83% 4/2 
Evidential 
value present 
Negative 
-d'context 
p=0.75 
Z=-1.59, 
p=0.0562 
Z=‐ 2.2, 
p=0.0141 
p=0.5012 
Z=0.64, 
p=0.739 
65% 2/4 
Evidential 
value present 
Positive 
-d'context 
p=0.5 
Z=-0.77, 
p=0.2212 
Z=-0.14, 
p=0.4424 
p>0.9999 
Z=0.12, 
p=0.5478 
42% 1/5 
Evidential 
value not 
present/absent 
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Disorganized
-BX errors 
p=0.125 
Z=-1.17, 
p=0.1218 
Z=0.13, 
p=0.5527 
p>0.9999 
Z=0.12, 
p=0.5493 
39% 3/1 
Evidential 
value not 
present/absent 
Negative 
-BX errors 
p>0.9999 
Z=0.6, 
p=0.7247 
-- p=0.2947 
Z=-1.05, 
p=0.1467 
5% 1/0 
Evidential 
value not 
present/absent 
Positive 
-BX errors 
-- -- -- -- -- -- 0/3 
Could not be 
generated: all 
results p>0.05 
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Figure 1. PRISMA Flow Diagram of Literature Search Results. 
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Figure 2. Point Estimate of Percent Errors by Trial Type for Short Delay Trials. Cue-probe interval was less than 3500ms. 
Points represent weighted means. Schizotypy-spectrum groups are portrayed in red and control groups are portrayed in black. 
At-risk group includes SPD, first-degree relatives of patients with schizophrenia, and psychometrically-identified schizotypy. 
Psychiatric controls include non-schizophrenia psychosis, non-psychotic depression, bipolar disorder, non-Cluster A  
personality disorders, and psychometrically-identified vulnerability to depression.  
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Figure 3. Point Estimate of Percent Errors by Trial Type for Long Delay Trials. Cue-probe interval was 3500ms or longer. 
Points represent weighted means. Schizotypy-spectrum groups are portrayed in red and control groups are portrayed in black. 
At-risk group includes SPD, ultra high-risk, first-degree relatives of patients with schizophrenia, and psychometrically 
Identified schizotypy. Psychiatric controls include non-schizophrenia psychosis, non-psychotic depression, bipolar disorder, 
non-Cluster A personality disorders, and psychometrically-identified vulnerability to depression. 
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Figure 4. Point Estimate of Reaction Time in Milliseconds by Trial Type for Short Delay Trials. Cue-probe interval was less 
than 3500ms. Points represent weighted means. Schizotypy-spectrum groups are portrayed in red and control groups are in 
black. At-risk group includes SPD, first-degree relatives of patients with schizophrenia, and psychometrically-identified 
schizotypy. Psychiatric controls include non-schizophrenia psychosis, bipolar disorder, non-Cluster A personality disorders, 
and psychometrically-identified vulnerability to depression. 
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Figure 5. Point Estimate of Reaction Time in Milliseconds by Trial Type for Long Delay Trials. Cue-probe interval was 
3500ms or longer. Points represent weighted means. Schizotypy-spectrum groups are portrayed in red and control groups are 
in black. At-risk group includes SPD, ultra high-risk, first-degree relatives of patients with schizophrenia, and 
psychometrically-identified schizotypy. Psychiatric controls include non-schizophrenia psychosis, bipolar disorder, non-
Cluster A personality disorders, and psychometrically-identified vulnerability to depression. 
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Figure 6. Point Estimate of D’context for Short Delay Trials. Cue-probe interval was less than 3500ms. Points represent 
weighted means and error bars represent standard deviations. At-risk group includes SPD, first-degree relatives of patients with 
schizophrenia, and psychometrically-identified schizotypy. Psychiatric controls include non-schizophrenia psychosis, non-
psychotic depression, bipolar disorder, bipolar disorder with psychotic features, non-Cluster A personality disorders, and 
psychometrically-identified vulnerability to depression.
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Figure 7. Point Estimate of D’context for Long Delay Trials. Cue-probe interval was 3500ms or longer. Points represent 
weighted means and error bars represent standard deviations. At-risk group includes SPD, ultra high-risk, first-degree relatives 
of schizophrenia patients, and psychometrically-identified schizotypy. Psychiatric controls include non-schizophrenia 
psychosis, non-psychotic depression, bipolar disorder, bipolar disorder with psychotic features, non-Cluster A personality 
disorders, and psychometrically-identified vulnerability to depression. 
d
’c
o
n
te
x
t 
LONG DELAY 
 
 
 174 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Forest Plots of Short and Long D’context Effects for Schizotypy-Spectrum 
Groups versus Healthy Control Groups. Short delay condition pictured on left and long 
delay condition on right. Note that forest plots for the two delay conditions are on 
different scales. The center of each white box represents the Hedges’ g estimate for a 
single study, the size of the white box represents the relative weight given to the study 
according to inverse variance, and the bars represent the 95% confidence intervals on the 
Hedges’ g estimate for that study. Effects in the negative direction indicate that the 
Long Delay D’context Effects for 
Schizotypy-Spectrum Group 
versus Healthy Control Group 
Short Delay D’context Effects for 
Schizotypy-Spectrum Group versus 
Healthy Control Group 
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schizotypy group performed worse than healthy control group. The black diamond at the 
bottom of the plot represents the summary statistic, or the estimated Hedges’ g for the 
overall effect, with the width of the diamond showing 95% confidence intervals on the 
overall effect.  
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Figure 9. Forest Plot of D’context Effects for Patients with Schizophrenia versus 
Psychiatric Comparisons. The center of each white box represents the Hedges’ g estimate 
for a single study, the size of the white box represents the relative weight given to the 
study according to inverse variance, and the bars represent the 95% confidence intervals 
on the Hedges’ g estimate for that study. Effects in the negative direction indicate that the 
schizophrenia group performed worse than the psychiatric comparison group. The black 
diamond at the bottom of the plot represents the summary statistic, or the estimated 
Hedges’ g for the overall effect, with the width of the diamond indicating the 95% 
confidence intervals on the overall effect.  
D’context Effects for Schizophrenia Patients 
vs. Psychiatric Comparison Patients 
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Figure 10. Forest Plot of D’context Effects for Patients with Schizophrenia versus 
Healthy Controls and At-Risk versus Healthy Controls. Effects for schizophrenia on top 
and at-risk at the bottom. The center of each white box represents Hedges’ g estimate for 
single studies, the size of the white box represents the relative weight given according to 
inverse variance, and bars represent 95% confidence intervals on Hedges’ g estimate for 
that study. Effects in negative direction indicate the schizotypy-spectrum group 
performed worse. Black squares represent summary statistics, estimated Hedges’ g for 
the overall effect, for each subgroup with the width of the square showing 95% 
confidence intervals on the overall effect. The black diamond represents the overall effect 
across subgroups.
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Figure 11. Forest Plot of Disorganized Symptom-D’context Correlations within 
Schizophrenia Groups. Authors’ conceptualizations were used. The center of each white 
box represents Pearson’s r estimate for single studies, the size of the white box shows 
relative weight given according to inverse variance, and bars represent 95% confidence 
intervals on Pearson’s r estimate. Effects in negative direction indicate that more severe 
symptoms are associated with lower d’context scores (stronger CI deficits). The black 
diamonds represents the summary statistic, estimated Pearson’s r for the overall effect, 
with the width of the diamond showing 95% confidence intervals on the overall effect. 
Correlation of Disorganized Symptoms with 
D’context in Schizophrenia Patients 
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Figure 12. Forest Plot of Negative Symptom-D’context Correlations within 
Schizophrenia Groups. Authors’ conceptualizations were used. The center of each white 
box represents Pearson’s r estimate for single studies, the size of the white box shows 
relative weight given according to inverse variance, and bars represent 95% confidence 
intervals on Pearson’s r estimate. Effects in negative direction indicate that more severe 
symptoms are associated with lower d’context scores (stronger CI deficits). The black 
diamonds represents the summary statistic, estimated Pearson’s r for the overall effect, 
with the width of the diamond showing 95% confidence intervals on the overall effect. 
Correlation of Negative Symptoms with 
D’context in Schizophrenia Patients 
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Figure 13. Forest Plot of Positive Symptom-D’context Correlations within Schizophrenia 
Groups. Authors’ conceptualizations were used. The center of each white box represents 
Pearson’s r estimate for single studies, the size of the white box shows relative weight 
given according to inverse variance, and bars represent 95% confidence intervals on 
Pearson’s r estimate. Effects in negative direction indicate that more severe symptoms 
are associated with lower d’context scores (stronger CI deficits). The black diamonds 
represents the summary statistic, estimated Pearson’s r for the overall effect, with the 
width of the diamond showing 95% confidence intervals on the overall effect. 
Correlation of Positive Symptoms with 
D’context in Schizophrenia Patients 
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Figure 14. Meta-Regression Plot of Total Number of Trials Predicting Hedges’ g for AY Errors in Schizotypy-Spectrum versus 
Healthy Controls. Circles represent individual studies, with the size of the circle showing relative weight given to the study. 
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Figure 15. Meta-Regression Plot of Total Number of Trials Predicting Hedges’ g for D’context in Schizotypy-Spectrum versus 
Healthy Controls. Circles represent individual studies, with the size of the circle showing relative weight given to the study. 
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Figure 16. Funnel Plot of Hedges’ g Effects for D’context in Short and Long Delay Conditions for All Schizotypy-Spectrum 
Groups versus Healthy Controls. Short delay condition pictured on left and long delay condition on right. Observed effects 
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from studies included in the meta-analysis are represented by white circles, and the observed point estimate is represented by a 
white diamond. Imputed effects from the trim-and-fill method are represented by black circles and the adjusted point estimate 
is represented by a black diamond.
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Figure 17. Funnel Plot of Hedges’ g Effects for D’context for Patients with 
Schizophrenia versus Psychiatric Comparisons. Observed effects are represented by 
circles and the point estimate is represented by a diamond; no values were imputed using 
the trim-and-fill method.  
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Figure 18. Funnel Plot of Fisher’s z Effects for Correlations between Disorganized 
Symptoms and D’context within Schizophrenia Groups. Observed effects from studies 
included in the meta-analysis are represented by white circles, and the observed point 
estimate is represented by a white diamond. Imputed effects from the trim-and-fill 
method are represented by black circles and the adjusted point estimate is represented by 
a black diamond.
Funnel Plot of Standard Error by Fisher’s z for Correlations 
between Disorganized Symptoms and D’context  
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APPENDIX B 
 
GENERAL METHODOLOGICAL DECISIONS 
  
 
 This appendix describes detailed methodological decisions that were made a 
priori, that is, before the analysis phase began. Whenever possible, decisions were 
informed by best practices in meta-analysis (Borenstein, 2009; Higgins & Green, 2011), 
by conventions in the CI literature, and/or by consultation with a clinical psychologist 
and expert schizotypy-spectrum researcher, Dr. Thomas Kwapil. General decisions that 
applied to multiple studies are described here. Basic information about included studies is 
provided in Appendix F and more specific information pertaining to individual studies is 
provided in Appendix G. 
Inclusion/Exclusion of Studies and/or Participants 
 
• When no control group was included, data were collected and summarized for point 
estimates only. 
• Studies that used the correct AX-CPT task but had additional parameters or task goals 
present simultaneously (e.g., ignoring background noise during the task, or the 
addition of colored letters to add another level of salience) were excluded. 
• Studies assessing CI in analogue conditions, based on psychoactive substances and 
genotyping were excluded from the proposed meta-analysis because they do not 
provide direct evidence of CI deficits in schizotypy. Genotyping studies were only 
included if the article or the authors provided data on schizotypy and control groups 
separately. 
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• When multiple documents were available for a study (e.g., a thesis document or 
unpublished manuscript that became a published article), all documents were 
searched and evaluated for appropriateness. When conflicting information was 
present, the document to be included was decided on a case-by-case basis via 
consultation with Dr. Kwapil. When non-overlapping information was available, all 
appropriate versions of the study were coded. 
• Every published article (including supplemental material, when available) was 
searched for keywords “subset”, “sample”, “previously”, “reported”, and “described.” 
When overlap was suspected, the full text of the article in question was re-read in a 
separate session from coding. When a study reported overlapping data with another 
study, the group or groups that had any degree of overlap in participants were 
excluded; that is, only one study was retained to avoid violating the assumption of 
independent data. Decisions on which articles to retain were made by consulting with 
Dr. Kwapil, and factors such as sample size, number and characteristics of groups 
included, and number of outcomes reported were used to guide selection. When the 
overlap between studies was unclear (e.g., study A overlaps with study B and study B 
overlaps with study C but it was not stated whether study A and C shared any 
participants), the authors were contacted for clarification. When no answer was 
received, we took a conservative approach: overlap was assumed and only one study 
was retained. When no overlap was reported in the text of the manuscript but it was 
apparent that two studies used the same group of participants (e.g., same means and 
standard deviations for demographic information), only one study was retained. 
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• Mood disorders with psychotic features and other non-schizophrenia psychoses were 
included as a psychiatric comparison group, not as a schizophrenia-spectrum group. 
Accordingly, studies including mood disorders with psychotic features in the 
schizophrenia group were excluded if data was not reported separately for these two 
groups. 
• When psychotic disorders were present in some relatives of patients with 
schizophrenia, this group was not included (as it no longer constitutes an examination 
of unaffected relatives); however, relative groups were still included if the authors did 
not report screening for psychotic disorders. 
Data Collection and Coding 
• Quantitative data from articles text, tables, appendices, and supplementary 
information were recorded. Effect sizes were recorded directly from the text or 
computed from summary data (means and standard deviations) and from standard, 
parametric analyses without covariates or other corrections. 
• When only significance limits were provided and no precise information was reported 
(e.g., p < 0.05), no data was coded. 
• When precise information on magnitude of between-group differences was given but 
no direction was provided (e.g., patients did not differ from controls on BY errors, 
t=XXX), the direction was guessed according to theoretical predictions and other 
findings in the literature. This only happened for 3 analyses and the literature was 
quite consistent in these cases (4/5, 5/5, and 8/8 of the other studies had effects in the 
expected direction, respectively, for the 3 analyses). 
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• Only Pearson correlations were coded. To ensure that Spearman correlations were not 
included, each article was searched for the terms “Spearman” and “rho.” When a 
specific range of Pearson correlation values was given (e.g., r ranged from 0.005 to 
0.18, the average of the range was coded; this was only the case for 2 studies. 
• When data was only available in a figure, no attempt was made to extract or estimate 
values from the figure and instead asked authors for the data. 
• When dichotomizing first-episode versus chronic illness status for patients with 
schizophrenia, a cutoff of 1.5 years was selected, according to precedence in the 
literature (Ellison-Wright, Glahn, Laird, Thelen, & Bullmore, 2008). If authors did 
not provide any information on length of illness or number of episodes, it was 
assumed that patients with schizophrenia were chronic. 
• When dichotomizing medicated versus unmedicated schizophrenia groups, a group 
was considered medicated if any of the patients were taking antipsychotic 
medications. 
• Dichotomization of cue duration at 500ms and cue-probe delay at 3500ms was 
determined a priori by looking at the distribution of durations for each variable across 
included studies. Those numbers were near a median split and made sense logically 
and based on the number of studies using each condition. 
• When information for task parameters, error rates, reaction time, d’context, or 
symptom correlations were missing, authors were contacted to request the 
information. 
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• When studies cited another article to describe the task and it was clear the parameters 
were the same (e.g., “We used an exact replica of XXX’s task.”), information from 
the cited study was coded. When studies cited another article but the parameters were 
obviously not the same (e.g., the article in question manipulated short and long delay 
conditions but the article they cited did not), then information was not coded. 
• When it was unclear whether an article’s reported sample size included participants 
who were dropped or excluded, a conservative approach was taking by subtracting 
this number out of the total sample. 
• Some studies use a correction factor (a’) in the case of absolute error rates (e.g., 100% 
AX accuracy) when calculating d’context. Studies using d’context versus a’context 
were not differentiated because the two values correlate so highly, around 0.99 
(Ceccherini-Nelli, Turpin-Crowther, & Crow, 2007). 
• When the authors did not provide d’context scores, these values were not calculated 
from AX and BX group summary data. Calculating regular d-prime from averaged 
versus collapsed data yields different results. Average d' is computed by calculating d' 
for each participant and then averaging the group results, whereas collapsed d' is 
computed by first averaging the hits and the false alarms of participants, then 
calculating d' from the averaged proportions. Collapsed d’ tends to underestimate true 
average d’ and is particularly unreliable when participants’ average values are 1.5+ 
standard deviations apart, or when hit and false alarm rates are largely asymmetrical 
(Macmillan & Kaplan, 1985). Since both undesirable cases are true for this current 
dataset, collapsed d’context would likely underestimate true average d’context to a 
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large extent. Indeed, this was tested with raw datasets that were available: it was 
found that collapsed d’context underestimated average d’ context by about 20%. 
Thus, collapsed d’context was not computed from summary data. 
• When raw data was available, d’context was calculated for each participant in excel 
using the following formula: d'context = NORMINV(AX hit rate,0,1) - 
NORMINV(BX err rate,0,1). Group d’context was then computed by averaging 
individual participants’ d’context values. 
• There were a few cases where it seemed clear that researchers did not standardize 
values when calculating d’context (e.g., their values were less than 1.0 for both 
patients and controls, and corresponded to the unstandardized AX hit rate minus BX 
error rate). This was the case for 3 studies and it was decided not to include those 
d’context values in analyses. 
• When calculating information from raw datasets, it was decided a priori to exclude 
participants who had 90% or more errors on any trial type and delete their data for all 
measures. There is no general consensus in the literature regarding exclusion criteria 
for low performance but a number of studies used the 90% cutoff. 
• For articles that examined healthy controls and their healthy relatives, these two 
groups were combined into a single healthy control group, as long as diagnostic 
inclusion/exclusion criteria were similar. 
• 5 studies included both patients with schizophrenia and their relatives (whereas 2 
other relative studies included relatives of non-participant patients), which presented 
a possible issue due to non-independence of data. When including data from non- 
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independent/matched groups in the same analysis, it is appropriate to account for the 
correlation between the two groups or to estimate this correlation from another study. 
One study (MacDonald, 2002) reported correlations between schizophrenia patients’ 
performance and their relatives’ performance on AY trials, BX trials, and d’context. 
The performance correlations were low, ranging -0.18 to 0.04. Nonetheless, effect 
sizes were compared between the groups when accounting for the correlation (using 
formula from Borenstein, 2009) versus not accounting for the correlation. The 
adjusted and non-adjusted effect sizes were almost identical, correlating at 
r=0.999992; therefore, it was decided a priori not to adjust for non-independence 
between patients with schizophrenia and their relatives in analyses. 
• When analyzing symptom correlations, data from both AX-CPT and DPX measures 
was used. For two studies that gave both tasks, the weighted average of the AX-CPT 
symptom-task correlations and DPX symptom-task correlations was taken (keeping 
the smaller N to be conservative). For primary, subgroup, moderation, and meta-
regression analyses, data from each task was included separately but the sample sizes 
were halved for the two studies including both tasks. 
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APPENDIX C 
 
SYSTEMATIC CODING SHEET 
 
 
A) Coding Characteristics Response 
A1 Coder 
 
  1 = C.C., 2 = L.C. 
 
A2 Date coded (mm/dd/yyyy) 
 
A3 Finished coding? (put "yes" when finished) 
 
A4 Comments/concerns about coding this study 
 
B) Study Characteristics Response 
B1 Report ID number 
 
B2 First author's last name 
 
B3 Second author's last name 
 
B4 Third author's last name 
 
B5 Year of publication 
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B6 Study number (if multiple studies within article) 
 
B7 Type of report 
 
  1 = Journal article   
  2 = Book   
  3 = Book chapter   
  3 = Dissertation   
  4 = Master's thesis   
  5 = Private report   
  6 = Conference paper   
  7 = Other (specify)   
B8 Published document 
 
  1 = Published   
  2 = Unpublished   
B9 Peer reviewed document 
 
  1 = Peer-reviewed   
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  2 = Not peer-reviewed   
C) Location Characteristics Response Article pg # 
Citation if authors referred 
to different article for info 
C1 Country where study conducted 
   
  1 = United States       
  2 = Not in United States (specify)       
C2 Type of setting where study conducted 
   
  1 = Hospital       
  2 = University       
  3 = Academic medical center       
  4 = Community clinic       
  5 = Veterans Affairs       
  6 = Private setting       
  7 = Other (specify)       
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D) Qualitative Characteristics of Schizotypy-
Spectrum Group #1 
Response Article pg # 
Citation if authors referred 
to different article for info 
D1 Type of schizotypy-spectrum group included 
   
  1 = Schizophrenia       
  2 = Schizoaffective       
  3 = Schizophreniform       
  4 = Schizotypal Personality Disorder       
  5 = Clinical high-risk/Ultra high-risk       
  6 = Unaffected relatives of schz-spectrum group       
  7 = Psychometrically identified schizotypy       
  8 = Non-schizophrenia psychotic patients       
  9 = Other (specify)       
D2 Determination of diagnostic status 
   
  1 = Record review       
  2 = Structured interview (specify which)       
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  3 = Unstructured interview       
  4 = Questionnaire (specify which)       
  5 = Did not specify       
D3 Patient status 
   
  1 = Inpatient       
  2 = Outpatient       
  3 = Not patients       
D4 Status of antipsychotic/neuroleptic medication 
   
  1 = Medicated with antipsychotics/neuroleptics       
  
2 = Unmedicated/Not medicated with 
antipsychotics/neuroleptics 
      
D5 Medication specifics 
   
  1 = Medication details not specified       
  2 = Never medicated/Medication-naïve       
  3 = Newly medicated       
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  4 = Chronically medicated       
  5 = Currently unmedicated, but medicated in past       
D5.5 Type of antipsychotics 
   
  1 = First generation       
  2 = Second generation       
D6 Duration of illness 
   
  1 = First-episode       
  2 = Chronic       
D7 
Other schizotypy-spectrum group inclusion/ 
exclusion criteria (cut and paste from article)    
 
 
 
E) Qualitative Characteristics of Schizotypy-
Spectrum Group #2 
Response Article pg # 
Citation if authors referred 
to different article for info 
[same variables as section D above]    
 
 
 
2
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F) Qualitative Comparison Group Characteristics Response Article pg # 
Citation if authors referred 
to different article for info 
F1 Comparison groups included 
   
  1 = Healthy controls       
  2 = Non-schizophrenia psychotic patients       
  3 = Non-psychotic depressed patients       
  4 = Bipolar patients       
  5 = Healthy controls' relatives       
  6 = Other (specify)       
F2 Comparison group diagnostic criteria 
   
  1 = No history of psychosis       
  2 = No current psychosis       
  3 = No history of mental illness       
  4 = No current mental illness       
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F3 Determination of diagnostic status 
   
  1 = Record review       
  2 = Structured interview (specify which)       
  3 = Unstructured interview       
  4 = Questionnaire (specify which)       
F4 
Other comparison group inclusion/exclusion 
criteria (cut and paste from article)    
 
 
G) AX-CPT Task Parameters Response Article pg # 
Citation if authors referred 
to different article for info 
G1 Total number of trials 
   
G2 Number of trial blocks 
   
G3 % AX trials 
   
G4 % AY trials 
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G5 % BX trials 
   
G6 % BY trials 
   
G7 Reaction time (RT) measurement 
   
  1 = Correct responses only       
  2 = All responses       
G8 Duration of cue (ms) 
   
G9 Duration of probe (ms) 
   
G10 Delay conditions used? 
   
  1 = No       
  2 = Yes       
G11 Delay conditions in separate trial blocks? 
   
  1 = No       
  2 = Yes       
G12 Duration of short delay cue-probe interval (ms) 
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G13 Duration of short delay inter-trial interval (ms) 
   
G14 Duration of long delay cue-probe interval (ms) 
   
G15 Duration of long delay inter-trial interval (ms) 
   
G16 
Duration of cue-probe interval, if no delay 
conditions used (ms)    
G17 
Duration of inter-trial interval, if no delay 
conditions used (ms)    
G18 Duration of response time allowed for cue (ms) 
   
G19 Duration of response time allowed for probe (ms) 
   
G20 Corrective feedback provided? 
   
  1 = No       
  2 = Yes       
G21 Other parameters (specify) 
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H) DPX Task Parameters Response Article pg # 
Citation if authors referred 
to different article for info 
[same variables as section G above]    
 
 
I) Symptom Measures (Authors’ Conceptualization) Response Article pg # 
Citation if authors referred 
to different article for info 
I1 Positive symptom measures 
   
I2 Positive symptom subscales 
   
I3 Negative symptom measures  
   
I4 Negative symptom subscales 
   
I5 Disorganized symptom measures  
   
I6 Disorganized symptom subscales 
   
I7 Other symptom measures: Specify 
   
I8 Other symptom subscales: Specify 
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I9 Dimensions not specified 
   
NOTE: Use these symptom measures for I1, I3, I5, I7       
  1 = Brief Psychiatric Rating Scale, 16-item scale       
  2 = Brief Psychiatric Rating Scale, 18-item scale       
  3 = Brief Psychiatric Rating Scale, 24-item scale       
  4 = Positive and Negative Syndrome Scale        
  
5 = Scale for the Assessment of Positive 
Symptoms 
      
  
6 = Scale for the Assessment of Negative 
Symptoms 
      
  7 = Scale of Prodromal Symptoms       
  8 = Schizotypal Personality Questionnaire       
  9 = DSM-5: Schizotypal Personality Disorder        
  10 = Schneiderian First Rank Symptoms        
  11 = Huber's pure defect Basic Symptoms       
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  12 = Clinical Language Disorder Rating Scale        
  13 = Communication Disturbance Index       
  14 = Other (specify)       
NOTE: Use these symptom subscales for I2, I4, I6, I8       
  1 = Total Score       
  2 = BPRS Hallucinations       
  3 = BPRS Unusual Thought Content       
  4 = BPRS Conceptual Disorganization       
  5 = BPRS Grandiosity       
  6 = BPRS Suspiciousness       
  7 = BPRS Emotional Withdrawal       
  8 = BPRS Motor Retardation       
  9 = BPRS Blunted Affect       
  10 = BPRS Self-Neglect       
  11 = BPRS Mannerisms and Posturing       
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  12 = BPRS Disorientation       
  13 = BPRS Bizarre Behavior       
  14 = PANSS Positive scale       
  15 = PANSS Negative Scale       
  16 = SAPS Hallucinations       
  17 = SAPS Delusions       
  18 = SAPS Bizarre Behavior       
  19 = SAPS Positive Formal Thought Disorder       
  20 = SANS Anhedonia       
  21 = SANS Avolition       
  22 = SANS Alogia       
  23 = SANS Affective Flattening       
  24 = SANS Attention       
  25 = SOPS Unusual Thought Content       
  26 = SOPS Suspiciousness       
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  27 = SOPS Perceptual Disturbances       
  28 = SOPS Grandiosity       
  29 = SOPS Social Anhedonia       
  30 = SOPS Avolition       
  31 = SOPS Decreased Expression of Emotion       
  
32 = SOPS Decreased Experience of Emotions 
and Self 
      
  33 = SOPS Deterioration in Role Functioning       
  34 = SOPS Decreased Ideational Richness       
  35 = SOPS Conceptual Disorganization       
  36 = SOPS Odd Behavior and Appearance       
  37 = SOPS Bizarre Thinking       
  38 = SOPS Trouble with Focus and Attention       
  39 = SOPS Personal Hygiene       
  40 = SPQ Odd Beliefs/Magical Thinking       
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  41= SPQ Unusual Perceptual Experiences       
  42 = SPQ Suspiciousness       
  43= SPQ  Ideas of Reference       
  44 = SPQ Constricted Affect       
  45 = SPQ Excessive Social Anxiety       
  46 = SPQ No Close Friends       
  47 = SPQ Odd Speech       
  48 = SPQ Odd Behavior       
  49 = DSM-5 SPD criterion 1       
  50 = DSM-5 SPD criterion 2       
  51 = DSM-5 SPD criterion 3       
  52 = DSM-5 SPD criterion 4       
  53 = DSM-5 SPD criterion 5       
  54 = DSM-5 SPD criterion 6       
  55 = DSM-5 SPD criterion 7       
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  56 = DSM-5 SPD criterion 8       
  57 = DSM-5 SPD criterion 9       
  58 = CDI Disorganized Speech       
  59 = Other (specify)       
  60 = Did not specify subscales       
 
J) Quantitative Characteristics of Schizotypy-
Spectrum Group #1 
Response Article pg # 
Citation if authors referred 
to different article for info 
J1 Sample size (n=__) 
   
J2 Diagnostic composition: % 
   
J3 Positive symptoms: M (SD) 
   
J4 Negative symptoms: M (SD) 
   
J5 Disorganized symptoms: M (SD) 
   
J6 Other symptoms (specify Sx type): M (SD) 
   
J7 Other symptoms (specify Sx type): M (SD) 
   
 
 
 
2
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J8 Length of illness in years: M (SD) 
   
J9 % Unmedicated 
   
J10 % Medicated with antipsychotic/neuroleptic  
   
J10.5a % Medicated: first-generation antipsychotic 
   
J10.5b % Medicated: second-generation antipsychotic 
   
J11 Dose of antipsychotic/neuroleptic (mg): M (SD) 
   
J12 % Taking other meds (if reported, specify type) 
   
J13 Age: M (SD) 
   
J14 Sex: % Female 
   
J15 Race/Ethnicity: % White 
   
J16 Race/Ethnicity: % Black 
   
J17 Race/Ethnicity: % Latin(a/o) 
   
J18 Race/Ethnicity: % Asian 
   
J19 Race/Ethnicity: % Other 
   
 
 
 
2
1
2
 
 
J20 Years of education: M (SD) 
   
J21 
Socioeconomic status (SES) or Years of father's 
education: M (SD)    
J22 IQ measure #1: Specify + M (SD) 
   
J23 IQ measure #2: Specify + M (SD) 
   
J24 
Community/occupational functioning measure 
#1: Specify + M (SD)    
J25 
Community/occupational functioning measure 
#2: Specify + M (SD)    
J26 Number of subjects dropped: Specify reason(s)  
   
J27 AX Errors (no delay conditions used): M (SD) 
   
J28 AY Errors (no delay conditions used): M (SD) 
   
J29 BX Errors (no delay conditions used): M (SD) 
   
J30 BY Errors (no delay conditions used): M (SD) 
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J31 Total Errors (no delay conditions used): M (SD) 
   
J32 
AX % Correct (no delay conditions used): M 
(SD)    
J33 
AY % Correct (no delay conditions used): M 
(SD)    
J34 
BX % Correct (no delay conditions used): M 
(SD)    
J35 
BY % Correct (no delay conditions used): M 
(SD)    
J36 
Total % Correct (no delay conditions used): M 
(SD)    
J37 
AX Reaction time (ms) (no delay conditions 
used): M (SD)    
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J38 
AY Reaction time (ms) (no delay conditions 
used): M (SD)    
J39 
BX Reaction time (ms) (no delay conditions 
used): M (SD)    
J40 
BY Reaction time (ms) (no delay conditions 
used): M (SD)    
J41 
Total Reaction time (ms) (no delay conditions 
used): M (SD)    
J42 d'context (no delay conditions used): M (SD) 
   
J43 a'context (no delay conditions used): M (SD) 
   
J44 AX Errors (short delay): M (SD) 
   
J45 AY Errors (short delay): M (SD) 
   
J46 BX Errors (short delay): M (SD) 
   
J47 BY Errors (short delay): M (SD) 
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J48 Total Errors (short delay): M (SD) 
   
J49 AX % Correct (short delay): M (SD) 
   
J50 AY % Correct (short delay): M (SD) 
   
J51 BX % Correct (short delay): M (SD) 
   
J52 BY % Correct (short delay): M (SD) 
   
J53 Total % Correct (short delay): M (SD) 
   
J54 AX Reaction time (ms) (short delay): M (SD) 
   
J55 AY Reaction time (ms) (short delay): M (SD) 
   
J56 BX Reaction time (ms) (short delay): M (SD) 
   
J57 BY Reaction time (ms) (short delay): M (SD) 
   
J58 Total Reaction time (ms) (short delay): M (SD) 
   
J59 d'context (short delay): M (SD) 
   
J60 a'context (short delay): M (SD) 
   
J61 AX Errors (long delay): M (SD) 
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J62 AY Errors (long delay): M (SD) 
   
J63 BX Errors (long delay): M (SD) 
   
J64 BY Errors (long delay): M (SD) 
   
J65 Total Errors (long delay): M (SD) 
   
J66 AX % Correct (long delay): M (SD) 
   
J67 AY % Correct (long delay): M (SD) 
   
J68 BX % Correct (long delay): M (SD) 
   
J69 BY % Correct (long delay): M (SD) 
   
J70 Total % Correct (long delay): M (SD) 
   
J71 AX Reaction time (ms) (long delay): M (SD) 
   
J72 AY Reaction time (ms) (long delay): M (SD) 
   
J73 BX Reaction time (ms) (long delay): M (SD) 
   
J74 BY Reaction time (ms) (long delay): M (SD) 
   
J75 Total Reaction time (ms) (long delay): M (SD) 
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J76 d'context (long delay): M (SD) 
   
J77 a'context (long delay): M (SD) 
   
J78 Other (specify): M (SD) 
   
K) Quantitative Characteristics of Schizotypy-
Spectrum Group #2 
Response Article pg # 
Citation if authors referred 
to different article for info 
 [same variables as Section J above] 
   
L) Quantitative Comparison Group Characteristics Response Article pg # 
Citation if authors referred 
to different article for info 
[same variables as Section J above]    
M) RESULTS: Between-
Group Comparisons #1 
Groups, 
direction 
of findings  
Analysis (1 = t-test, 
2 = ANOVA, 3 = 
Planned contrasts, 4 
= Other 
F t df 
Signifi-
cance 
(p)  
Measure of 
Effect Size (1 
= Cohen's d, 2 
= η2, 3 = other  
Effect 
Size 
M1 Positive symptoms 
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M2 Negative symptoms 
        
M3 Disorganized symptoms 
        
M4 Other symptoms #1 
        
M5 Other symptoms #2 
        
M6 Age 
        
M7 Sex 
        
M8 Race/Ethnicity 
        
M9 Years of education 
        
M10 SES/Father's education 
        
M11 IQ measure #1 
        
M12 IQ measure #2 
        
M13 
Community/ 
occupational #1         
M14 Community/ 
        
 
 
 
2
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occupational #2 
M15 # subjects dropped 
        
M16 
AX Errors  
(no delay conditions)         
M17 
AY Errors  
(no delay conditions)         
M18 
BX Errors  
(no delay conditions)         
M19 
BY Errors  
(no delay conditions)         
M20 
Total Errors  
(no delay conditions)         
          
M21 AX % Correct  
        
 
 
 
2
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(no delay conditions) 
M22 
AY % Correct  
(no delay conditions)         
M23 
BX % Correct  
(no delay conditions)         
M24 
BY % Correct  
(no delay conditions)         
M25 
Total % Correct  
(no delay conditions)         
M26 
AX RT  
(no delay conditions)         
M27 
AY RT  
(no delay conditions)         
M28 BX RT  
        
 
 
 
2
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(no delay conditions) 
M29 
BY RT  
(no delay conditions)         
M30 
Total RT  
(no delay conditions)         
M31 
d'context  
(no delay conditions)         
M32 
a'context  
(no delay conditions)         
M33 AX Errors (short delay) 
        
M34 AY Errors (short delay) 
        
M35 BX Errors (short delay) 
        
M36 BY Errors (short delay) 
        
M37 Total Errors  
        
 
 
 
2
2
2
 
 
(short delay) 
M38 
AX % Correct  
(short delay)         
M39 
AY % Correct  
(short delay)         
M40 
BX % Correct  
(short delay)         
M41 
BY % Correct  
(short delay)         
M42 
Total % Correct  
(short delay)         
M43 AX RT (short delay) 
        
M44 AY RT (short delay) 
        
M45 BX RT (short delay) 
        
 
 
 
2
2
3
 
 
M46 BY RT (short delay) 
        
M47 Total RT (short delay) 
        
M48 d'context (short delay) 
        
M49 a'context (short delay) 
        
M50 AX Errors (long delay) 
        
M51 AY Errors (long delay) 
        
M52 BX Errors (long delay) 
        
M53 BY Errors (long delay) 
        
M54 Total Errors (long delay) 
        
M55 
AX % Correct  
(long delay)         
M56 
AY % Correct  
(long delay)         
M57 BX % Correct  
        
 
 
 
2
2
4
 
 
(long delay) 
M58 
BY % Correct  
(long delay)         
M59 
Total % Correct  
(long delay)         
M60 AX RT (long delay) 
        
M61 AY RT (long delay) 
        
M62 BX RT (long delay) 
        
M63 BY RT (long delay) 
        
M64 Total RT (long delay) 
        
M65 d'context (long delay) 
        
M66 a'context (long delay) 
        
          
M67 ANOVA: Main effect of 
        
 
 
 
2
2
5
 
 
Trial type, errors 
M68 
ANOVA: Main effect of 
Group, errors         
M69 
ANOVA: Group x Trial 
Type interaction, errors         
M70 
ANOVA: Main effect of 
Trial type, RT         
M71 
ANOVA: Main effect of 
Group, RT         
M72 
ANOVA: Group x Trial 
Type interaction, RT         
M73 
ANOVA: Main effect of 
Trial type, d'context         
M74 ANOVA: Main effect of 
        
 
 
 
2
2
6
 
 
Group, d'context 
M75 
ANOVA: Group x Trial 
Type interaction, 
D'context 
        
M76 
ANOVA: BXerrors - 
AYerrors         
M77 ANOVA: BXRT - AYRT 
        
M78 
ANOVA: Main effect of 
Delay, errors         
M79 
ANOVA: Main effect of 
Delay, RT         
M80 
ANOVA: Main effect of 
Delay, d'context         
M81 ANOVA: Group x 
        
 
 
 
2
2
7
 
 
Delay interaction, 
errors 
M82 
ANOVA: Group x 
Delay interaction, RT         
M83 
ANOVA: Group x 
Delay interaction, 
d'context 
        
M84 
ANOVA: Trial Type x 
Delay interaction, 
errors 
        
M85 
ANOVA: Trial Type x 
Delay interaction, RT         
M86 
ANOVA: Trial Type x 
Delay interaction, 
d'context 
        
 
 
 
2
2
8
 
 
M87 
ANOVA: Group x Trial 
Type x Delay 
interaction, errors 
        
M88 
ANOVA:  Group x Trial 
Type x Delay, RT         
M89 
ANOVA:  Group x Trial 
Type x Delay 
interaction, d'context 
        
M90 Other (specify) 
        
N) RESULTS: Between-
Group Comparisons #2 
Groups 
and 
direction 
of findings  
Analysis (1 = t-test, 
2 = ANOVA, 3 = 
Planned contrasts, 4 
= Other 
F t df 
Signifi-
cance 
(p)  
Measure of 
Effect Size (1 
= Cohen's d, 2 
= η2, 3 = other  
Effect 
Size 
[same variables as Section M above]        
 
 
 
2
2
9
 
 
N) RESULTS: Between-
Group Comparisons #2 
Groups 
and 
direction 
of findings  
Analysis (1 = t-test, 
2 = ANOVA, 3 = 
Planned contrasts, 4 
= Other 
F t df 
Signifi-
cance 
(p)  
Measure of 
Effect Size (1 
= Cohen's d, 2 
= η2, 3 = other  
Effect 
Size 
[same variables as Section M above]        
P) RESULTS: Symptom and Function Associations in all 
Schizotypy-Spectrum Groups 
Bivariate 
Correlations (r) 
Significance 
(p) 
Article 
pg # 
P1 Positive symptoms with d'context 
   
P2 Positive symptoms with BX errors 
   
P3 Positive symptoms with BX-AY errors 
   
P4 Positive symptoms with BX reaction time 
   
P5 Negative symptoms with d'context 
   
P6 Negative symptoms with BX errors 
   
P7 Negative symptoms with BX-AY errors 
   
 
 
 
2
3
0
 
 
P8 Negative symptoms with BX reaction time 
   
P9 Disorganized symptoms with d'context 
   
P10 Disorganized symptoms with BX errors 
   
P11 Disorganized symptoms with BX-AY errors 
   
P12 Disorganized symptoms with BX reaction time 
   
P13 IQ with d'context 
   
P14 IQ with BX errors 
   
P15 IQ with BX-AY errors 
   
P16 IQ with BX reaction time 
   
P17 Community/occupational functioning with d'context 
   
P18 Community/occupational functioning with BX errors 
   
P19 Community/occupational functioning with BX-AY errors 
   
P20 Community/occupational functioning with BX reaction time 
   
P21 Other symptoms (specify type) with d'context 
   
 
 
 
2
3
1
 
 
P22 Other symptoms (specify type) with BX errors 
   
P23 Other symptoms (specify type) with BX-AY errors 
   
P24 Other symptoms (specify type) with BX reaction time 
   
Q) RESULTS: Symptom and Function Associations in Schizotypy-
Spectrum Group #1 
Bivariate 
Correlations (r) 
Significance 
(p) 
Article 
pg # 
[same variables as section P above]    
    
R) RESULTS: Symptom and Function Associations in Schizotypy-
Spectrum Group #2 
Bivariate 
Correlations (r) 
Significance 
(p) 
Article 
pg # 
[same variables as section P above] 
   
S) RESULTS: Symptom and Function Associations in Comparison 
Group 
Bivariate 
Correlations (r) 
Significance 
(p) 
Article 
pg # 
[same variables as section P above]    
 
 
 
2
3
2
 
 
T) RESULTS: Symptom and Function Associations in All 
Participants 
Bivariate 
Correlations (r) 
Significance 
(p) 
Article 
pg # 
[same variables as section P above] 
   
    
U) Follow-Up characteristics Response 
Article 
pg # 
Citation if authors 
referred to different 
article for info 
U1 Follow-up conducted? 
   
  1 = No (if No, stop here: ignore U2&U3, ignore sections V-X)       
  2 = Yes       
U2 Duration of follow-up 
   
U3 List changes from baseline to follow-up (e.g., sample size) 
   
 
 
 
2
3
3
 
 
V) Follow-Up: Between-
Group Comparisons #1 
Groups 
and 
direction 
of findings  
Analysis (1 = t-test, 
2 = ANOVA, 3 = 
Planned contrasts, 4 
= Other 
F t df 
Signifi-
cance 
(p)  
Measure of 
Effect Size (1 
= Cohen's d, 2 
= η2, 3 = other  
Effect 
Size 
[same variables as section M above]        
W) Follow-Up: Between-
Group Comparisons #2 
Groups 
and 
direction 
of findings  
Analysis (1 = t-test, 
2 = ANOVA, 3 = 
Planned contrasts, 4 
= Other 
F t df 
Signifi-
cance 
(p)  
Measure of 
Effect Size (1 
= Cohen's d, 2 
= η2, 3 = other  
Effect 
Size 
[same variables as section M above]        
X) Follow-Up: Between-
Group Comparisons #3 
Groups 
and 
direction 
of findings  
Analysis (1 = t-test, 
2 = ANOVA, 3 = 
Planned contrasts, 4 
= Other 
F t df 
Signifi-
cance 
(p)  
Measure of 
Effect Size (1 
= Cohen's d, 2 
= η2, 3 = other  
Effect 
Size 
[same variables as section M above] 
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APPENDIX D 
OUR CONCEPTUALIZATIONS OF SYMPTOM DIMENSIONS 
 
Positive 
Symptoms 
Brief Psychiatric Rating Scale: hallucinations, unusual thought content, 
grandiosity, suspiciousness 
Scale for the Assessment of Positive Symptoms: hallucinations, 
delusions 
Scale of Prodromal Symptoms, Perceptual Aberration Scale, Magical 
Ideation Scale: unusual thought content, suspiciousness, grandiosity, 
perceptual abnormalities 
Positive and Negative. Syndrome Scale: delusions, hallucinations, 
grandiosity, suspiciousness/persecution. 
Based on Liddle (1987) reality distortion: delusions, hallucinations. 
DSM-5 Schizotypal Personality Disorder criteria: ideas of reference, 
odd beliefs/magical thinking, unusual perceptual experiences, 
suspiciousness/paranoid ideation 
Schneiderian First Rank Symptoms: delusional perception, audible 
thoughts, voices arguing/discussing, voices commenting on one's actions, 
thought withdrawal, thought insertion, thought broadcast, passivity of 
affect, passivity of impulse, passivity of volition, somatic passivity 
Schizotypal Personality Questionnaire: unusual perceptual 
experiences, referential, paranoia, odd beliefs 
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Negative 
Symptoms 
 
Brief Psychiatric Rating Scale: emotional withdrawal, motor 
retardation, blunted affect, self-neglect 
Scale for the Assessment of Negative Symptoms: anhedonia, avolition, 
alogia, affective flattening, attention 
Scale of Prodromal Symptoms, Physical Anhedonia Scale, Social 
Anhedonia Scale: social isolation, avolition, decreased expression of 
emotion, decreased experience of self, decreased ideational richness, 
deterioration in role functioning 
Positive and Negative. Syndrome Scale: blunted affect, emotional 
withdrawal, poor rapport, passive/apathetic social withdrawal, lack of 
spontaneity and flow of 
Disorganized 
Symptoms 
 
Brief Psychiatric Rating Scale: conceptual disorganization, mannerisms 
and posturing, disorientation, bizarre behavior 
Scale for the Assessment of Positive Symptoms:  bizarre behavior, 
positive formal thought disorder 
Scale for the Assessment of Negative Symptoms: attention 
Positive and Negative Syndrome Scale: conceptual disorganization, 
difficulty in abstract thinking, poor attention. 
Based on Liddle (1987) disorganisation: inappropriate affect, poverty of 
content of speech, disturbances in the form of thought. 
Standard speech task: number of speech 
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This table details the symptom conceptualizations we have categorized as appropriate for 
running symptom correlations with a subset of studies. These include authors' 
conceptualizations we agreed with and our own conceptualization when none was 
provide or when raw data were available for us to calculate our own symptom 
composites. 
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APPENDIX E 
DEALING WITH MULTIPLE OUTCOMES IN P-CURVE ANALYSIS 
 
 
 For studies that gave both the AX-CPT and the DPX, only p-values from the AX-
CPT were used, which was selected because it is used more frequently than the DPX. For 
studies that gave multiple measurements of a single symptom dimension or reported on 
item-level correlations rather than overall scales, the measurement or item was chosen 
that was deemed to best represent that symptom dimension or to be most strongly related 
to CI ability in theory. Specifically, one study reported correlations with both the Scale 
for the Assessment of Negative Symptoms (SANS) and word count on a speech task. The 
SANS scale was selected because it is more commonly used in the literature to assess 
negative symptoms. For a different study that reported correlations separately for 
hallucination and delusion items, the delusion item was selected to represent the positive 
dimension because it is cognitive–rather than perceptual—in nature and the CI is a 
cognitive task. The same study reported on the following negative symptom items: 
affective flattening, alogia, avolition, and anhedonia. The alogia item was selected 
because it was deemed to represent the cognitive—rather than affective—aspects of the 
negative symptom dimension. Finally, that same study reported on the following 
disorganization symptom items: bizarre behavior, formal thought disorder, and attention. 
The formal thought disorder item was selected because it is considered most specific to 
disorganization and is a hallmark of disorganized cognition. 
 
 
 
2
3
8
 
 
APPENDIX F 
 
LIST OF INCLUDED STUDIES WITH BASIC SAMPLE AND TASK INFORMATION 
 
 
Study Sample Size and Type Task 
Barch, D., Carter, C., Braver, T., Sabb, F., MacDonald, A., Noll, D., & 
Cohen, J. (2001). Selective deficits in prefrontal cortex function in 
medication-naive patients with schizophrenia. Archives of General  
 
Psychiatry, 58, 280-288. 
14 first-episode schizophrenia 
12 healthy control 
AX-CPT 
Barch, D., Carter, C., MacDonald, A., Braver, T., & Cohen, J. (2003). 
Context-processing deficits in schizophrenia: diagnostic specificity, 4-
week course, and relationships to clinical symptoms. Journal of Abnormal 
Psychology, 112, 132-43. 
49 first-episode schizophrenia 
30 non-schizophrenia psychotic 
control 
72 healthy control 
AX-CPT 
Barch, D., Mitropoulou, V., Harvey, P., New, A., Silverman, J., & Siever, 
L. (2004). Context-Processing Deficits in Schizotypal Personality 
26 schizotypal personality 
disorder 
AX-CPT 
 
 
 
2
3
9
 
 
Disorder. Journal of Abnormal Psychology, 113, 556-568. 35 healthy control 
Barch, D., Yodkovik, N., Sypher-Locke, H., & Hanewinkel, M. (2008). 
Intrinsic motivation in schizophrenia: relationships to cognitive function, 
depression, anxiety, and personality. Journal of Abnormal Psychology, 
117, 776–87. 
57 chronic schizophrenia 
37 healthy control 
AX-CPT 
Becker, T.. (2012). Understanding the relationship between goal 
maintenance and disorganized speech. Unpublished Dissertation. 
49 chronic schizophrenia 
28 healthy control 
AX-CPT 
Braver T., Barch D., Cohen J. (1999): Mechanisms of cognitive control: 
Active memory, inhibition, and the pre-frontal cortex (Technical Report 
PDP.CNS.99.1). Pittsburgh, PA: Carnegie Mellon University. 
16 first-episode schizophrenia 
16 healthy control 
AX-CPT 
Buchanan, R., Keefe, R., Lieberman, J., Barch, D., Csernansky, J., Goff, 
D., … & Marder, S. (2011). A randomized clinical trial of MK-0777 for 
the treatment of cognitive impairments in people with schizophrenia. 
Biological Psychiatry, 69, 442–449. 
47 chronic schizophrenia AX-CPT 
   
 
 
 
2
4
0
 
 
Ceccherini-Nelli, A., Turpin-Crowther, K., & Crow, T. (2007). Schneider's 
first rank symptoms and continuous performance disturbance as indices of 
dysconnectivity of left- and right-hemispheric components of language in 
schizophrenia. Schizophrenia Research, 90, 203-213. 
17 chronic schizophrenia 
14 non-schizophrenia psychotic 
control 
15 depressed control 
16 healthy control 
AX-CPT 
Chung, Y., Mathews, J., & Barch, D. (2011). The effect of context 
processing on different aspects of social cognition in schizophrenia. 
Schizophrenia Bulletin, 37, 1048-56. 
41 chronic schizophrenia 
27 healthy control 
AX-CPT 
Cohen, J., Barch, D., Carter, C., & Servan-Schreiber, D. (1999). Context-
processing deficits in schizophrenia: Converging evidence from three 
theoretically motivated cognitive tasks. Journal of Abnormal Psychology, 
108, 120–133. 
53 chronic schizophrenia 
25 depressed control 
31 healthy control 
AX-CPT 
  
 
 
 
2
4
1
 
 
Delawalla, Z., Barch, D.M., Eastep, J., Thomason, E., Hanewinkel, M., 
Thompson, P., & Csernansky, J. (2006). Factors mediating cognitive 
deficits and psychopathology among siblings of individuals with 
schizophrenia. Schizophrenia Bulletin, 32, 525–537 
27 chronic schizophrenia 
31 relatives of schizophrenia 
81 healthy control 
AX-CPT 
Delawalla, Z., Csernansky, J., & Barch, D. (2008). Prefrontal Cortex 
Function in Nonpsychotic Siblings of Individuals with Schizophrenia. 
Biological Psychiatry, 63, 490-497 
30 relatives of schizophrenia 
92 healthy control 
AX-CPT 
Dias, E., Bickel, S., Epstein, M., Sehatpour, P., & Javitt, D. (2013). 
Abnormal task modulation of oscillatory neural activity in schizophrenia. 
Frontiers in Psychology, 4. 
17 chronic schizophrenia 
13 healthy control 
AX-CPT 
Edwards, B., Barch, D., & Braver, T. (2010). Improving prefrontal cortex 
function in schizophrenia through focused training of cognitive control. 
Frontiers in Human Neuroscience, 4, 32. 
22 chronic schizophrenia 
14 healthy control 
AX-CPT 
Fisher, M. (2016). Personal Communication. 34 chronic schizophrenia AX-CPT 
  
 
 
 
2
4
2
 
 
Fornito, A., Yoon, J., Zalesky, A., Bullmore, E., & Carter, C. (2011). 
General and Specific Functional Connectivity Disturbances in First-
Episode Schizophrenia During Cognitive Control Performance. Biological 
Psychiatry, 70, 64–72. 
23 first-episode schizophrenia 
25 healthy control 
AX-CPT 
Gold, J., Barch, D., Carter, C., Dakin, S., Luck, S., MacDonald, A., & ... 
Strauss, M. (2012). Clinical, functional, and intertask correlations of 
measures developed by the Cognitive Neuroscience Test Reliability and 
Clinical Applications for Schizophrenia Consortium. Schizophrenia 
Bulletin, 38, 144-152. 
 
Henderson, D., Poppe, A., Barch, D., Carter, C., Gold, J., Ragland, J., & ... 
MacDonald, A. (2012). Optimization of a goal maintenance task for use in 
clinical applications. Schizophrenia Bulletin, 38, 104-113. 
138 chronic schizophrenia 
136 healthy control 
DPX 
  
 
 
 
2
4
3
 
 
Holmes, A., MacDonald, A., Carter, C., Barch, D., Andrew, S., & Cohen, 
J. (2005). Prefrontal functioning during context processing in 
schizophrenia and major depression: an event-related fMRI study. 
Schizophrenia Research, 76, 2-3. 
7 chronic schizophrenia 
10 depressed control 
9 healthy control 
AX-CPT 
Jones, J, Sponheim, S., Macdonald, A. (2010, Study 3). The dot pattern 
expectancy task: Reliability and replication of deficits in schizophrenia. 
Psychological Assessment, 22, 131-141 
47 chronic schizophrenia 
48 healthy control 
DPX 
Lesh, T., Tanase, C., Geib, B., Niendam, T., Yoon, J., Minzenberg, M., 
Ragland, J., ... Carter, C. (2015). A multimodal analysis of antipsychotic 
effects on brain structure and function in first-episode schizophrenia. Jama 
Psychiatry, 72, 226-34. 
23 first-episode schizophrenia 
(medicated) 
22 first-episode schizophrenia 
(unmedicated) 
37 healthy control 
AX-CPT 
  
 
 
 
2
4
4
 
 
Lewis, D., Cho, R., Carter, C., Eklund, K., Forster, S., Kelly, M., & 
Montrose, D. (2008). Subunit-Selective Modulation of GABA Type A 
Receptor Neurotransmission and Cognition in Schizophrenia. American 
Journal of Psychiatry, 165, 1585–1593. 
15 chronic schizophrenia 
AX-CPT 
Lopez-Garcia, P., Cristobal-Huerta, A., Espinoza, L., Molero, P., Sanchez-
Pedreño, F., & Hernández-Tamames, J. A. (2016). The influence of the 
COMT genotype in the underlying functional brain activity of context 
processing in schizophrenia and in relatives. Progress in Neuro-
Psychopharmacology & Biological Psychiatry, 71, 176–182. 
15 chronic schizophrenia 
spectrum patients 
16 relatives of schizophrenia 
20 healthy control 
DPX 
López-García, P., Young, L., Marín, J., Molero, P., & Ortuño, F. (2015). 
The impact of the Val158Met COMT polymorphism on context processing 
in patients on the schizophrenia spectrum and their relatives. Schizophrenia 
Research: Cognition, 2, 179–184. 
40 chronic schizophrenia 
spectrum patients 
26 relatives of schizophrenia 
63 healthy control 
DPX 
  
 
 
 
2
4
5
 
 
MacDonald, A. (2002). A differential deficit in context processing 
associated with the genetic liability to schizophrenia: A sibling study. 
ProQuest Information & Learning, US. 
AX-CPT: 24 chronic 
schizophrenia, 24 relatives of 
schizophrenia, 29 healthy control 
DPX: 17 chronic schizophrenia, 
16 relatives of schizophrenia, 28 
healthy control 
AX-CPT, 
DPX 
MacDonald, A., & Carter, C. (2003). Event-related FMRI study of context 
processing in dorsolateral prefrontal cortex of patients with schizophrenia. 
Journal of Abnormal Psychology, 112, 689–97. 
17 chronic schizophrenia 
17 healthy control 
AX-CPT 
McClure, M., Barch, D., Flory, J., Harvey, P., & Siever, L. (2008). Context 
processing in schizotypal personality disorder: evidence of specificity of 
impairment to the schizophrenia spectrum. Journal of Abnormal 
Psychology, 117, 342–354 
63 schizotypal personality 
disorder 
25 non-Cluster A personality 
disorder 
42 healthy control 
AX-CPT 
  
 
 
 
2
4
6
 
 
McClure, M., Barch, D., Romero, M., Minzenberg, M., Triebwasser, J., 
Harvey, P., & Siever, L. (2007). The Effects of Guanfacine on Context 
Processing Abnormalities in Schizotypal Personality Disorder. Biological 
Psychiatry, 61, 1157–1160. 
29 schizotypal personality 
disorder 
AX-CPT 
McClure, M., Harvey, P., Goodman, M., Triebwasser, J., New, A., 
Koenigsberg, H., … Siever, L. (2010). Pergolide treatment of cognitive 
deficits associated with schizotypal personality disorder: continued 
evidence of the importance of the dopamine system in the schizophrenia 
spectrum. Neuropsychopharmacology, 35, 1356–1362. 
24 schizotypal personality 
disorder 
AX-CPT 
 
Merrill, A., Karcher, N., Cicero, D., Becker, T., Docherty, A., & Kerns, J. 
(2017). Evidence that communication impairment in schizophrenia is 
associated with generalized poor task performance. Psychiatry Research, 
249, 172-179. 
43 chronic schizophrenia 
19 healthy control 
AX-CPT 
  
 
 
 
2
4
7
 
 
Niendam, T., Lesh, T., Yoon, J., Westphal, A., Hutchison, N., Ragland, J., 
& ... Carter, C. (2014). Impaired context processing as a potential marker 
of psychosis risk state. Psychiatry Research: Neuroimaging, 221, 13-20 
25 ultra high-risk AX-CPT 
Paavola, J. (2013). Personality dimensions and cognitive functioning of 
relatives of persons diagnosed with schizophrenia and bipolar I disorder: A 
comparative and predictive study. Unpublished dissertation. 
47 relatives of patients with 
schizophrenia 
57 healthy control 
 
DPX 
Perlstein, W., Dixit, N., Carter, C., Noll, D., & Cohen, J. (2003). Prefrontal 
cortex dysfunction mediates deficits in working memory and prepotent 
responding in schizophrenia. Biological Psychiatry, 53, 25-38. 
16 chronic schizophrenia 
15 healthy control 
AX-CPT 
Poppe, A., Carter, C., Minzenberg, M., & MacDonald, A. (2015). Task-
based functional connectivity as an indicator of genetic liability to 
schizophrenia. Schizophrenia Research, 162, 1-3. 
19 chronic schizophrenia 
33 relatives of schizophrenia 
50 healthy control 
AX-CPT 
  
 
 
 
2
4
8
 
 
Poppe, A., Barch, D., Carter, C., Gold, J., Ragland, J., Silverstein, S., & 
MacDonald, A. (2016). Reduced Frontoparietal Activity in Schizophrenia 
is Linked to a Specific Deficit in Goal Maintenance: a Multi-site 
Functional Imaging Study. Schizophrenia Bulletin, 42, 1149–1157. 
47 chronic schizophrenia 
56 healthy control 
DPX 
Reilly, J., Hill, S., Gold, J., Keefe, R., Clementz, B., Gershon, E., 
Keshavan, M., ... Sweeney, J. (2017). Impaired Context Processing is 
Attributable to Global Neuropsychological Impairment in Schizophrenia 
and Psychotic Bipolar Disorder. Schizophrenia Bulletin, 43, 397-406 
402 chronic schizophrenia 
304 bipolar with psychotic 
features control 
210 healthy control 
DPX 
Richard, A., Carter, C., Cohen, J., & Cho, R. (2013). Persistence, 
diagnostic specificity and genetic liability for context-processing deficits in 
schizophrenia. Schizophrenia Research, 147, 75-80. 
63 first-episode schizophrenia 
31 relatives of patients with 
schizophrenia 
83 healthy control 
47 non-schizophrenia psychotic 
control 
AX-CPT 
  
 
 
 
2
4
9
 
 
Sheffield, J., Gold, J., Strauss, M., Carter, C., MacDonald, A., Ragland, J., 
Silverstein, S., ... Barch, D. (2014). Common and specific cognitive 
deficits in schizophrenia: relationships to function. Cognitive, Affective & 
Behavioral Neuroscience, 14, 161-74. 
104 chronic schizophrenia 
132 healthy control 
AX-CPT, 
DPX 
Sheffield, J., Repovs, G., Harms, M., Carter, C., Gold, J., MacDonald, A., 
… Barch, D. (2015). Fronto-parietal and cingulo-opercular network 
integrity and cognition in health and schizophrenia. Neuropsychologia, 73, 
82–93 
46 chronic schizophrenia 
54 healthy control 
DPX 
Sloat, V. (2007). Context processing in psychometrically defined 
schizotypes. Unpublished dissertation. 
25 psychometrically-identified 
schizotypy 
18 psychometrically-identified 
vulnerable to depression 
38 healthy control 
AX-CPT 
  
 
 
 
2
5
0
 
 
Stratta, P., Daneluzzo, E., Bustini, M., Prosperini, P., & Rossi, A. (2000). 
Processing of context information in schizophrenia: relation to clinical 
symptoms and WCST performance. Schizophrenia Research, 44, 57–67. 
20 chronic schizophrenia 
20 healthy control 
AX-CPT 
Thoma, P., & Daum, I. (2008). Working memory and multi-tasking in 
paranoid schizophrenia with and without comorbid substance use disorder. 
Addiction, 103, 774–786. 
23 chronic schizophrenia 
22 depressed control 
20 healthy control 
AX-CPT 
Thoma, P., Zoppelt, D., Wiebel, B., & Daum, I. (2007). Context processing 
and negative symptoms in schizophrenia. Journal of Clinical and 
Experimental Neuropsychology, 29, 428-435 
26 chronic schizophrenia 
13 healthy control 
AX-CPT 
Todd, J., Whitson, L., Smith, E., Michie, P., Schall, U., & Ward, P. (2014). 
What’s intact and what’s not within the mismatch negativity system in 
schizophrenia. Psychophysiology, 51, 337–347. 
33 chronic schizophrenia 
58 healthy control 
AX-CPT 
  
 
 
 
2
5
1
 
 
Woodward, N., et al. (2016). Personal Communication. 
15 first-episode schizophrenia 
35 chronic schizophrenia 
19 bipolar with psychotic features 
control 
39 healthy control 
AX-CPT 
Yoon, J., Nguyen, D., McVay, L., Deramo, P., Minzenberg, M., Ragland, 
J., Niendam, T., ... Carter, C. (2012). Automated classification of fMRI 
during cognitive control identifies more severely disorganized subjects 
with schizophrenia. Schizophrenia Research, 135, 1-3. 
51 first-episode schizophrenia 
51 healthy control 
AX-CPT 
Yoon, J., Westphal, A., Minzenberg, M., Niendam, T., Ragland, J., Lesh, 
T., … Carter, C. (2014). Task-evoked substantia nigra hyperactivity 
associated with prefrontal hypofunction, prefrontonigral disconnectivity 
and nigrostriatal connectivity predicting psychosis severity in medication 
naïve first episode schizophrenia. Schizophrenia Research, 159, 521–526. 
12 first-episode schizophrenia 
15 healthy control 
AX-CPT 
 
  
 
 
 
2
5
2
 
 
Zhang, Z., Chen, X., Yu, P., Zhang, Q., Sun, X., Gu, H., … Ji, F. (2015). 
Evidence for the contribution of NOS1 gene polymorphism (rs3782206) to 
prefrontal function in schizophrenia patients and healthy controls. 
Neuropsychopharmacology, 40, 2015–2016. 
339 chronic schizophrenia 
665 healthy control 
DPX 
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APPENDIX G 
 
INFORMATION AND METHODOLOGICAL DECISIONS FOR SPECIFIC STUDIES 
 
 
Study Additional Information and Methodological Decisions 
Barch, D., Carter, C., Braver, T., Sabb, F., MacDonald, A., 
Noll, D., & Cohen, J. (2001). Selective deficits in prefrontal 
cortex function in medication-naive patients with 
schizophrenia. Archives of General Psychiatry, 58, 280-288. 
Accuracy was normalized using an arcsine transformation. 
Barch, D., Carter, C., MacDonald, A., Braver, T., & Cohen, 
J. (2003). Context-processing deficits in schizophrenia: 
diagnostic specificity, 4-week course, and relationships to 
clinical symptoms. Journal of Abnormal Psychology, 112, 
132-43. 
For the signal detection measures, a correction factor was 
applied in cases of a perfect hit rate or false alarm rate. This 
correction factor was (hit rate = 2E-(1/N); false alarm = 1 - 
{2E-(1/N)}; N = number of target or non-target trials 
  
 
 
 
2
5
4
 
 
Barch, D., Mitropoulou, V., Harvey, P., New, A., 
Silverman, J., & Siever, L. (2004). Context-Processing 
Deficits in Schizotypal Personality Disorder. Journal of 
Abnormal Psychology, 113, 556-568. 
For reaction time data, median responses were used to reduce 
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APPENDIX H 
 
ADDITIONAL POINT ESTIMATE DATA 
 
 
Table H1  
 
Point Estimates of Errors by Group and Trial Type. 
 
First-Episode, 
Unmedicated 
First-Episode, 
Medicated 
Chronic 
Schizophrenia 
At-Risk  
Group 
Healthy 
Controls 
Psychiatric 
Comparison 
Short Delay M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) 
% AX Errors 6.01 (1.63) 8.40 (6.95)* 8.63 (5.00) 3.70 (1.96) 2.83 (1.09) 6.66 (4.49) 
% AY Errors 12.00 (1.00) 9.90 (9.67)* 16.87 (5.25) 8.76 (4.40) 9.37 (3.66) 11.50 (4.54) 
% BX Errors 23.62 (2.71) 12.53 (10.53)* 21.83 (3.36) 12.36 (5.71) 8.71 (2.95) 12.30 (5.22) 
% BY Errors 6.18 (2.02) 2.40 (4.97)* 7.08 (2.90) 2.07 (0.87) 2.21 (1.37) 2.74 (1.81) 
Long Delay M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) 
% AX Errors 17.07 (5.82) 4.00 (5.00)* 12.10 (5.68) 13.50 (5.67) 6.32 (3.05) 9.17 (4.68) 
% AY Errors 9.76 (6.24) 21.00 (19.00)* 17.61 (5.89) 11.25 (9.38) 11.83 (4.16) 15.22 (5.00) 
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% BX Errors 21.19 (1.46) 14.00 (13.00)* 22.87 (8.18) 16.17 (6.44) 8.39 (2.83) 11.74 (3.15) 
% BY Errors 2.51 (1.25) 2.00 (4.00)* 6.92 (9.25) 1.85 (1.95) 3.49 (7.38) 2.63 (1.10) 
 
*Unweighted standard deviation is displayed when only one study provided data. 
 
Percent errors by trial type for short (cue-probe interval <3500ms) and long (cue-probe interval >3500ms) delay trials. Means  
 
and standard deviations are weighted by sample size. Data also presented in Figures 2 and 3.
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Table H2  
 
Point Estimates of Reaction Times by Group and Trial Type. 
 
 
First-Episode, 
Unmedicated 
First-Episode, 
Medicated 
Chronic 
Schizophrenia 
At-Risk  
Group 
Healthy 
Controls 
Psychiatric 
Comparison 
Short Delay M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) 
AXRT 524.89 (13.96) 414.17 (66.75)* 481.28 (42.38) 433.34 (38.04) 430.11 (37.12) 452.45 (42.79) 
AYRT 644.83 (27.87) 467.22 (60.63)* 638.47 (53.84) 571.32 (38.37) 570.22 (38.15) 571.96 (50.58) 
BXRT 679.83 (65.46) 418.62 (104.68)* 516.58 (54.29) 498.60 (45.21) 429.46 (64.74) 561.13 (64.16) 
BYRT 525.94 (34.53) 408.25 (109.39)* 526.51 (52.31) 431.81 (34.90) 419.08 (42.05) 452.41 (34.22) 
Long Delay M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) 
AXRT 588.24 (26.25) 616.00 (204.00)* 550.72 (82.49) 520.37 (41.37) 480.11 (45.19) 496.07 (31.40) 
AYRT 694.36 (64.03) 785.00 (152.00)* 694.20 (63.79) 633.71 (57.97) 616.04 (50.91) 635.77 (29.53) 
BXRT 692.42 (64.03) 723.00 (286.00)* 595.84 (91.63) 553.58 (52.87) 508.29 (90.29) 540.26 (43.13) 
BYRT 574.36 (60.49) 626.00 (203.00)* 580.69 (53.06) 507.78 (56.69) 479.80 (49.84) 515.12 (34.09) 
 
*Unweighted standard deviation is displayed when only one study provided data. 
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RT=reaction time. Reaction time by trial type for short (cue-probe interval <3500ms) and long (cue-probe interval >3500ms) 
delay trials. Means and standard deviations are weighted by sample size. Data also presented in Figures 4 and 5.  
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Table H3  
 
Point Estimates of d’context by Group. 
 
 
First-Episode, 
Unmedicated 
M (SD) 
First-Episode, 
Medicated 
M (SD) 
Chronic 
Schizophrenia 
M (SD) 
At-Risk  
Group 
M (SD) 
Healthy 
Controls 
M (SD) 
Psychiatric 
Comparison 
M (SD) 
Short delay 
d’context 
2.43 (0.38) 2.89 (1.03)* 2.43 (0.57) 3.45 (0.68) 3.54 (0.54) 3.09 (0.45) 
Long delay 
d’context 
1.99 (0.35) 3.26 (1.02)* 2.10 (0.73) 2.67 (0.44) 3.06 (0.51) 2.72 (0.29) 
*Unweighted standard deviation is displayed when only one study provided data. 
 
D’context for short (cue-probe interval <3500ms) and long (cue-probe interval >3500ms) delay trials. Means and standard  
 
deviations are weighted by sample size. Data also presented in Figures 6 and 7. 
 
